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Abstract: 
 
Optically active molecules play a fundamental role in the functions of live. The 
enantioselective synthesis of chiral building blocks is crucial for the production of high value 
compounds such as pharmaceuticals or pesticides. Besides homogenous transition metal and 
enzymatic catalysts, artificial metalloenzymes - that consist of metal cofactors anchored 
within protein scaffolds - have been developed in the past decade to access optically pure 
compounds. The creation and optimization of these hybrid systems requires structural 
information. The asymmetric transfer hydrogenation of functional carbonyl, imine or enone 
groups to obtain the corresponding alcohols, amines or alkanes in high optical purity is 
achieved by transition metal piano stool complexes as well as by a number of different 
enzymes. In this thesis, two artificial transfer hydrogenases based on the streptavidin-biotin 
system for the asymmetric reduction of cyclic imines are structurally characterized. Potential 
substrate binding modes are proposed and the origins of the enantioselectivities are discussed. 
The Sharpless osmium-catalyzed asymmetric dihydroxylation of olefins is a powerful method 
to obtain chiral vicinal diols from variously substituted substrate molecules. The 
enantioselectivity of the reaction is governed by the interactions between the substrate olefins 
and the bulky chiral ligands bound to the catalytic osmium tetroxide center. In this thesis, an 
artificial olefin dihydroxylase is structurally characterized which is based on the embedding 
of an osmium tetroxide catalyst within streptavidin. Although none of the four osmium-
binding sites located in the crystal structures was bound to the biotin-binding pocket, the 
activity pattern of various streptavidin mutants suggests that the active site is located in 
proximity to this position. During the processing of the diffraction data of one of the 
streptavidin-osmium crystals, an ambiguous packing disorder was diagnosed for which a 
quantitative model is proposed in the final chapter of this thesis. 
Human carbonic anhydrase II is a well-characterized monomeric protein and numerous 
arylsulfonamide inhibitors with nanomolar and subnanomolar affinities for this enzyme are 
described in the literature. The potential of this protein to act as a host for the creation of an 
artificial transfer hydrogenase is evaluated by the structural characterization of an 
arylsulfonamide-tethered transition metal piano stool complex bound to human carbonic 
anhydrase II. This study is also investigating the structural origins of the high affinities of 
piano stool arylsulfonamide complexes for human carbonic anhydrase II and the implications 
for future metallodrug design. 
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A number of ruthenium-arene piano stool complexes have been demonstrated to strongly 
inhibit the growth of human cancer cell lines by unspecific interactions with nucleobases. To 
introduce DNA-specificity via second coordination sphere interactions, two ruthenium arene 
complexes have been biotinylated and bound to streptavidin. The structural basis of the DNA-
specificity governed by the streptavidin-ruthenium arene complex is investigated.  
The in vivo activity of artificial metalloenzymes is a prerequisite for their genetic optimization 
by directed evolution. Moreover, hybrid enzymes have the potential to be used in vivo to 
complement metabolic pathways or to act as bioorthogonal catalyst in the activation of 
prodrugs. The strategy of enzyme-encapsulation into cell-penetrating nanoreactors is 
investigated which allows the shuttling of artificial metalloenzymes into cells. 
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I  Preamble 
 
 
Chiral molecules such as amino acids or nucleotides are involved in fundamental processes of 
life. At the same time, our society relies on a great amount of high-value chiral compounds 
including pharmaceuticals, pesticides, aroma and flavor compounds, dyes and pigments, 
liquid crystals and others. Homogenous transition metal- and enzymatic catalysis are crucial 
technologies for the synthesis of optically pure building blocks. In the past, these two 
disciplines inspired one another to develop efficient catalytic processes, which are 
characterized by a high substrate specificity, a high activity, a long catalyst lifetime, a low 
reaction temperature and the employment of environmentally benign reactants and solvents. 
Due to the availability of scientific techniques such as site-directed protein mutagenesis and 
synthetic chemistry it is possible to engineer hybrid catalysts, which consist of an active 
metallocofactor anchored within a rigid protein scaffold. These artificial metalloenzymes 
(AME hereafter) combine principles of transition metal- and enzymatic catalysis. It is 
important to know the structure of an artificial metalloenzyme to understand its reaction 
mechanism and to optimize its function.  
In this thesis, hybrid catalysts are structurally characterized, which are based on the well-
characterized streptavidin-biotin complex. The structural information will be used to elucidate 
the reaction mechanism and to propose amino acid mutations for the improvement of the 
catalyst’s activity and selectivity. The investigation concerns hybrid catalysts for two 
important reactions, the asymmetric transfer hydrogenation of cyclic imines and the 
asymmetric cis-dihydroxylation of olefins. 
In addition to streptavidin-biotin, the potential of a second protein-ligand complex, the human 
carbonic anhydrase II-arylsulfonamide system, is explored by protein crystallography to be 
engineered into an artificial metalloenzyme. The strategy is based on the tethering of a 
number of catalytically active ruthenium-arene piano stool complexes to an arysulfonamide 
anchor, which has a nanomolar affinity for human carbonic anhydrase II (hCAII hereafter). 
Since hCAII is an important drug target, the structural characterization of hCAII-ruthenium 
arene aryslsulfonamide complexes is valuable for the design of novel metallodrugs. The 
ruthenium-arene piano stool functionalities of the complexes tested for catalysis and as 
inhibitors of hCAII were reported to inhibit the growth of human ovarian cancer cell lines. 
The goal of another chapter of this thesis is to increase the specificity of these ruthenium 
complexes for different DNA-targets. In the context of a presenter-protein strategy, 
	
  5	
  
biotinylated ruthenium-arene complexes are attached to different streptavidin (Sav hereafter) 
mutants and the DNA-binding selectivity of the complexes is rationalized by crystal structure 
analysis.  
For the optimization of AMEs by the high-throughput in vivo screening of genetic diversity or 
for the application of AMEs in metabolic engineering, strategies have to be developed to 
create hybrid catalysts that are robust, reactive and selective under physiological conditions. 
Towards this end, an artificial transfer hydrogenase is encapsulated into a cell-permeable 
nanoreactor. The activity of the catalyst inside the nanoreactor is tested by a fluorescence 
assay developed specifically to detect transfer hydrogenation activity.  
The final chapter of the thesis discusses an ambiguous packing disorder, which was observed 
in a streptavidin crystal soaked with K2[OsO2(OH)4]. A quantitative model for the packing 
anomalies is proposed.  
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II Aim of the Thesis 
 
 
1. Artificial Metalloenzymes for Asymmetric Catalysis 
 
To reveal the mechanism and determine amino acid residues crucial for the optimization of 
artificial metalloenzymes for the asymmetric transfer hydrogenation of cyclic imines and the 
asymmetric cis-dihydroxylation of olefins, the crystal structures are to be solved of complexes 
of: 
i. streptavidin mutants with biotinylated transition metal piano stool complexes,  
ii. streptavidin with K2[OsO2(OH)4]  
iii. human carbonic anhydrase II with benzene sulfonamide-anchored transition metal 
piano stool complexes. 
 
2. Structural Analysis of Piano Stool Ruthenium Complexes Bound to Streptavidin and 
Human Carbonic Anhydrase II: Implications for Future Metallodrug Design 
 
The potential of benzene sulfonamide transition metal piano stool complexes as inhibitors of 
human carbonic anhydrase II has to be evaluated by crystal structure analysis.  
For the structural and mechanistic elucidation of the specific DNA-binding properties of a 
biotinylated ruthenium-p-cymene piano stool complex bound to streptavidin the crystal 
structure of the complex needs to be solved.  
 
3. Towards in Vivo Catalysis with Artificial Metalloenzymes 
 
For future in vivo applications of streptavidin-biotin-based artificial metalloenzymes, an 
artificial transfer hydrogenase has to be encapsulated in a cell-permeable vesicle. To 
investigate the enzymatic activity inside the vesicle, a colorimetric transfer hydrogenation 
assay will be developed.   
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4. Quantitative Model of a Streptavidin-­‐K2[OsO2(OH)4] Crystal with an Ambiguous 
Packing Disorder  
 
Crystal packing disorder is a common problem in crystallography. Upon soaking apo-
streptavidin crystals with K2[OsO2(OH)4] and processing of the collected diffraction data, a 
crystal packing disorder was detected. A quantitative model has to be generated to describe 
the disorder and to solve the structure. 
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III  Artificial Metalloenzymes in Asymmetric Catalysis 
 
 
1.  Introduction  
1.1. Asymmetric Homogenous Transition Metal Catalysis 
A molecule is chiral when it can not be superimposed with its mirror image. The image and 
the mirror image of the chiral molecule are two enantiomers. Due to their different 
stereochemistry, opposite enantiomers of a small molecule can have very different biological 
effects.1 The production of optically active (chiral) fine chemicals is relevant for the synthesis 
of more complex compounds such as pharmaceuticals, pesticides, aroma and flavor 
compounds, dyes and pigments, liquid crystals and others. 
In asymmetric transition metal catalysis, optically pure metal complexes are employed to 
produce chiral building blocks from achiral precursors (Scheme M1).2 Thereby, chirality is 
induced from the catalyst to the product molecule. In case both catalyst and substrate are part 
of one reaction phase (e.g. a solution), one refers to homogeneous catalysis. Many transition 
metal catalyzed reactions have a maximum performance in organic solvents and at elevated 
temperatures. Limitations in the enantioselectivity of the catalyst can be circumvented by the 
step-wise enrichment of one enantiomer through selective recrystallization or (dynamic) 
kinetic resolution.2 However, highly enantioselective catalysts are desired to produce chiral 
building blocks with close to 100 % optical purity in one step.  
 
1.2.  Asymmetric Biocatalysis 
Enzymes differ from homogenous small molecule catalysts in structural and functional 
terms.3 Most enzymes have evolved to catalyze a specific transformation in an aqueous 
environment at physiological conditions (e.g. pH about 7.5 and 37 °C) within a complex 
matrix of molecules. These special reaction conditions account for a complex biopolymeric 
architecture composed of recyclable amino acid units, which is optimized by evolution. The 
environmentally benign reaction conditions and the high selectivity of an enzyme are 
attractive features and responsible for a great amount of research in the area of biocatalysis. 
Enzymes consist of a substrate-specific active site pocket to bind the transition state of a 
reaction with high affinity. The selective substrate binding to the enzyme allows a strong 
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asymmetric induction with close to 100 % optical purity in the product molecule. Metals play 
often a pivotal role in asymmetric enzyme catalysis.4,5 They guide function in many different 
ways: e.g. by stabilizing the protein structure, by arranging the substrate in a reactive 
conformation in the active site, by acting as a Lewis acid to increase the electrophilicity of a 
reaction partner or another amino acid (Figure M7), by compensating negative charges in 
transition states or by donating or accepting electrons from substrates or cofactors. However, 
enzymes are not always suitable to catalyze reactions of interest since they may not bind the 
substrate molecule or because they denature in organic solvent and at elevated temperatures. 
 
1.3.  Strategies for Artificial Metalloenzyme Design 
An alternative approach to find a highly selective enzyme for an important chemical 
transformation is the creation of artificial metalloenzymes. The hybrid asymmetric catalysts 
can be created by the incorporation of a transition metal into a rigid protein scaffold. Thereby, 
the high activity of the metal catalyst is combined with the enantioselectivity of an enzymatic 
substrate binding pocket. 
In the past decades, numerous techniques have emerged, which can be employed for the 
engineering of artificial metalloenzymes: e.g. the synthesis of metallocofactors (MC 
hereafter), heterologous protein expression, site-directed and random mutagenesis, synthesis 
of monoclonal antibodies, protein crystal structure analysis and computational modeling. 
Given a chemical transformation of interest, three major strategies have been described in 
literature for the formation of AMEs: i) the redesign of a natural biomolecular scaffold 
employing an active MC,6–10 ii) the design of an AME based on the transition state of a 
reaction11,12 and iii) the directed evolution of existing metalloenzymes to acquire novel 
functions.13 The focus of this thesis is on the first concept.  
 
Redesign of Biomolecular Scaffolds Using Active Metallocofactors:  
The first examples of AMEs were based on the covalent and non-covalent chemical 
modification of existing protein scaffolds with MCs.14,15 The general concept is to use a 
readily available biomolecular scaffold, either protein or DNA/RNA, to define the reaction 
environment of an incorporated active MC. Thereby, the activity and selectivity of the hybrid 
catalyst can be improved for a given substrate by modulation of the 1st (including atoms 
covalently attached to metal) and 2nd (including atoms non-bonded to the metal) coordination 
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sphere of the metal (Figure M1). The individual steps towards the achievement of such a 
hybrid catalyst are described in the following paragraphs. 
 
Search for Biomolecular Scaffold: 
The choice of an appropriate biochemical scaffold is typically guided by the following 
criteria: i) availability of structural information from X-ray crystallography or NMR, ii) 
presence of a cavity of sufficient size to accommodate the MC and the substrate, iii) the 
possibility to tightly anchor the MC inside the cavity, iv) the cavity should be part of a rigid 
fold to constrain structural and functional unidirectionality, v) the biomolecule should be 
readily available in big amounts and high purity from a natural source, through synthesis or 
by heterologous expression (e.g. in E. coli), which allows screening of the functional effects 
of amino acid exchanges, vi) the biomolecule should ideally be stable at temperatures above 
room temperature, tolerate organic solvents, high ion concentrations and different pH values 
and vii) the biomolecule-MC complex should be easy to crystallize to get structural 
information of the catalyst by X-ray crystallography, which can be used to optimize the AME 
by chemical and genetic means.  
 
Anchoring of the MC:  
The MC can be anchored to the biomolecule: i) in a covalent fashion by ligation to a reactive 
amino acid (e.g. Cys, Lys, Ser) or nucleotide,16–20 ii) in a supramolecular fashion by ligation 
of a natural affinity tag (e.g. biotin, heme or acridine) to an active metal function (Figure 
M1),8,9,14,21,22 iii) in a dative fashion by direct coordination of the active metal to amino acid 
side chains or nucleotides in the cavity of the biomolecule23–29 or iv) by genetic encoding of a 
non-natural amino acid well suited for metal coordination.30  
 
 
Figure M1: Supramolecular anchoring of metallocofactor within a protein scaffold. Letters M 
and L indicate metal and ligand, respectively.  
protein
L
L
Mlinker
anchor
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Chemical Optimization of the AME: 
The advantage of using MCs in AME design as compared to transition state-based design 
methods is a relatively easy access to an initial activity of the hybrid catalyst. Furthermore, it 
holds the potential to screen chemical diversity for its impact on the activity and selectivity of 
a chemical transformation. It should be considered in the design process of the MC to have a 
facile access to a broad cofactor diversity compatible with the biomolecular scaffold by using 
reliable reactions with little side products, easy product purification and by avoiding residual 
reactive groups in the MC that can undergo undesired reactions with the biomolecule.  
 
Genetic Optimization of the AME: 
Integral part of AME design is the possibility to employ the transcription and translation 
machinery of bacteria to generate chemical diversity (amino acid substitutions) from genetic 
diversity (DNA) and, thus, to simulate natural evolution in a laboratory. Linkage of genotype 
and phenotype allows the application of genetic algorithms in AME design such as: 1) 1st 
generation diversification, 2) 1st generation activity screening and selection of fittest 
members, 3) characterization and diversification of fittest 1st generation members, 4) 2nd 
generation activity screening and selection of fittest members, and so on.31 The velocity of 
evolution of AMEs varies depending on the rate of the diversification techniques and the 
product screening method. 
 
1.4. Streptavidin-Biotin Technology in Artificial Metalloenzyme Design 
A suitable system for the engineering of a supramolecular AME is the streptavidin-biotin 
complex. The affinity of the cofactor biotin (vitamin H) for the bacterial protein streptavidin 
is very high (KD = 10-14-10-15 M) and the strongest non-covalent interaction known in 
Nature.32 Sav, which is a close structural homolog of the chicken protein avidin, is a 222-
symmetrical homotetrameric protein (~ 66 kDa), the monomers of which consist of a rigid 
beta-barrel fold (Figure M2).33 Each beta-barrel can bind one biotin molecule within its core. 
No cooperativity was observed for the individual biotin binding events.34 There are two types 
of relatedness between biotin binding sites in a Sav tetramer: cis (small distance between two 
biotin molecules) and trans (long distance between two biotin molecules). Each biotin 
molecules is located within a deep binding pocket. The valeric acid chain of biotin faces 
towards a vestibule, which can accommodate a functional group tethered to the carboxylic 
acid of biotin. Depending on the size of the functional group, biotinylated ligands bound to 
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cis-related Sav monomers can influence one another.35 The affinity of many functionalized 
biotin molecules for Sav is still in the nanomolar or subnanomolar range.32 Sav is stable up to 
a temperature of 110 °C,36 in organic solvent (45 % DMSO)37 and at high and low pH (pH 3 - 
11). Sav can be obtained in high quantities (200 mg/L) by heterologous expression in E. coli. 
Complexes of Sav and functionalized biotin can be crystalized and characterized by X-ray 
protein crystallography, which allows structure-based intuitive and computational design and 
the assessment of hybrid catalysts.  
Wilson and Whitesides were the first to use the avidin-biotin system to incorporate a rhodium 
diphosphine complex for the catalytic asymmetric hydrogenation of an olefin.14 Follow-up 
research by Ward and Reetz has demonstrated that Sav can be engineered into a highly 
enantioselective hybrid catalyst for C-H activation,38 hydrogenation,22,39–42 transfer 
hydrogenation,43–45 allylic alkylation,46 sulfoxidation27 and ring-closing metathesis.47  
 
 
Figure M2: 222-symmetric streptavidin homotetramer (ribbon model) in complex with biotin 
(sphere model, PDB 3RY2). The left panel shows a top-view on two cis-related biotin binding 
pockets and the right panel a side view indicating the positions of two trans-related biotin-
binding sites. 
 
1.5. Carbonic Anhydrase-Arylsulfonamide System in Artificial Metalloenzyme 
Design 
The numerous impressive hybrid catalysts afforded so far by engineering of the Sav-biotin 
complex encourages the adaptation of the concept to expand the scope of catalysts and 
reactions. This motivation is reinforced by the fact that due to the interference of cis-related 
cofactors in the Sav-biotin-based AME, structure-based design is difficult.35 Engineering of 
90°
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asymmetric cis-related Sav monomers (e.g. to bind the cofactor in one monomer and the 
substrate selectively in the cis-related monomer) is very difficult to achieve.48,49 Furthermore, 
in vivo screening to optimize the activity and selectivity of the Sav-MC complexes in E. coli 
is hampered by competitive biotin present in the cell.50  
Carbonic anhydrases (CA hereafter) exist in all organisms and are responsible mainly for i) 
the fixation and release of carbon dioxide (respiration, gas-exchange), ii) Na+ transport (signal 
transduction and intracellular pressure) and iii) pH regulation.51 The reaction of water and 
carbon dioxide into bicarbonate by CA is one of the fastest reactions in Nature (kcat/KMCO2 ≈ 
108 M-1s-1). In humans, 16 isoforms of CA exist which are located in the cytosol, in 
mitochondria, bound to the cell membrane and in saliva. The structurally (a total of 429 
structures including 304 ligand-bound structures in the PDB, as of October 2012) and 
functionally best studied isoform is human carbonic anhydrase II. The monomeric enzyme 
consists of a central beta-sheet surrounded by numerous alpha-helices and loops that form a 
deep cone-shaped cavity with a catalytic Zn(II)His3 motive at the bottom (Figure M3). In the 
enzymatic reaction, a water molecule is activated by binding to the Lewis acid Zn(II). A 
closely-bound carbon dioxide is attacked by the activated water to form bicarbonate.  
A wealth of arylsulfonamide derivatives (some of which are in clinical use) have been 
described to inhibit hCAII and bind with up to picomolar affinity.51,52 Arylsulfonamides can 
be engineered to bind to hCAII in a multivalent fashion, meaning by i) mimicking the 
transition state of the native reaction (the sulfonamide group), ii) by hydrophobic interactions 
(aryl group) and iii) by further interactions (e.g. hydrophobic or ionic). Studies of hCAII 
ligand design have confirmed the more general ligand design principles that i) a good ligand 
often resembles the transition state of the native reaction, ii) hydrophobic protein-ligand 
interactions are far simpler to engineer than ionic or electrostatic interactions and iii) 
multivalency is an effective design principle; i.e. to append a high-affinity secondary 
component (hydrophobic protein-ligand interaction) to a low-affinity primary component (e.g. 
ionic protein-ligand interaction).51 
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Figure M3: Human carbonic anhydrase (ribbon model) in complex with benzenesulfonamide 
(sphere model, PDB 2WEJ). Histidines and Zn(II) of the Zn(II)His3 motif are depicted in stick 
representation. 
 
In summary, the following aspects render hCAII to be an interesting candidate for AME 
design: 
• it is monomeric, stable and of intermediate molecular weight (~29 kDa) 
• numerous sulfonamide-based ligands are known with nanomolar and subnanomolar 
affinity 
• it can be easily expressed in high yield in E. coli and purified by affinity 
chromatography 
• it is structurally well-defined 
• a number of straightforward assays are available (e.g. dansyl amide assay) to examine 
ligand binding  
• its structure does not change drastically when it binds ligands 
• a range of ligand motifs is easily synthetically accessible  
• ligand design can be improved/guided by computational methods (e.g. in silico affinity 
screening of metallocofactors) 
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2. Artificial Transfer Hydrogenases Based on the Streptavidin-Biotin Technology 
for the Reduction of Cyclic Imines 
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Enantiopure amines are privileged compounds which find
wide use in the pharmaceutical, agrochemical, and flavor and
fragrance industries. In this context, enzymatic,[1] homoge-
neous,[2] and chemoenzymatic[3] approaches offer comple-
mentary means for the preparation of these targets.
The asymmetric transfer hydrogenation (ATH) of ketones
using d6 piano stool complexes as catalyst has been the subject
of numerous studies,[4] leading to a unified picture of the
reaction mechanism.[5] The ATH of imines, however, has
received less attention.[6] Interestingly, the reaction proceeds
through a different enantioselection mechanism: for a given
aminosulfonamide ligand configuration, the opposite enan-
tiomers (alcohol vs amine) are produced.[7] In addition, it has
been argued that the imine must be protonated for the
reaction to proceed.[8]
In recent years, artificial metalloenzymes, resulting from
the introduction of a catalyst within a protein environment,
have attracted attention as potential alternatives to tradi-
tional catalysts.[9] Based on our experience in artificial ATHs
for the reduction of ketones,[10] we set out to test these systems
toward the enantioselective reduction of imines and to
compare their salient features with related homogeneous
systems.
As a starting point, we screened d5 and d6 piano stool
complexes bearing the biotinylated aminosulfonamide ligand
(abbreviated Biot-p-L) combined with wild-type streptavidin
(Sav) for the production of salsolidine 1 (Scheme 1).[11]
This screening led to the identification of [Cp*Ir(Biot-p-
L)Cl] (5!Sav) as the most promising catalyst. This contrasts
with ATH of ketones for which [(h6-arene)Ru(Biot-p-L)Cl] 2
and 3 proved superior (Table 1).[12] In all but one case, both
amine 1 and 1-phenylethanol 6 were produced with the same
configuration for a given artificial metalloenzyme.
Next, we screened complex 5 with the saturation muta-
genesis library S112X (Table 2 and Supporting Information,
Table S1). Noteworthy features include:
1) Incorporation of [Cp*Ir(Biot-p-L)Cl] (5) into Sav S112X
produces predominantly (R)-1.
2) The best (R)-selectivities are obtained for the smallest
amino acids at position 112 (S112G, S112A). The optimal
pH is 6.50, affording the product in 85% ee at 55 8C
(Table 2, entries 3 and 14).
3) The active biotinylated catalyst resides in the biotin-
binding vestibule: addition of four equivalents of biotin to
Scheme 1. Artificial metalloenzymes based on the biotin-streptavidin
technology for the ATH of imines. MOPS=3-morpholinopropanesul-
fonic acid.
Table 1: Results for the chemical optimization of artificial transfer
hydrogenases.
Entry Complex ee [%]
[conv.] 1[a]
ee [%]
[conv.] 6[b]
1 2 22 (R) [97] 70 (R) [84]
2 3 12 (R) [76] 45 (S) [56]
3 4 52 (R) [94] 15 (R) [26]
4 5 57 (R) [quant.] 13 (R) [47]
[a] The reaction was carried out at 55 8C for 15 h using 1 mol% complex
2–5 (690 mm final concentration) and 0.33 mol% tetrameric WT Sav at
pH 8.0 (MOPS buffer 2.9m) containing 3.65m HCO2Na (see Supporting
Information for experimental details). [b] Data from Ref. [12].
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[Cp*Ir(Biot-p-L)Cl]!S112A affords (R)-1 in low ee
(Table 2, entry 13).
4) (S)-selectivities result from the presence of a cationic
residue at position S112 (e.g. S112K and S112R, Table 2,
entries 4 and 5).
5) Decreasing the temperature to 5 8C allows improvement
of the enantioselectivity to 91% (R) for 5!S112A and
78% (S) for 5!S112K (Table 2, entries 7 and 15). Impor-
tantly, these reactions are not sensitive to traces of oxygen:
no degassing is required prior to catalysis.
6) Up to 4000 turnovers can be achieved with no erosion of
selectivity (Table 2, entry 18). On a preparative scale
(100 mg substrate, 0.025 mol% catalyst), the ee could be
further increased to 96%, with an isolated yield of 86%
(Table 2, entry 19).
7) [Cp*Ir(Biot-p-L)Cl]!S112A produces the same preferred
enantiomer for alcohol (R)-6 and amine (R)-1. Similarly,
[Cp*Ir(Biot-p-L)Cl]!S112K affords (S)-6 and amine (S)-
1, respectively (Table 2, entries 6 and 12). This suggests
that both imine and ketone reduction proceed through the
same enantioselection mechanism. We thus conclude that
the second coordination sphere interactions provided by
the host protein outweigh the preference of the related
homogeneous catalyst.
8) Increasing the ratio of [Cp*Ir(Biot-p-L)Cl] vs Sav tetra-
mer from one to four leads to a gradual erosion of
enantioselectivity (93 to 88% ee, Table 2, entries 16 and
17). This suggests that an empty biotin binding site
adjacent to a [Cp*Ir(Biot-p-L)Cl] moiety within Sav may
be favorable for selectivity.
9) Performing catalysis with Sav mutants obtained from an
ethanol precipitation step on a dialyzed protein extract
yields results very similar to those obtained with dilute
samples of pure protein for both S112K and S112A
(Table 2, compare entries 8–10 and 20–21). This finding
demonstrates that [Cp*Ir(Biot-p-L)Cl] (5) tolerates cel-
lular components.[13] This opens fascinating perspectives
for parallel screening as it significantly shortens the
protein purification effort (from 12 to 3 days).
To gain structural insight into the best (R)-selective
artificial metalloenzyme, crystals of S112A Sav were soaked
with a solution containing an excess of cofactor 5. The X-ray
crystal structure was solved to 1.9! resolution. Strong
residual density in the Fo"Fc map indicated that all biotin-
binding sites are fully occupied by ligand Biot-p-L (Figure 1a,
Table 2: Selected results for the genetic optimization of artificial transfer
hydrogenases for the production of Salsolidine 1.[a]
Entry Sav
mutant
T
[8C]
t
[h]
pH Conv. [%] ee [%]
1 no prot. 25 5 7.25 quant. rac.
2 WT Sav 55 2 7.25 quant. 57 (R)
3 S112G 55 2 7.25 quant. 60 (R)
4 S112R 55 2 7.25 quant. 19 (S)
5 S112K 55 2 7.50 94 35 (S)
6 S112K 55 64 7.25 30[b] 6 (S)
7 S112K 5 48 7.50 quant. 78 (S)
8 S112K 25 24 7.25 39[c] 44 (S)
9 S112K[d] 25 24 7.25 30[c] 42 (S)
10 empty plasmid 25 24 7.25 43[c] 1 (S)
11 S112A 55 2 7.25 quant. 79 (R)
12 S112A 55 64 7.25 69[b] 27 (R)
13 S112A 55 2 7.25 59[e] 14 (R)
14 S112A 55 2 6.50 quant. 85 (R)
15 S112A 5 24 6.50 quant. 91 (R)
16 S112A 5 24 6.50 quant.[f ] 93 (R)
17 S112A 5 24 6.50 quant.[g] 88 (R)
18 S112A 5 96 6.50 quant.[h] 96 (R)
19 S112A 5 115 6.50 86[h,i] 96 (R)
20 S112A 25 24 7.25 77[j] 64 (R)
21 S112A[d] 25 24 7.25 65[j] 61 (R)
22 H87A 55 2 7.25 quant. 48 (R)
23 H127A 55 2 7.25 quant. 54 (R)
24 S112AK121T 5 24 6.50 90 54 (R)
[a] See Table 1 and Supporting Information for full experimental details;
S112P was expressed as inclusion bodies and thus was not tested.
[b] Acetophenone reduction yielding 1-phenylethanol 6. [c] 50 mm [Cp*Ir-
(Biot-p-L)Cl] (5 ; i.e. 1 mol% vs 1) and 25 mm S112 K (tetramer).
[d] Precipitated protein from cell free extracts (Supporting Information).
[e] Four equivalents (vs tetrameric Sav) biotin added. [f ] 0.25 mol%
complex 5 and 0.25 mol% S112A tetramer. [g] 1 mol% complex 5 and
0.25 mol% S112A tetramer. [h] 0.025 mol% complex 5 and 0.025 mol%
S112A tetramer. [i] 86% yield of isolated product on 100 mg scale.
[j] 39 mm [Cp*Ir(Biot-p-L)Cl] (5 ; i.e. 1 mol% vs 1) and 20 mm S112A
(tetramer).
Figure 1. Close-up view of the X-ray crystal structure (PDB: 3pk2) of
complex 5!S112A Sav showing two symmetry-related cofactors in the
biotin-binding pocket of the protein tetramer. Fo"Fc omit map colored
in green (contoured at 3 s) and anomalous difference density map (5
s) in red (a). Surface representation with basic residues in blue, acidic
in red, polar and apolar in gray (b); (chloride: yellow sphere).
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note that due to crystallographic symmetry all Sav monomers
are identical). Adjacent to the ethylendiaminemoiety of Biot-
p-L a strong peak (15s) in the anomalous difference map
suggested the position of iridium. To avoid negative Fo!Fc
density the iridium atom occupancy was set to 50%. This most
likely indicates partial dissociation of the {IrCp*Cl} fragment
upon soaking, since alternative conformations appear steri-
cally not possible. The iridium atoms of two symmetry-related
cofactors (face-to-face) are separated by 5.2!. Despite the
purity of the complex used for soaking, no Fo!Fc density was
found for Cp* and chloride ligands. To prevent steric clashes
between symmetry-related Cp* groups, this bulky moiety was
modeled with a dihedral angle S-N-Ir-Cp*centroid = 98.38 (and
S-N-Ir-Cl = !34.28). This sets the configuration at Ir in the
structure to (S)-[Cp*Ir(Biot-p-L)Cl] (and correspondingly
(R)-[Cp*Ir(Biot-p-L)H]).
Compared to the recently characterized [(h6-benzene)Ru-
(Biot-p-L)Cl] (3"S112K; PDB: 2qcb, an (S)-selective
ATH),[10] the absolute configuration at the metal is (S) in
both cases, but the metal fragment is rotated along the aryl!S
bond by about 1508. This prevents steric clashes between the
benzene moiety and K121 of the adjacent monomer B
(Figure S2b).
Additional anomalous difference density indicating iri-
dium was found in the vicinity of the Ne atoms of H87 and
H127 (Figure S2c,d). These species, however, are not
involved in catalysis, as demonstrated by the results obtained
with the H87A and H127Amutants which are nearly identical
to those obtained with WT Sav (Table 2, entries 22 and 23).
Assuming that the absolute configuration revealed in the
X-ray structure is catalytically active, two transition states
leading to the observed (R)-products (alcohol or amine) can
be envisaged: non-concerted + CH···p or concerted + non-
CH···p, respectively (Figure 2b,c). Qualitative modeling of
the imine substrate into a vacated neighboring biotin site was
carried out for both possible transition states leading to (R)-1.
For the concerted + non-CH···p mechanism, steric clashes
between the substrate"s aro-
matic group and the protein
project the imine moiety into
the Cp* fragment (Figure S2e).
In contrast, for the non-con-
certed + CH···p interaction,
no steric clashes with the pro-
tein are apparent (Figure 2e).
Interestingly, the imine func-
tionality lies close to the ammo-
nium group of K121 (of the
adjacent monomer). This con-
tact may replace the amine
group of the ligand for the
delivery of a proton to the
substrate (Figure 2b,e). To test
this possibility, the double
mutant S112AK121T was
tested in catalysis (Table 2,
entry 24). The erosion in enan-
tioselectivity suggests that the
non-concerted + CH···p mech-
anism is operative both for the ATH of ketones and imines.
In summary, introduction of a biotinylated iridium piano
stool complex [(h5-Cp*)Ir(Biot-p-L)Cl] (5) within streptavi-
din affords an artificial imine reductase. Both (R)-1 (96% ee)
and (S)-1 (78% ee) are accessible with the same organome-
tallic moiety. This corresponds to a dDG! of 3.3 kcalmol!1 for
a single-point mutation. With the implementation of labo-
ratory evolution protocols for the optimization of artificial
metalloenzymes for the reduction of more challenging imines
in mind,[1,14] we have shown that the screening can be
performed in air with up to 4000 TON and, most importantly,
on precipitated protein rather than on rigorously purified Sav
samples used thus far. Based on X-ray structural data, we
suggest that the reaction proceeds, both for the imine and the
ketone reduction, through a non-concerted + CH···p inter-
action,[7b,15] whereby the residue K121 may be involved in the
protonation step.
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Supporting Figure 1: HABA displacement titration with biotin (red squares) and complex 5 
(blue diamonds).4   
 
 
X-RAY CRYSTAL STRUCTURE OF [Cp*Ir(Biot-p-L)Cl]  S112A SAV 
 
Crystallization 
Mutant S112A of the Sav fragment 13-159 with a N-terminal T7-tag was expressed and 
crystallized within 3 days by the hanging drop vapor diffusion technique upon mixing 6.5 µL 
protein solution (26 mg/mL in water) and 3.5 µL precipitation buffer (2.0 M ammonium 
sulfate, 0.1 M sodium acetate, pH 4.0), followed by equilibration against 500 µL precipitation 
buffer. Single S112A Sav crystals were transferred into 10 µL of 10 mM [Cp*Ir(Biot-p-L)Cl] 
5 in precipitation buffer (10 % final DMF concentration). After 3 h, the crystals were 
transferred into cryobuffer containing 30 % glycerol in precipitation buffer. Finally, crystals 
were shock-frozen and stored in liquid nitrogen.  
 
Data Collection and Structure Solution  
X-ray diffraction data of a 5  S112A Sav crystal were collected at the Swiss Light Source 
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(beam line PX3) at a wavelength of 0.9793 Å. Data indexing, integration and scaling were 
carried out with programs MOSFLM and SCALA of the CCP4-Suite5 (Supporting Table 2). 
The structure was solved by molecular replacement with program MOLREP6 using as search 
model the structure with PDB code 2qcb,7 lacking ligand and water molecules. Rigid body 
and full restraint refinement, including TLS and individual B-factor refinement, was carried 
out with program REFMAC-5.8 Electron and anomalous scattering density visualization as 
well as model building was performed with programs O9 and COOT.10 Ligand-protein 
interactions were analyzed using program LIGPLOT11 and structure validation using 
MOLPROBITY
. Structural figures were drawn with program DINO
Supporting Table 2  
. 
Data Processing 
Resolution (Å) 46.0 - 1.9 
Space Group I4122 
Cell dimensions (Å) a = 57.6, b = 57.6, c = 184.0 Į,ȕ,Ȗ = 90Û 
Rmerge (%) 10.9 (20.1)* 
No. unique reflections 11601 
Multiplicity 5.5 (4.0) 
Completeness 91.2 (87.4) 
I/sig(I) 9.7 (4.5) 
Structure Refinement 
Resolution (Å) 46.0 - 1.9 
Rwork/Rfree 18.5/20.4 
B-factors (Å2) 
   Protein 
   BIR 
   BI1  
   BI2  
 
9.5 
23.1 
29.1 
43.4                                                         

 http://molprobity.biochem.duke.edu/ 
 http://www.dino3d.org/ 
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   Water 18.4 
R.m.s deviations from ideal values 
   Bond lengths (Å) 
   Bond angles (Û 
 
0.011 
2.162 
* values in parenthesis are for the highest resolution bin (2.0 - 1.9 Å). Please find ligands BIR, 
BI1 And BI2 described in the text.    
 
Structure Descr iption 
Overall structure: The asymmetric unit contains one S112A Sav monomer. Application of 
crystal symmetry yields the 222-symmetrical (D2) tetramer (Supporting Figure 2a). The 
final model comprises residues 13-134 with 95.8 % of the residues found in the most-favored 
regions of a Ramachandran plot, and no Ramachandran outliers. As observed before,7 both 
the N-terminal T7 tag (residues 1-12) and 25 residues at the C-terminus are not resolved, 
probably due to disorder. The flexible loop comprising residues 45-53 was found in the open 
conformation, as described elsewhere.12 In addition, the structure comprises three ligands 
(BIR, BI1 and BI2) and 71 water molecules. 
[Cp*Ir (Biot-p-L)Cl] in the biotin-binding site: Residual positive electron density was 
detected in the biotin-binding pocket and in the vestibule surrounded by loops 112-122 and 
45-53 (Figure 2a). As expected from the large f’’ (8.3 e-) of Ir at the measured wavelength, a 
strong peak (15 ı) in the anomalous difference map was found in the vestibule close to 
residue A112 and next to a molecular 2-fold symmetry axis. Coordinates for 5 (ligand PDB 
identifier BIR) were generated from ligand [Ș6-(benzene)Ru(Biot-p-L)Cl] of structure 2qcb. 
The Ru and the benzene group in 2qcb were replaced by Ir and Cp*, respectively. Parameters 
of bond lengths and angles between Ir and N4, N5, Cp* as well as Cl for structure refinement 
were adapted from complex [Cp*Ir(en)Cl] (en: ethylendiamine) from the Cambridge 
Structural Database (CSD code CICFEA). The interactions of the biotin moiety of 5 and 
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S112A Sav are the same as described elsewhere for wild type Sav (Figure 2a).13 The valeric 
acid carbonyl and amide of 5 form H-bonds to N49-N (2.8 Å) and S88-OȖ (2.9 Å), 
respectively. Nitrogen N5 of the ethylenediamine group of 5 lies within H-bonding distance to 
the carbonyl oxygen of K121 (2.8 Å). 
 
Ir idium binding to H87 and H127: Further anomalous difference density peaks were found 
close to H87 and H127 (24 and 7-10 ı, respectively, Supporting Figure 2a, c and d). The 
density next to the H87 imidazole was fitted with [Ir(OH2)5]3+ and an occupancy of 70 % 
(ligand PDB identifier BI1). Thereby, the axial position of the octahedral complex is saturated 
by H87-Nİ (Supporting Figure 2c). Residue H127 is located in a cavity formed between two 
symmetry-related Sav monomers. The imidazole side chains of two symmetry-related H127 
LQWHUDFW E\ ʌ-stacking. Anomalous difference density peaks in the vicinity to the H127 
imidazole were modeled with three iridium atoms of varying occupancy according to the peak 
strength (ligand PDB identifier BI2, Supporting Figure 2d). The positions of these atoms 
relative to the orientation of the H127-Nİ lone-pair orbital does not suggest coordinative 
interactions. Due to a lack of experimental data no further ligands to the iridium atoms were 
modeled. 
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         e)                 f)  
Suppor ting Figure 2: Cofactor binding in Sav mutants. S112A Sav tetramer, view along 
molecular 2-fold axis, showing residues in vicinity to anomalous difference peaks (a, PDB 
code 3pk2). Close-up view of cofactor in complex [Ș6-(benzene)Ru(Biot-p-L)]  S112K Sav 
(b, PDB code 2qcb, basic residues in blue, acidic in red, polar and apolar in grey). Ligand 
[Ir(OH2)5]3+ bound to H87-Nİ (c) and Ir atoms in vicinity to H127 (d, Fo-Fc omit map in 
green contoured at 3 ı and anomalous difference density in red contoured at 5 ı). Substrate-
catalyst complex for proposed concerted & non-&+āāāāʌWUDQVLWLRQVWDWHe) and non-concerted 
	&+āāāāʌWUDQVLWLRQVWDWHf), viewed from the empty neighboring biotin-binding pocket. 
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2.2.  Comment on Publication 
2.2.1. Asymmetric Imine Transfer Hydrogenation Catalysts: Organometallic 
Complexes, Enzymes and Artificial Metalloenzymes  
As an alternative to the powerful asymmetric hydrogenation, the asymmetric transfer 
hydrogenation (ATH) of C=O, C=N or activated C=C double bonds into chiral alcohols, 
amines and alkanes gained much interest in the last two decades for the production of fine 
chemicals and pharmaceuticals. The formal hydride transfer between a donor and an acceptor 
molecule is catalyzed in Nature by the family of oxidoreductases,53 while in the laboratory 
mainly d6 piano stool transition metal complexes, and to a smaller extend, organocatalysts are 
used. While homogenous catalysts for the ATH of many ketones have been described, the 
efficient enantioselective and “green” reduction of imines is still a challenge.54 The 
asymmetric transfer hydrogenation of ketones and imines is a valuable reaction to test the 
scope and limitations of AME design based on the (strept)avidin-biotin technology and other 
protein-ligand complexes. Novel asymmetric transfer hydrogenation hybrid catalysts can 
contribute in the production of high-value optically active amines. 
 
Organometallic Complexes for Asymmetric Transfer Hydrogenation of Imines: 
d6 piano stool-shaped transition metal complexes have been proven versatile for the 
asymmetric transfer hydrogenation of ketones, enones and imines.2,54,55 Named habitually 
after the Japanese chemist and Nobel Prize laureate, these Noyori-type catalysts consist of a 
central transition metal (Ru(II), Ir(III) and Rh(III)), an arene cap (e.g. benzene, p-cymene or 
pentamethylcyclopentadienyl, Cp*) and three “leg”-substituents (Scheme M1).56 The 
presence of bidentate ligands such as aminoethylalcohol or tosylethylenediamine (TosEN 
hereafter) has an accelerating effect on the reaction rate.56 Chiral derivatives of TosEN (e.g. 
tosyldiphenylethylendiamine, (R,R)- or (S,S)-TosDPEN hereafter) allow for the 
enantioselective hydride transfer from the catalyst to the substrate. As a hydride source, 
isopropanol, an azeotropic mixture of formic acid and triethylamine (5:2) or sodium formate 
are commonly used. The reaction performs best in polar solvents such as acetonitrile, 
dichloromethane, isoproanol or water. 
The catalytic cycle is initiated by hydrogen chloride abstraction of the 18 electron metal 
chloro-complex to yield a planar 16-electron complex (Scheme M1). Hydride transfer from 
formate to the 16-electron complex yields the activated metal hydrido complex. Depending on 
the substrate, the substrate-catalyst transition state can be stabilized i) by CHπ interactions 
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between the catalyst’s arene cap and an aromatic group of the substrate and ii) by the 
formation of a 6-membered-ring arrangement between catalyst and substrate. No direct 
substrate-metal coordination is involved in the reaction mechanism (outer sphere mechanism). 
The chirality at the metal determines the chirality of the product. Besides the beneficial 
interactions between catalyst and substrate via the CHπ bond and the cyclic intermediate, 
the origins of the enantioselection stem from the repulsion of the substrate by the phenyl 
groups of the ligand. Release of the product yields the 16-electron species, which can undergo 
the next catalytic cycle.   
 
 
Scheme M1: Catalytic cycle of asymmetric transfer hydrogenation of ketone and imines with 
[(η6-benzene)Ru(S,S-TosDPEN)Cl] catalyst. The proposed transition state of the analogous 
reaction with the salsolidine precursor is depicted on the right side.57 
 
In the last two decades, numerous piano stool transition metal complexes with various chiral 
ligands have been described for the effective enantioselective reduction of many different 
ketones into the corresponding alcohols, including sterically demanding aliphatic and 
aromatic, unfunctionalized and functionalized ketones (Figure M4).54 
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Figure M4: Scope of homogenous asymmetric transfer hydrogenation of ketones with piano 
stool transition metal complexes.2,54,55  
 
In contrast, examples of organometallic catalysts for the ATH of imines to obtain chiral 
primary and secondary amines are rarer (Figure M5 and Table M1). Chiral terminal alkyl 
and aryl amines can be obtained by transition metal-catalyzed reductive amination58 or via 
formation of the N-diphenylphosphinylimines from the corresponding ketones and subsequent 
transfer hydrogenation.59 Generally, cyclic imines yield higher ees and react faster than linear 
ones.60 The homogeneous ATH of the cyclic imine salsolidine precursor in water compared to 
organic solvents is possible but requires longer reaction times (Table M1).  
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Figure M5: Scope of homogenous asymmetric transfer hydrogenation of imines with piano 
stool transition metal complexes.59,61,62 
 
 
Table M1: Homogenous asymmetric transfer hydrogenation of salsolidine precursor. 56,63–65 
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Catalyst Catalyst loading vs. 
substrate (mol%) 
Solvent Hydride 
source 
Time (h) Conv. 
(%) 
Ee (%) 
M1 0.5 CH2Cl2 
 
HCO2H/ 
Et3N 
3 99 95 (S) 
M1 0.6 H2O NaCO2H 16 90 99 (S) 
M2 1 H2O NaCO2H 24 88 92 (S) 
M3 0.5 CH3CN HCO2H / 
Et3N 
0.2 96 89 (S) 
 
 
Enzymes for Asymmetric Transfer Hydrogenation of Imines: 
Hydrolases, amine oxidases, transaminases, decarboxylases and imine reductases have been 
used to obtain chiral amines i) from racemic amines or amides, ii) from ketones or iii) from 
imines (Figure M6).59 Product formation is achieved by i) kinetic resolution, ii) dynamic 
kinetic resolution or deracemization, and iii) asymmetric synthesis.60 Using hydrolases, 
oxidases and transaminases, numerous chiral aliphatic and aromatic primary and secondary 
amines have been synthesized for academic and industrial use.  
 
Figure M6: Biocatalytic routes to chiral terminal amines.  
 
In Nature, hydrogen transfer reactions are carried out by oxidoreductases. During enzymatic 
ATH, cofactors such as NADH, NADPH, FADH2 or tetrahydrofolate act as hydride sources. 
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close proximity to the cofactor (Figure M7).66 In the holoenzyme, metals (e.g. Zn(II)) and/or 
amino acids act as general acids to increase the electophilicity of the substrate’s C=O, C=N or 
C=C double bond by hydrogen bonding. This facilitates the transfer of the coenzyme’s 
reactive hydride, which is located in close proximity to the reactive double bond. Very high 
entioselectivities (>99 % ee) are induced by the tight interaction between holoenzyme and 
substrate (Figure M7). The enantioselection is guided by the interactions of the substrate with 
the 1st and the 2nd coordination sphere around the reactive hydride. Once product and cofactor 
have been released from the enzyme, latter can be recharged with a H- by different enzymes 
such as formate-, glucose- and alcohol dehydrogenase or NDAPH-reductase, which use 
formate, sugars or electrons from water (via photosystem II and I) as electron source.53  
 
 
Figure M7: Crystal structure (PDB 1LDE) of the active site of horse liver alcohol 
dehydrogenase in complex with inhibitor N-formyl piperidine (orange). The hydride-donating 
NADPH is shown in blue, the Zn(II)Cys2His motif in grey and the inhibitor- and coenzyme-
binding residues in white.  
 
The spectrum of ketoreductases that allow asymmetric reduction of numerous aliphatic and 
aromatic ketones of commercial relevance is broad.59 The investigation of novel 
ketoreductases is achieved by i) the activity screening of microorganisms, ii) the expression 
and activity screening of reductases from metagenomes and iii) the adaptation of 
characterized ketoreductases by saturation mutagenesis or directed evolution. Common 
features of established ketoreductases are the use of cofactors NADH or NADPH, the 
application in whole cells or in purified form, the tolerance to some organic solvents and 
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elevated temperatures. Glucose dehydrogenase or formate dehydrogenase are often used to 
recycle the cofactor (Figure M8).  
For example, Hasagawe and coworkers from the company Kaneka Cooperation screened 10 
microorganisms for their activity to selectively reduce 4-chloroacetoacetate (COBE) into (R)-
4-chloro-3-hydroxybutyrate (CHBE), a synthesis precursor of the ACE inhibitor captopril.59 
Highest activity and enantioselectivity was found for the strain Candida magnolia. The 
NADPH-dependent COBE-reductase of Candida magnolia was expressed in E. coli together 
with glucose dehydrogenase for cofactor recycling. This biocatalyst yielded >99 % ee in favor 
of the R-alcohol at 55 °C in a biphasic system of water and organic solvent, which was 
subsequently used to separate the product. Furthermore, a variant of the Candida magnolia 
COBE-reductase was engineered by structure-based rational design, which was functional in 
conjunction with the cofactor NADH instead of NADPH. This allowed the coexpression of a 
formate dehydrogenase (FDH) in E. coli to recycle the cofactor with formate instead of 
glucose (Figure M8). 
  
 
Figure M8: Biocatalytic transfer hydrogenation of a ketone using an engineered alcohol 
dehydrogenase. 
 
In contrast to ketoreductases, only few examples of the biocatalytic asymmetric transfer 
hydrogenation of imines are reported and none of these processes is yet of commercial 
relevance. In these reactions whole cells as well as purified enzymes are used as catalysts 
(Figure M9). Water hydrolysis of the imine substrate limits the screening of the catalyst and 
mainly cyclic imines are used. Nagasawa and coworkers screened hundreds of yeast, fungi 
and bacterial strains for the reduction of 2-methyl-pyrroline (2-MPN).67 Only five 
streptomyces sp. strains were found to be active. An NADPH-dependent, R-selective imine 
reductase, that produces (R)-2-methyl-pyrrolidine with 99 % ee, could be isolated from the 
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cell extract by step-wise fractionation. In another example, based on the homology model of a 
leucine dehydrogenase from Bacillus stereothermophilus and the crystal structure of a 
phenylalanine dehydrogenase from Rhodococcus sp. M4, Bommarius and coworkers created 
libraries of active site mutants of the leucine dehydrogenase and tested them in the 
asymmetric reductive amination of various ketones.68 While the wild type leucine 
dehydrogenase did not yield any conversion of methylisobutylketone, the corresponding R-
amine was obtained in 99.8 % ee with mutant K68S-E114V-N261I-V291C (Figure M9). 
  
 
Figure M9: Asymmetric transfer hydrogenation of imines using whole cells and purified 
enzymes.67–71 
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Artificial Metalloenzymes for Asymmetric Transfer Hydrogenation of Imines: 
Artificial metalloenzymes can be useful to complement both organometallic- and biocatalysts 
for the asymmetric reduction of imines. Research in the Ward group has demonstrated that the 
streptavidin-biotin system can be used to create enantioselective artificial transfer 
hydrogenases (ATHase) for ketones. Based on the crystal structure of the streptavidin-biotin 
complex, different racemic biotinylated Noyori-type complexes, [(η6-benzene)Ru(Biot-L)Cl] 
and [(η6-p-cymene)Ru(Biot-L)Cl], with biotin located in ortho-, meta- and para-position of 
the phenylsulfonamide ligand, were designed and tested in the transfer hydrogenation of 
various arylalkylketones in water and in presence of the hydride source sodium formate 
(Figure M10). Various Sav mutants with mutations mainly in position 64, 112, 121 and 124 
in proximity to the assumed metal location were screened in complex with the racemic 
complexes [(η6-benzene)Ru(Biot-p-L)Cl] and [(η6-p-cymene)Ru(Biot-p-L)Cl]. While racemic 
product was formed in absence of Sav, once the cofactor was bound to Sav, the arene cap of 
the catalyst had the most dramatic effect on the enantioselectivity going from 87 % ee (R-
alcohol) to 57 % ee (S-alcohol) using substrate 4-bromoacetophenone (Figure M10). 
Additionally, the enantioselectivity was effected by the amino acid mutations: The 
enantiomeric excess of the reaction improved from 57 % to 75 % when comparing SavWT to 
the double mutant SavS112A-K121N. The strong effect on the activity and the enantioselectivity 
of i) the variation of the catalyst’s arene cap (benzene vs. p-cymene) and ii) the mutations in 
proximity to the active metal center demonstrated the contribution of the 1st and 2nd 
coordination sphere around the metal to control catalysis. The crystal structure of SavS112K in 
complex with [(η6-benzene)Ru(Biot-p-L)Cl] allowed for the rationalization of the influence of 
the arene cap and the Sav mutations.  
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Figure M10: Artificial transfer hydrogenase (PDB 2QCB, protein depicted in ribbon and MC 
as well as amino acids in stick representation) for the reduction of arylalkylketones.  
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3. A Dual Anchoring Strategy for the Localization and Activation of Artificial 
Metalloenzymes based on the Streptavidin-Biotin Technology 
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Abstract	
  
	
  Artificial	
   metalloenzymes	
   result	
   from	
   anchoring	
   an	
   active	
   catalyst	
   within	
   a	
   protein	
  environment.	
   Towards	
   this	
   goal,	
   various	
   localization	
   strategies	
   have	
   been	
   pursued:	
  covalent-­‐,	
   supramolecular-­‐	
  or	
  dative	
  anchoring.	
  Herein	
  we	
  show	
  that	
   introduction	
  of	
  a	
  suitably	
   positioned	
   histidine	
   residue	
   contributes	
   to	
   firmly	
   anchor	
   via	
   a	
   dative	
   bond	
   a	
  biotinylated	
  rhodium	
  pianostool	
  complex	
  within	
  streptavidin.	
  The	
  in	
  silico	
  design	
  of	
  the	
  artificial	
  metalloenzyme	
  was	
  confirmed	
  by	
  X-­‐ray	
  crystallography.	
  The	
  resulting	
  artificial	
  metalloenzyme	
  displays	
  	
  significantly	
  improved	
  catalytic	
  performance,	
  both	
  in	
  terms	
  of	
  activity	
   and	
   selectivity	
   in	
   the	
   transfer	
   hydrogenation	
   of	
   imines.	
   Depending	
   on	
   the	
  position	
  of	
  the	
  histidine	
  residue,	
  both	
  enantiomers	
  of	
  salsolidine	
  can	
  be	
  obtained.	
  	
  	
  
Introduction	
  	
  In	
  recent	
  years,	
  the	
  field	
  of	
  artificial	
  metalloenzymes	
  has	
  attracted	
  increasing	
  attention	
  as	
   alternative	
   to	
   the	
   more	
   traditional	
   heterogeneous-­‐,	
   homogeneous-­‐	
   and	
   enzymatic	
  catalysts.1-­‐6	
   Artificial	
   metalloenzymes	
   result	
   from	
   incorporation	
   of	
   a	
   catalytically	
  competent	
  organometallic	
  moiety	
  within	
  a	
  protein	
  scaffold.	
  Towards	
  this	
  goal,	
  covalent-­‐,	
  dative-­‐	
  and	
  supramolecular	
  anchoring	
  strategies	
  have	
  been	
  pursued.	
  We	
   and	
   others	
   have	
   been	
   relying	
   on	
   the	
   biotin-­‐(strept)avidin	
   technology	
   to	
   create	
  artificial	
   metalloenzymes.7-­‐10	
   The	
   catalytic	
   performance	
   of	
   these	
   can	
   be	
   optimized	
  relying	
   on	
   either	
   chemical-­‐	
   or	
   genetic-­‐	
  means.11	
   Recent	
   structural	
   and	
   kinetic	
   data	
   of	
  artificial	
  metalloenzymes	
  based	
  on	
  the	
  biotin-­‐streptavidin	
  technology	
  highlighted	
  that:	
  i)	
  the	
  metal	
   is	
   located	
   in	
   a	
   shallow	
   energy	
  minimum	
   resulting	
   in	
   poorly	
   localized	
  metal	
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moieties	
   (as	
   reflected	
   by	
   low	
   occupancy	
   in	
   the	
   X-­‐ray	
   structure);	
   ii)	
   the	
   presence	
   of	
  second	
   coordination	
   sphere	
   provided	
   by	
   streptavidin	
   significantly	
   influences	
   the	
  selectivity	
   of	
   the	
   resulting	
   artificial	
   metalloenzymes.12	
   In	
   contrast,	
   the	
   activity	
   (TOF,	
  TON)	
   is	
   only	
  moderately	
   affected	
   upon	
   incorporation	
   in	
   streptavidin.	
   This	
   presents	
   a	
  serious	
   limitation	
   towards	
   the	
   implementation	
   of	
   directed	
   evolution	
   protocols	
   of	
  artificial	
  metalloenzymes.	
  Indeed,	
  it	
  requires	
  the	
  precise	
  quantification	
  of	
  the	
  protein	
  as	
  any	
   non-­‐protein	
   bound	
   metal	
   would	
   lead	
   to	
   an	
   erosion	
   of	
   enantioselectivity.10	
   We	
  speculated	
  that,	
  in	
  addition	
  to	
  the	
  biotin	
  anchor,	
  a	
  properly	
  positioned	
  histidine	
  residue	
  provided	
   by	
   streptavidin	
   may	
   contribute	
   to	
   firmly	
   localize	
   the	
   metal-­‐containing	
  biotinylated	
  cofactor	
  and	
   to	
  activate	
   the	
  precatalyst,	
  Scheme	
  1.	
  Herein	
  we	
  present	
  our	
  efforts	
  towards	
  the	
  design	
  and	
  application	
  of	
  a	
  dually	
  anchored	
  artificial	
  metalloenzyme	
  for	
  the	
  reduction	
  of	
  prochiral	
  imines.	
  
	
  
Results	
  and	
  Discussion	
  
Ligand	
  Design	
  With	
  the	
  aim	
  of	
  generating	
  a	
  widely	
  applicable	
  d6-­‐pianostool	
  complex	
  for	
  a	
  variety	
  of	
  catalytic	
  applications	
  upon	
  introduction	
  in	
  streptavidin	
  (Sav	
  hereafter),	
  we	
  set	
   out	
   to	
   link	
   the	
   biotin	
   anchor	
   to	
   the	
   cyclopentadienyl	
  moiety.	
   This	
   strategy	
   leaves	
  three	
  coordination	
  sites	
  available	
   for	
   catalysis	
  and/or	
  activation	
  via	
  additional	
   ligands	
  (Scheme	
  1).	
  In	
  order	
  to	
  gain	
  a	
  semi-­‐quantitative	
  insight	
  on	
  the	
  position	
  of	
  the	
  biotinylated	
  pianostool	
  complex	
   5	
   upon	
   incorporation	
   within	
   Sav	
   and	
   which	
   amino	
   acid	
   position	
   may	
   be	
  amenable	
   to	
  bind	
  to	
   the	
  metal	
  upon	
  mutation	
  to	
  a	
  histidine,	
  docking	
  simulations	
  were	
  performed.	
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Scheme	
   1	
   Dual	
   anchoring	
   strategy	
   to	
   localize	
   and	
   activate	
   a	
   biotinylated	
   pianostool	
  catalyst	
  precursor	
  upon	
  incorporation	
  into	
  streptavidin.	
  	
  
	
  
Docking	
  Simulations	
  All	
  X-­‐ray	
  crystal	
  structures	
  containing	
  a	
  biotinylated	
  metal	
  complex	
  obtained	
  within	
  the	
  Ward	
  group	
  indicate	
  that	
  the	
  position	
  of	
  the	
  biotin	
  moiety	
  and	
  the	
  Cα	
  of	
   the	
   protein	
   is	
   essentially	
   invariant,	
   irrespective	
   of	
   the	
   nature	
   of	
   the	
  metal	
   complex	
  bound	
   to	
   biotin.12-­‐15	
   Therefore,	
   the	
   DFT-­‐optimized	
   structure	
   of	
   the	
   monomeric	
  biotinylated	
  complex	
  [η5-­‐(Biot-­‐2)RhCl2(H2O)]	
  was	
  manually	
  positioned	
  into	
  the	
  WT	
  Sav	
  (PDB	
   code	
   1MK5)	
   by	
   superimposing	
   the	
   biotin	
   anchor	
   of	
   the	
   complex	
   to	
   the	
   native	
  biotin	
  present	
  in	
  the	
  crystal	
  structure.	
  Having	
  properly	
  positioned	
  the	
  biotin	
  moiety,	
  the	
  native	
  biotin	
  was	
  deleted.	
  Simulations	
  were	
  performed	
  in	
  NAMD16	
  using	
  the	
  CHARMM27	
  force-­‐field17	
   with	
   parameters	
   developed	
   in	
   our	
   group18	
   or	
   elsewhere19	
   (See	
   SI	
   for	
  details).	
  The	
  system	
  was	
  subsequently	
  minimized	
  for	
  1000	
  Conjugate	
  Gradient	
  steps,	
  followed	
  by	
  a	
   short	
   molecular	
   dynamics	
   simulation	
   (Langevin	
   NVT	
   ensemble)	
   of	
   500	
   ps.	
   The	
  structure	
  in	
  the	
  final	
  snapshot	
  was	
  minimized	
  again	
  for	
  1000	
  steps	
  to	
  yield	
  the	
  docked	
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structure.	
  Only	
   the	
  aquo	
  complex	
   [η5-­‐(Biot-­‐2)RhCl2(H2O)]	
  and	
  atoms	
  within	
  5	
  Å	
  of	
   the	
  complex	
  were	
  allowed	
   to	
  relax	
  during	
   the	
  simulation,	
   the	
  rest	
  of	
   the	
  protein	
  was	
  kept	
  frozen.	
  The	
  resulting	
  structure	
   is	
  depicted	
   in	
  Figure	
  1	
  a.	
  With	
  respect	
   to	
   the	
  rhodium-­‐center,	
  the	
  two	
  closest	
  lying	
  Cβ   atoms	
  are	
  provided	
  by	
   S112	
  (5.62	
  Å),	
  K121	
  (6.09	
  Å	
  of	
  the	
  adjacent	
   monomer).	
   Next,	
   mutations	
   were	
   introduced	
   at	
   either	
   positions	
   S112H	
   or	
  K121H.	
  The	
  rhodium-­‐bound	
  water	
  was	
  replaced	
  by	
  a	
  bond	
   to	
   the	
  Nε	
  histidine	
  and	
   the	
  procedure	
  described	
  above	
  was	
  applied	
  yielding	
  [(η5-­‐Biot-­‐2)RhCl2]	
  5	
  ⊂	
  S112H	
  Sav	
  and	
  [(η5-­‐Biot-­‐2)RhCl2]	
  5	
  ⊂	
  K121H	
  Sav,	
  Figure	
  1	
  b	
  and	
  1	
  c	
  respectively.	
  These	
  simulations	
  thus	
  suggest	
  that	
  an	
  ethylene	
  spacer	
  between	
  the	
  Cp*-­‐	
  and	
  the	
  biotin	
  moieties	
   positions	
   the	
   metal	
   center	
   in	
   an	
   environment,	
   suitable	
   for	
   additional	
   dative	
  anchoring	
  to	
  a	
  histidine	
  side	
  chain	
  upon	
  mutation	
  of	
  either	
  S112H	
  or	
  K121H.	
  	
  
	
  
	
  
(a)	
  	
  	
   	
   	
  	
   	
  	
  (b)	
   	
   	
   (c)	
  
	
  
Figure	
  1	
  Docked	
  structure	
  of	
  [η5-­‐(Biot-­‐2)RhCl2(H2O)]	
  ⊂	
  WT	
  Sav	
  (a);	
  [(η5-­‐Biot-­‐2)RhCl2]	
  
5	
  ⊂	
  S112H	
  Sav	
  (b)	
  and	
  [(η5-­‐Biot-­‐2)RhCl2]	
  5	
  ⊂	
  K121H	
  Sav	
  (the	
  His	
  is	
  provided	
  by	
  the	
  adjacent	
  Sav	
  monomer	
  of	
  the	
  homotetrameric	
  structure)(c).	
  The	
  pianostool	
  complex	
  and	
  streptavidin’s	
   side-­‐chains	
   at	
   positions	
   112	
   and	
   121	
   are	
   displayed	
   as	
   stick	
  representation,	
   Sav	
   as	
   solvent	
   accessible	
   surface	
   (red	
   anionic-­‐,	
   blue	
   cationic-­‐	
   white	
  apolar	
  and	
  grey	
  polar	
  residues).	
  	
  
	
  
Synthesis	
   Having	
   identified	
   a	
   suitable	
   spacer	
   between	
   the	
   biotin	
   anchor	
   and	
   the	
   Cp*	
  moiety,	
  the	
  corresponding	
  d6-­‐piano	
  stool	
  complexes	
  were	
  synthesized.	
  For	
  this	
  purpose,	
  tetramethylcyclopentenone	
   1	
   was	
   used	
   as	
   starting	
   material	
   for	
   the	
   synthesis	
   of	
   the	
  cyclopentadienyl	
  precursor	
  H-­‐2	
  according	
  to	
  a	
  slightly	
  modified	
  protocol	
  of	
  Teuben	
  and	
  coworkers.20	
   Reaction	
   with	
   RhCl3·(H2O)n	
   or	
   with	
   [Ir(COD)Cl]2,	
   followed	
   by	
   an	
   in-­‐situ	
  oxidation	
  with	
   HCl	
   yielded	
   the	
   dinuclear	
   pianostool	
   complexes	
   [η5-­‐(2)RhCl2]22+	
  3	
   and	
  
	
  43	
  
[η5-­‐(2)IrCl2]22+	
   4	
   respectively.21,22	
   Subsequent	
   biotinylation	
   using	
   the	
  pentafluorophenylester	
  of	
  biotin,	
  allowed	
  the	
  isolation	
  of	
  the	
  analytically	
  pure,	
  dimeric,	
  [η5-­‐(Biot-­‐2)RhCl2]2	
  52	
  and	
  [η5-­‐(biot-­‐2)IrCl2]2	
  62	
  respectively	
  (See	
  SI	
  for	
  details).	
  	
  	
  
	
  
	
  
Scheme	
  2	
  Synthesis	
  of	
  biotinylated	
  pianostool	
  complexes	
  (a)	
  and	
  asymmetric	
  transfer	
  hydrogenation	
  conditions	
  used	
  towards	
  the	
  production	
  of	
  salsolidine	
  8	
  (b).	
  	
  
	
  
Catalysis	
  As	
  model	
  reaction	
  we	
  selected	
  the	
  asymmetric	
  transfer	
  hydrogenation	
  (ATH)	
  of	
  the	
   prochiral	
   imine	
   7	
   using	
   biotinylated	
   dimeric	
   catalyst	
   precursors	
   52	
   and	
   62.	
   This	
  reaction	
   is	
   frequently	
  used	
  as	
  a	
  benchmark	
  as	
   it	
  offers	
  a	
  straightforward	
  access	
   to	
   the	
  alkaloid	
  salsolidine	
  8	
  (Scheme	
  2c).23	
  Selected	
  results	
  are	
  collected	
  in	
  Table	
  1	
  and	
  can	
  be	
  summarized	
  as	
  follows:	
  1)	
  The	
  iridium	
  catalyst	
  precuror	
  [η5-­‐(Biot-­‐2)IrCl2]2	
  62	
   leads	
  to	
  higher	
  conversions	
  that	
  the	
   rhodium	
   congener	
   [η5-­‐(Biot-­‐2)RhCl2]2	
   52.	
   The	
   same	
   trend	
   applies	
   upon	
  incorporation	
  in	
  WT	
  Sav	
  albeit	
  with	
  reduced	
  conversions	
  (Entries	
  1-­‐4).	
  2)	
  The	
  presence	
  of	
  a	
  histidine	
  residue	
  at	
  position	
  S112	
  Sav	
  has	
  a	
  dramatic	
  effect	
  on	
  the	
  activity	
  and	
  the	
  selectivity	
  of	
  the	
  ATH.	
  	
  Salsolidine	
  8	
  is	
  produced	
  in	
  95	
  %	
  conversion	
  and	
  41	
  %	
  ee	
  (S)	
  using	
  [η5-­‐(Biot-­‐2)RhCl2]	
  5	
  ⊂	
  S112H	
  at	
  55°C	
  and	
  pH	
  6.5.	
  The	
  activity	
  and	
  the	
  selectivity	
   can	
   be	
   further	
   improved	
   upon	
   lowering	
   the	
   pH	
   to	
   5.0	
   (quantitative	
  
artificial metalloenzyme:
5 or 6 + Sav isoforms
7
N
O
O
NH
O
O
O 1. ACN, nBuLi, -80°C, 
    then HCl
2. LiAlH4, AlCl3 
3. HCl (4M in dioxane)
M = Rh: RhCl3,  n H2O
reflux, 4 days in MeOH
NH3+
M
+H3N
Cl Cl
Cl
MCl
Cl-
NH3+ Cl
-
Biot-OC6F5
Et3N, DMF
.
M
N
H
Cl Cl
Cl
M
N
H
Cl
NHO H
HN
H S
O
HN OH
NH
HS
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1 H–2:90% yield
M = Rh, 3: 85% yield
M = Ir,  4: 60% yield
M = Rh, 52: 85% yield
M = Ir,  62: 80% yield
a)
b)
MOPS buffer
HCOONa
M = Ir:  [IrCl(COD)]2, HCl
reflux, 16h in MeOH
8
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conversion	
  with	
  1	
  mol	
  %	
  catalyst	
  5	
  and	
  55	
  %	
  ee	
  (S))	
  (Table	
  1,	
  entries	
  5	
  and	
  6).	
  In	
  stark	
  contrast,	
  the	
  presence	
  of	
  a	
  histidine	
  residue	
  at	
  position	
  S112H	
  has	
  a	
  detrimental	
  effect	
  on	
  ATH	
  with	
  iridium	
  (Table	
  1,	
  entry	
  8).	
  3)	
  Introduction	
  of	
  a	
  histidine	
  residue	
  at	
  position	
  K121H	
  Sav	
  affords	
  (R)-­‐salsolidine	
  8	
  in	
  up	
   to	
   79	
   %	
   ee	
   using	
   the	
   rhodium	
   catalyst	
   at	
   55°C	
   (Table	
   1,	
   entries	
   9	
   and	
   10).	
  Unexpectedly,	
   lowering	
   the	
   temperature	
   to	
   5°C	
   leads	
   in	
   both	
   hybrid	
   catalysts	
   to	
   an	
  erosion	
  of	
  enantioselectivity	
  (Table	
  1,	
  entries	
  7	
  and	
  11).	
  Again	
  here,	
  rac-­‐8	
   is	
  produced	
  with	
  the	
  iridium	
  catalyst	
  in	
  the	
  presence	
  of	
  K121H	
  Sav.	
  4)	
  All	
  point	
  mutants	
  tested	
  devoid	
  of	
  a	
  histidine	
  at	
  either	
  position	
  S112	
  or	
  K121	
  afforded	
  nearly	
   racemic	
   salsolidine	
   8	
   (ee	
   <	
   20	
   %)	
   (Table	
   1,	
   entries	
   13-­‐18).	
   Interestingly,	
   the	
  double	
   mutant	
   S112H-­‐K121H	
   Sav	
   gave	
   very	
   low	
   levels	
   of	
   enantioselectivity,	
   Table	
   1	
  entry	
  18.	
  5)	
   Compared	
   to	
   [η5-­‐(Biot-­‐2)RhCl2]	
   5	
   ⊂ 	
   WT	
   Sav,	
   both	
   histidine	
   bearing	
   artificial	
  metalloenzymes	
  [η5-­‐(Biot-­‐2)RhCl2]	
  5	
  ⊂	
  S112H	
  Sav	
  and	
  [η5-­‐(Biot-­‐2)RhCl2]	
  5	
  ⊂	
  K121H	
  display	
  increased	
  turnover	
  frequencies:	
  1	
  hour-­‐1	
  for	
  the	
  WT	
  Sav	
  compared	
  to	
  6	
  hour-­‐1	
  for	
  both	
  S112H	
  and	
  K121H	
  mutants.	
  	
  	
  
Table	
  1	
  Selected	
  results	
  for	
  the	
  asymmetric	
  transfer	
  hydrogenation	
  of	
  prochiral	
  imine	
  7	
  catalyzed	
  by	
  a	
  dually	
  anchored	
  artificial	
  metalloenzymes.	
  	
  
Entry [(η5-Biot-L)MCl2]2 Sav 
isoform 
Temp 
(°C) 
pH M 
loading 
Conv. (%) ee (%) 
1 Rh – 55 6.5a 2% 26 rac. 
2 Ir – 55 6.5a 2% 87 rac. 
3 Rh WT 55 6.5a 2% 18 rac. 
4 Ir WT 55 6.5a 2% 60 6 (S) 
5 Rh S112H 55 6.5a 2% 95 41(S) 
6 Rh S112H 55 5.0b 1%  quant. 55(S) 
7 Rh S112H 5 5.0b 1% 5 45(S) 
8 Ir S112H 55 6.5a 2% 27 11(S) 
9 Rh K121H 55 6.5a 2% 95 50(R) 
10 Rh K121H 55 5.0b 1% quant. 79(R) 
11 Rh K121H 5 5.0b 1% 5 50(R) 
12 Ir K121H 55 6.5a 2% 37 rac. 
13 Rh S112C 55 6.5a 2% 93 14(S) 
14 Rh S112E 55 6.5a 2% 26 rac. 
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15 Rh S112K 55 6.5a 2% 40 13(S) 
16 Rh S112M 55 6.5a 2% 98 19(R) 
17 Rh K121N 55 6.5a 2% 44 rac. 
18 Rh S112H-
121H 
55 6.5a 2% 40 9 (R) 
	
  aThe	
   reaction	
   was	
   carried	
   out	
   in	
   a	
   MOPS	
   buffer	
   at	
   pH	
   6.5	
   using	
   HCOONa	
   as	
   hydride	
  source:	
   2	
   mol%	
   monomeric	
   	
   biotinylated	
   catalyst	
   5	
   or	
   6	
   (458	
   µM	
   final	
   metal	
  concentration),	
  4	
  mol	
  %	
  biotin	
  binding	
  sites	
  (916	
  µM	
  final	
  concentration)	
  and	
  substrate	
  
7	
   (22.9	
  mM	
   final	
   concentration,	
   total	
   reaction	
   volume	
  200	
  µL)	
   (See	
   SI).	
   bThe	
   reaction	
  was	
  carried	
  out	
   in	
  a	
  MOPS	
  buffer	
  at	
  pH	
  5.0	
  using	
  HCOONa	
  as	
  hydride	
  source:	
  1	
  mol%	
  monomeric	
   biotinylated	
   catalyst	
  5	
   or	
  6	
   (458	
  µM	
   final	
  metal	
   concentration),	
   2	
  mol	
  %	
  biotin	
   binding	
   sites	
   (916	
   µM	
   final	
   concentration)	
   and	
   substrate	
   7	
   (45.8	
   mM	
   final	
  concentration,	
  total	
  reaction	
  volume	
  200	
  µL)	
  (See	
  SI).	
  	
  	
  
X-­‐ray	
  Characterization	
  Next,	
  X-­‐ray	
  crystal	
  structure	
  analyses	
  were	
  carried	
  out	
  with	
  the	
  most	
   selective	
   artificial	
   metalloenzymes:	
   [(η5-­‐Biot-­‐2)RhCl2]	
  ⊂ 	
   S112H	
   and	
   [η5-­‐(Biot-­‐
2)RhCl2]	
   ⊂ 	
   K121H,	
   respectively.	
   Crystals	
   of	
   apo-­‐streptavidin	
   mutants	
   S112H	
   and	
  K112H	
  were	
  soaked	
  at	
  pH	
  6	
  with	
  an	
  excess	
  complex	
  [η5-­‐(Biot-­‐2)RhCl2]2	
  52.	
  The	
  crystal	
  structures	
  of	
  5	
  ⊂ 	
  S112H	
  and	
  5	
  ⊂K121H	
  could	
  be	
  solved	
  to	
  2.4	
  Å	
  and	
  1.8	
  Å	
  resolution,	
  respectively.	
   Both	
   structures	
   contain	
   strong	
   electron	
   density	
   in	
   the	
   Fo-­‐Fc	
  map	
   in	
   the	
  biotin-­‐binding	
   pocket	
   and	
   in	
   the	
   proximity	
   of	
   the	
   histidine	
   residue	
   either	
   at	
   position	
  H112	
  or	
  H121.	
  The	
  monomeric	
  complexes	
  [η5-­‐(Biot-­‐2)Rh]2+	
  and	
  [η5-­‐(Biot-­‐2)RhCl]+	
  were	
  modeled	
  with	
  full	
  occupancy	
  in	
  the	
  electron	
  densities	
  localized	
  around	
  H112	
  and	
  H121’	
  respectively	
   (Figure	
  2	
  and	
  SI	
  Figure	
  1).	
  As	
  highlighted	
  by	
   the	
  docking	
  simulations,	
   the	
  H121’	
  of	
  an	
  adjacent	
  monomer	
  in	
  homotetrameric	
  streptavidin	
  lies	
  closest	
  to	
  the	
  Rh	
  in	
  the	
   5	
  ⊂ 	
   K121H	
   structure,	
   Figure	
   1	
   c	
   and	
   2b.	
   Dative	
   bonds	
   were	
   modeled	
   between	
  rhodium	
   and	
   the	
   corresponding	
   histidine:	
   Rh–NδHis112	
   2.3	
   Å	
   for	
  5	
  ⊂ 	
   S112H	
   and	
   Rh–NεHis121’	
   2.3	
   Å	
   for	
   5	
   ⊂ 	
   K121H.	
   The	
   Rh····Rh	
   distances	
   between	
   two	
   biotinylated	
  molecules	
  bound	
   to	
  neighboring	
  symmetry-­‐related	
  Sav	
  monomers	
  are	
  9.5	
  Å	
  and	
  9.2	
  Å	
  for	
   5	
  ⊂	
   S112H	
   and	
   5	
  ⊂	
   K121H,	
   respectively.	
   The	
   position	
   of	
   the	
   complexes	
   in	
   the	
  S112H	
   and	
  K121H	
   isoforms	
  differs	
   by	
   an	
   approximate	
   180°	
   rotation	
   of	
   the	
   Cp*Rh(Cl)	
  group	
  along	
  an	
  axis	
  pointing	
  towards	
  the	
  biotin	
  binding	
  pocket.	
  For	
  the	
  complex	
  bound	
  to	
   S112H,	
   no	
   additional	
   electron	
   density	
   to	
   complete	
   the	
   three-­‐legged	
   pianostool	
  geometry	
  could	
  be	
  detected	
  whereas	
  the	
  presence	
  of	
  a	
  chloride	
  ligand	
  was	
  apparent	
  for	
  the	
  K121H	
  structure.	
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(a)	
   	
   	
   	
   	
   	
   (b)	
  
Figure	
  2.	
  Close-­‐up	
  view	
  of	
  the	
  X-­‐ray	
  crystal	
  structure	
  of	
  [(η5-­‐Biot-­‐2)Rh]2+	
  ⊂S112H	
  Sav	
  (a);	
   and	
   [(η5-­‐Biot-­‐2)RhCl]+	
   ⊂	
   K121H	
   Sav	
   (b).	
   The	
   protein	
   is	
   displayed	
   as	
   surface	
  representation	
   and	
   the	
   ligand	
   molecules	
   as	
   well	
   as	
   residues	
   112	
   and	
   121	
   in	
   stick	
  representation.	
  The	
  positions	
  of	
   ligand	
  molecules	
  are	
   indicated	
  by	
   the	
  2Fo-­‐Fc	
  electron	
  density	
  (blue,	
  contoured	
  at	
  1.2	
  σ)	
  and	
  anomalous	
  difference	
  density	
  (red,	
  contoured	
  at	
  4	
  
σ,	
  due	
  to	
  weak	
  absorption	
  at	
  a	
  wavelength	
  of	
  1.00	
  Å	
  no	
  anomalous	
  density	
  was	
  observed	
  in	
  structure	
  [(η5-­‐Biot-­‐2)RhCl]+⊂K121H	
  Sav).	
  Rhodium	
  is	
  colored	
  in	
  purple	
  and	
  chlorine	
  in	
   green.	
   The	
   primed	
   residues	
   (H121’	
   and	
   K121’)	
   are	
   provided	
   by	
   the	
   adjacent	
   Sav	
  monomer.	
  
	
  	
  
Outlook	
  Dual	
   anchoring	
   of	
   a	
   biotinylated	
   three-­‐legged	
   rhodium	
   pianostool	
   complex	
   affords	
   an	
  artificial	
  transfer	
  hydrogensase.	
  It	
  was	
  shown	
  that	
  coordination	
  of	
  the	
  catalyst	
  precursor	
  to	
   a	
   suitably	
   positionned	
   histidine	
   residue	
   has	
   a	
   significant	
   impact	
   on	
   the	
   catalyst’s	
  performance,	
   both	
   in	
   terms	
   of	
   activity	
   and	
   of	
   selectivity.	
   The	
   computational	
   design	
  towards	
  the	
  identification	
  of	
  the	
  spacer-­‐length	
  and	
  site	
  of	
  mutation	
  was	
  confirmed	
  by	
  X-­‐ray	
  crystallography	
  for	
  the	
  most	
  selective	
  artificial	
  metalloenzymes	
  [η5-­‐(Biot-­‐2)RhCl2]	
  5	
  
⊂	
  K121H	
  and	
   [η5-­‐(Biot-­‐2)RhCl2]	
  5	
  ⊂	
   S112H.	
  Current	
   efforts	
   are	
   aimed	
  at	
   computing	
  the	
   transition	
   state	
   to	
   identify	
   and	
   engineer	
   additional	
   second	
   coordination	
   sphere	
  interactions	
   to	
   improve	
   the	
   catalytic	
   performance	
   of	
   these	
   dually-­‐anchored	
   artificial	
  metalloenzymes.	
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X-­‐ray	
  Crystal	
  Structures	
  Protein	
   Crystallization	
   and	
   Biotinylated	
   Complex	
   Soaking.	
   Crystals	
   of	
   streptavidin	
  mutants	
   Sav	
  K121H	
  and	
   Sav	
   S112H	
   (residues	
  13-­‐159	
  of	
  mature	
   streptavidin	
   fused	
  N-­‐terminally	
  to	
  the	
  12	
  residues	
  of	
  a	
  T7-­‐tag)15	
  were	
  obtained	
  within	
  one	
  month	
  by	
  hanging-­‐drop	
   vapor	
   diffusion	
   technique	
   mixing	
   2	
   µL	
   crystallization	
   buffer	
   (0.1	
   M	
   MES,	
   19	
   %	
  PEG500,	
  pH	
  6.0)	
  and	
  3	
  µL	
  protein	
  solution	
  (20	
  mg/mL	
  in	
  water)	
  prior	
  to	
  equilibration	
  of	
  the	
   solution	
   against	
   a	
   reservoir	
   of	
   500	
   µL	
   crystallization	
   buffer.	
   Subsequently,	
   single	
  crystals	
  of	
  mutants	
  Sav	
  K121H	
  and	
  Sav	
  S112H	
  were	
  soaked	
  for	
  4	
  h	
  at	
  room	
  temperature	
  in	
   a	
   soaking	
  buffer,	
  which	
  was	
  prepared	
  by	
  mixing	
  1	
  µL	
  of	
   a	
  10	
  mM	
  stock	
   solution	
  of	
  complex	
  52	
   ([η5	
  -­‐(Biot-­‐2)RhCl2]2)	
   in	
  dimethyl	
   formamide	
  and	
  9	
  µL	
  crystallization	
  buffer.	
  After	
  the	
  soaking,	
  crystals	
  were	
  shock-­‐frozen	
  in	
  liquid	
  nitrogen.	
  	
  Data	
  Processing	
  and	
  Refinement.	
  X-­‐ray	
  diffraction	
  data	
  were	
  collected	
  at	
  the	
  Swiss	
  Light	
  Source	
  beam	
  line	
  X06DA	
  and	
  processed	
  with	
  software	
  XDS16	
  or	
  MOSFLM	
  (CCP4	
  Suite)17.	
  The	
  structures	
  were	
  solved	
  by	
  molecular	
  replacement	
  using	
  program	
  PHASER18	
  (CCP4	
  Suite)	
   and	
   the	
   structure	
   2qcb	
   from	
   the	
   PDB	
   as	
   model	
   input	
   with	
   ligand	
   and	
   water	
  molecules	
   removed.	
   For	
   structure	
   refinement	
   PHENIX.REFINE19	
   was	
   used.	
  Crystallographic	
  details	
  are	
  given	
  in	
  Supporting	
  Table	
  1.	
  Structural	
  figures	
  were	
  drawn	
  with	
  software	
  DINO.	
  The	
  structures	
  were	
  deposited	
  in	
  the	
  pdb	
  repository	
  with	
  the	
  codes	
  4GJS	
   and	
   4GJV	
   for	
   [η5-­‐(Biot-­‐2)RhCl]+	
   ⊂ 	
   K121H	
   and	
   [η5-­‐(Biot-­‐2)Rh]2+	
   ⊂ 	
   S112H	
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respectively.	
  	
  Supporting	
  Table	
  1:	
  Summary	
  of	
  data	
  processing	
  and	
  refinement.	
  	
  
 Data	
  processing  Complex [η5-­‐(Biot-­‐2)RhCl]+	
  	
  	
  	
  	
  	
  	
  	
  	
  K121H [η5-­‐(Biot-­‐2)Rh]2+	
  ⊂	
  S112H Wavelength	
   of	
   X-­‐ray	
  experiment	
  (Å) 1.00 1.55 Software MOSFLM XDS Resolution	
  (Å) 40.80	
  -­‐	
  1.85 150.00	
  -­‐	
  2.40 Space	
  group C2 I4122 Cell	
  dimensions	
  (Å) a=81.7,	
   b=81.3,	
  c=47.0,	
  β=104.8 a=57.6,	
   b=57.6,	
  c=183.8 Rmerge 8.1	
  (18.5) 9.8	
  (79.2) No	
  unique	
  reflections 24972 10085 Multiplicity 2.7 3.4 I/sig(I) 6.0	
  (2.3) 10.3	
  (1.6) Completeness	
  (%) 98.5	
  (96.3) 86.2	
  (73.2) CC	
  (1/2) n/d 62.5	
   Refinement  Resolution	
  (Å) 28.32	
  -­‐	
  1.85 19.88	
  -­‐	
  2.40 	
  Rwork/Rfree	
  (%) 20.3	
  (25.0) 18.5	
  (23.0) RMSDbond	
  (Å) 0.007 0.032 RMSDangle	
  (deg) 1.365 1.121 Bfactor	
  	
  	
  	
  all	
  atoms	
  	
  	
  solvent	
  	
  [η5-­‐(Biot-­‐2)RhCl]+	
  /[η5-­‐(Biot-­‐2)Rh]2+ 
	
  23	
  33	
  32 
	
  36	
  33	
  44 Values	
  in	
  brackets	
  refer	
  to	
  the	
  highest	
  resolution	
  shell	
  	
  	
  	
  
Structure	
  of	
  [η5-­‐(Biot-­‐2)RhCl]+	
  ⊂ 	
  Sav	
  K121H	
  There	
  are	
  two	
  streptavidin	
  monomers	
  in	
  the	
  asymmetric	
  unit	
  from	
  which	
  a	
  tetramer	
  can	
  be	
   formed	
   by	
   application	
   of	
   the	
   crystallographic	
   2-­‐fold	
   symmetry	
   axis	
   parallel	
   b	
  (Supporting	
   Figure	
   1a).	
  The	
  12	
  N-­‐terminal	
   residues	
  of	
   the	
  T7-­‐tag	
  and	
  25	
  residues	
  at	
  the	
   C-­‐terminus	
   are	
   not	
   resolved,	
   probably	
   due	
   to	
   disorder.	
   Strong	
   residual	
   electron	
  density	
  in	
  the	
  Fo-­‐Fc	
  omit	
  map	
  was	
  present	
  in	
  the	
  biotin	
  binding	
  pocket	
  and	
  its	
  vestibule	
  reaching	
  to	
  residue	
  His121’	
  of	
  the	
  neighboring	
  SAV	
  monomer	
  suggesting	
  the	
  cleavage	
  of	
  Rh-­‐dimer	
  52	
  upon	
  binding	
  to	
  Sav	
  K121H.	
  The	
  initial	
  ligand	
  model	
  to	
  be	
  fit	
  in	
  the	
  residual	
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electron	
  density	
  comprised	
  a	
   rhodium-­‐bound	
  pentamethylcyclpentadienyl	
   ring	
   (Cp*Rh	
  group),	
  which	
  was	
   covalently	
   attached	
   to	
   biotin	
   via	
   an	
   ethylene	
   spacer	
   and	
   an	
   amide	
  bond.	
   The	
   geometry	
   of	
   the	
   [η5-­‐(Biot-­‐2)Rh]2+	
   moiety	
   was	
   derived	
   from	
   the	
   X-­‐ray	
  structure	
  of	
  the	
  closely	
  related	
  small	
  molecule	
  rhodium	
  complex	
  1-­‐(4-­‐nitrophenyl)-­‐1H-­‐imidazol-­‐3-­‐yl)-­‐dichloro-­‐(η5-­‐pentamethylcyclopentadienyl)-­‐rhodium	
  (CSD	
  code	
  FACHEY,	
  
Supporting	
   Figure	
   1e,	
   right	
   side).	
   Ligand	
   restraints	
   were	
   adapted	
   manually	
   using	
  software	
  REEL	
  (PHENIX	
  package).	
  The	
  biotin	
  moiety	
  is	
  bound	
  to	
  the	
  streptavidin	
  pocket	
  as	
  described	
  by	
  Weber	
  et	
  al.20	
  An	
  H-­‐bond	
  is	
  formed	
  between	
  the	
  ligand’s	
  carbonyl	
  group	
  and	
  the	
  backbone	
  nitrogen	
  of	
  residue	
  N49.	
  Due	
  to	
  structural	
  heterogeneity,	
  the	
  ethylene	
  spacer	
  and	
  portions	
  of	
  the	
  aromatic	
  5-­‐membered	
  ring	
  of	
  complex	
  [η5-­‐(Biot-­‐2)Rh]2+	
  are	
  not	
  properly	
  resolved	
  in	
  the	
  electron	
  density	
  (Supporting	
  Figure	
  1b).	
  The	
  position	
  of	
  the	
   rhodium	
   atom	
   as	
   bound	
   to	
   the	
   Cp*	
   ring	
   is	
   well	
   defined	
   by	
   the	
   strong	
   residual	
  positive	
  electron	
  density	
  signal	
  (12	
  σ)	
  in	
  bonding	
  distance	
  (2.3	
  Å)	
  to	
  the	
  Nε	
  of	
  His121’	
  of	
  the	
   neighboring	
   SAV	
   monomer.	
   Close	
   to	
   the	
   metal,	
   residual	
   density	
   suggested	
   the	
  presence	
   of	
   an	
   additional	
   chloride	
   ligand.	
   There	
   is	
   no	
   density	
   at	
   the	
   third	
   rhodium	
  coordination	
  site.	
  In	
  the	
  refinement,	
  bond	
  angles	
  Cp*centroid-­‐Rh-­‐Cl,	
  Cp*centroid-­‐Rh-­‐NεH121’	
  and	
  Cl-­‐Rh-­‐NεH121’	
  were	
  restrained	
  to	
  the	
  values	
  given	
  by	
  the	
  X-­‐ray	
  structure	
  of	
  the	
  related	
  small	
  molecule	
  pianostool	
  complex	
  with	
  CSD	
  code	
  FACHEY	
  (Supporting	
  Figure	
  1e).	
  	
  Strong	
  density	
  (11	
  σ)	
  was	
  found	
  in	
  the	
  Fo-­‐Fc	
  map	
  close	
  to	
  His127	
  and	
  was	
  modeled	
  as	
  a	
  rhodium	
   ion	
   covalently	
   attached	
   to	
   the	
   histidine-­‐Nε,	
   suggesting	
   the	
   binding	
   of	
   an	
  additional	
  rhodium,	
  due	
  to	
  the	
  use	
  of	
  a	
  large	
  excess	
  biotinylated	
  complex	
  52	
  for	
  soaking.	
  Finally,	
  the	
  structure	
  contains	
  328	
  water	
  molecules.	
  	
  	
  
Structure	
  of	
  [η5-­‐(Biot-­‐2)Rh]2+	
  ⊂ 	
  Sav	
  S112H	
  There	
  is	
  one	
  streptavidin	
  molecule	
  in	
  the	
  asymmetric	
  unit.	
  The	
  SAV	
  tetramer	
  is	
  obtained	
  by	
  application	
  of	
  the	
  crystallographic	
  dyads	
  parallel	
  to	
  c	
  and	
  along	
  the	
  a-­‐b	
  diagonal.	
  As	
  in	
  the	
   structure	
   of	
   complex	
   [η5-­‐(Biot-­‐2)RhCl]+	
  ⊂	
   Sav	
   K121H,	
   12	
   N-­‐terminal	
   and	
   25	
   C-­‐terminal	
  amino	
  acids	
  are	
  not	
  resolved.	
  Strong	
  residual	
  electron	
  density	
  in	
  the	
  Fo-­‐Fc	
  omit	
  map	
  was	
   evident	
   in	
   the	
   biotin-­‐binding	
   pocket	
   and	
   its	
   vestibule	
   close	
   to	
   the	
   imidazole	
  ring	
  of	
  His112	
  of	
  the	
  same	
  subunit	
  (Supporting	
  Figure	
  2c).	
  As	
  expected	
  from	
  the	
  small	
  f’’	
  (3.6	
  e-­‐)	
  of	
  Rh	
  at	
  the	
  employed	
  wavelength,	
  only	
  a	
  weak	
  peak	
  (5.3	
  σ)	
  in	
  the	
  anomalous	
  difference	
  map	
  was	
   found	
   in	
   the	
  vestibule	
   in	
   the	
  same	
  position	
  close	
   to	
  residue	
  H112.	
  Complex	
  [η5-­‐(Biot-­‐2)Rh]2+	
  was	
  modeled	
  in	
  the	
  densities	
  (Supporting	
  Figure	
  2d).	
  As	
  in	
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the	
  structure	
  of	
   [η5-­‐(Biot-­‐2)RhCl]+	
  ⊂	
  Sav	
  K121H,	
   the	
  ethylene	
  spacer	
  and	
  the	
  methyl-­‐substituted	
   5-­‐membered	
   ring	
   of	
   complex	
   [η5-­‐(Biot-­‐2)Rh]2+	
   are	
   not	
   resolved	
   in	
   the	
  electron	
  density.	
  The	
  distance	
  between	
  the	
  Cp*-­‐bound	
  Rh	
  and	
  NδH112	
  is	
  2.3	
  Å	
  indicating	
  a	
  coordinative	
  bond.	
  No	
  further	
  electron	
  density	
  was	
  detected	
  in	
  the	
  coordination	
  sphere	
  of	
  the	
  rhodium.	
  However,	
  the	
  positions	
  are	
  likely	
  to	
  be	
  occupied	
  by	
  two	
  water	
  molecules,	
  which	
   would	
   give	
   rise	
   to	
   a	
   pianostool-­‐type	
   of	
   ligand	
   coordination	
   sphere	
   around	
   the	
  metal.	
  	
  	
  Additional	
  strong	
  electron	
  density	
  in	
  the	
  Fo-­‐Fc	
  omit	
  map	
  was	
  found	
  next	
  to	
  the	
  following	
  protein	
  nitrogen	
  atoms:	
  backbone	
  G48(N)	
  (5	
  σ),	
  K80(Nζ)	
  (3	
  σ),	
  R84(Nη)	
  (7	
  σ),	
  H87(Nε)	
  (7	
  σ)	
  and	
  H127(Nε)	
  (14	
  σ,	
  4.6	
  σ	
  peak	
  in	
  anomalous	
  scattering	
  density).	
  A	
  rhodium	
  atom	
  was	
  modeled	
  next	
  to	
  His127	
  and	
  chloride	
  in	
  all	
  other	
  positions.	
  	
  Again	
  here	
  this	
  is	
  most	
  probably	
  due	
  to	
  the	
  use	
  of	
  a	
  large	
  excess	
  biotinylated	
  complex	
  52	
  for	
  soaking	
  purposes.	
  Besides	
   these	
   ligands,	
   the	
   structure	
   contains	
   23	
   water	
   molecules.	
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Supporting	
   Figure	
   1:	
   X-­‐ray	
   structures	
   of	
   [η5-­‐(Biot-­‐2)RhCl]+	
  ⊂	
   K121H	
   and	
   [η5-­‐(Biot-­‐
2)Rh]2+	
  ⊂	
   S112H.	
   a)	
  Top	
  view	
  of	
   two	
  cis-­‐related	
  biotin-­‐binding	
  pockets	
  of	
   tetrameric	
  complex	
  [η5-­‐(Biot-­‐2)RhCl]+	
  ⊂	
  K121H	
  in	
  surface	
  representation	
  (red:	
  acidic	
  amino	
  acids,	
  blue:	
   basic	
   amino	
   acids).	
   The	
   2Fo-­‐Fc	
   map	
   covering	
   complex	
   [η5-­‐(Biot-­‐2)RhCl]+	
   and	
  His121	
  is	
  contoured	
  at	
  1.2	
  σ.	
  b)	
  Close-­‐up	
  view	
  of	
  the	
  ligand	
  binding	
  site	
  of	
  complex	
  [η5-­‐(Biot-­‐2)RhCl]+	
  ⊂	
  K121H.	
  c)	
  [η5-­‐(Biot-­‐2)Rh]2+	
  ⊂	
  S112H,	
  view	
  as	
  in	
  a).	
  d)	
  Close-­‐up	
  view	
  of	
   complex	
   [η5-­‐(Biot-­‐2)Rh]2+	
   ⊂ 	
   S112H.	
   Significant	
   anomalous	
   scattering	
   density	
  (contoured	
  at	
  4	
  σ,	
  red)	
  indicates	
  the	
  position	
  of	
  the	
  rhodium.	
  e)	
  Comparison	
  of	
  the	
  piano	
  stool	
   structures	
   of	
   complex	
   [η5-­‐(Biot-­‐2)RhCl]+	
   as	
   bound	
   to	
   Sav	
   K121H	
   (left)	
   and	
   CSD	
  ligand	
   FACHEY	
   (right).	
   Green	
   and	
   blue	
   colored	
   numbers	
   indicate	
   bond	
   distances	
   and	
  angles,	
   respectively	
   (numbers	
   in	
   parentheses	
   refer	
   to	
   symmetry-­‐related	
   ligand	
   [η5-­‐(Biot-­‐2)RhCl]+	
  in	
  same	
  asymmetric	
  unit).	
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3.2. Comment on Publication 
3.2.1. Towards the Directed Evolution of Artificial Transfer Hydrogenases 
Artificial metalloenzymes are an emerging alternative to asymmetric homogenous- and 
biocatalysts to obtain chiral building blocks, although to date their use is limited to academic 
research. In the previous chapter an artificial transfer hydrogenase for the asymmetric 
reduction of a cyclic imine with very high enantioselectivity and turnover number (TON = 
4000) was reported. To date, it has been shown in numerous examples that the chemical and 
genetic optimization of artificial metalloenzymes based on the streptavidin-biotin technology 
is possible. The scope of this technology can be further expanded by the use of high-
throughout screening methods such as directed evolution.  
The following requirements have to be fulfilled to do directed evolution with streptavidin 
mutants and biotinylated metal catalysts in vivo: 
• the stability of the MC in a cellular matrix  
• the binding of the MC to Sav in a cellular matrix 
• a protein accelerated activity of Sav-MC complex  
• a high-throughput screening method with high sensitivity, e.g. HPLC analysis of the 
products. 
 
Many biotinylated metal complexes tested so far lose activity upon binding to Sav (a 
noteworthy exception is the C-H activating AME38). This is a significant limitation to the 
application of directed evolution optimization protocols since the background activity of the 
free cofactor is high and Sav-bound MC would not be detectable by increased product 
formation.  
One strategy to accelerate the activity of a Sav-bound biotinylated metal complex would be to 
engineer an amino acid side chain (e.g. histidine) in proximity to the metal, which can 
coordinate to the metal. Locking the catalyst may have a beneficial effect on the activity and 
selectivity due to i) improved interactions between a well-defined (as compared to a flexible) 
catalyst-1st and -2nd coordination sphere and the substrate and ii) by variation of the electronic 
properties of the metal (ligand-accelerated catalysis).  
Different anchoring strategies of functional metal complexes in rigid protein scaffolds have 
been described to create artificial metalloenzymes: covalent, supramolecular and dative 
anchoring. So far the supramolecular strategy based on the streptavidin-biotin technology was 
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shown to give the most active and selective AMEs for asymmetric catalysis.6 This study will 
give interesting information about the compatibility and potential positive effects of a 
combination of supramolecular and dative anchoring. 
Strong ligand accelerating effects have been demonstrated for a number of bidentate ligands 
(e.g. TosEN) in the transfer hydrogenation of ketones and imines with Noyori-type Ru-
benzene, Ru-p-cymene, IrCp* or RhCp* catalysts.56 The energy of the transition state seems 
to be lowered in presence of an acidic terminal aminoproton as of the TosEN ligand (Scheme 
M1). However, moderate ligand acceleration was also observed with monodentate tertiary 
amines and 2,2’-bipyridyl, which lack acidic protons.  
A Noyori type IrCp* complex can be biotinylated at the arene cap. Upon anchoring of such a 
complex to SavWT, the IrCp* unit would have three vacant coordination sites and would be 
loosely positioned in the vestibule of the biotin binding pocket (Scheme 2_1). An engineered 
histidine in proximity to the metal can occupy one coordination site. A positive effect on the 
activity and enantioselectivity of the reaction may result through the high effective molarity of 
the imidazole ligand. 
 
3.2.2. Substrate Binding Models and Potential Influence of the 1st and 2nd 
Coordination Sphere on Catalysis   
Based on the crystal structures of complexes (SavK121H-[η5-(Biot-2_2)RhClL2]+) and 
(SavS112H-[η5-(Biot-2_2)RhL3]2+) and the information about the stereochemistry of the 
products preferentially formed by these hybrid catalysts, qualitative models for the substrate 
binding to the ATHases can be proposed (Figure M11).  
 
Figure M11: Model of salsolidine precursor binding to SavS112H-[η5-(Biot-2_2)RhL3]2+ (left) 
and SavK121H-[η5-(Biot-2_2)RhClL2]+ (right). The metallocofactor is represented in grey and 
H112
H112*
H121
H121*
N49
N118*
N118* A65-S69
N49
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the salsolidine precursor in purple. Green numbers indicate residues, which are potentially 
interesting for mutagenesis.  
 
In both structures the RhCp*-unit of the cofactor is located in the vestibule of the biotin-
binding site close to the surface of the protein. Upon cofactor binding to both Sav mutants, 
shallow depressions are formed, which are defined by protein residues within loops 45-51, 64-
71, 112-118 and the arene cap of the cofactors. From the substrate modeling we conclude that 
only few and unspecific interactions exist between substrate and protein, while the arene cap 
of the cofactor is likely to contribute strongly to design the pose of the substrate binding. 
Thus, we speculate that the 1st coordination sphere has a greater impact on activity and 
selectivity than the 2nd coordination sphere (although in the first place the protein defines the 
cofactor position). Further experiments are needed to support this hypothesis. Mutations in 
proximity to the assumed substrate-binding site (in addition to either S112H or K121H) can 
help to elucidate the influence of the 2nd coordination sphere. The following amino acid 
positions would be of special interest due to their close proximity to the presumed substrate 
binding sites (Figure M11):  
• double or triple mutants of SavK121H: saturation mutatagenesis in positions Asn49, 
Gly48 (part of loop 45-51) and Asn118 (part of loop 112-118) 
• double or multiple mutants of SavS112H: Asn49 (part of loop 45-51), Ala65, Asp67, 
Ser69 (part of loop 64-71) and Asn118 (part of loop 112-118)  
 
Additionally would the application of other piano stool complexes (e.g. biotinylation of 
benzene or p-cymene instead of Cp*) help to elucidate the impact of the 1st coordination 
sphere and the metal on catalysis. Computational docking studies may help to obtain a 
quantitative model of the substrate binding to the complexes and rationalize the different 
activities and enntioselectivities. 
 
3.2.3. Comparison of a Mono- and a Bis-Anchored Metallocofactor-Streptavidin 
Complex for Artificial Transfer Hydrogenation 
The activity and enantioselectivity of the best R-selective dual-anchor ATHase (SavK121H-[η5-
(Biot-2_2)RhClL2]+) is lower than that of the best mono-anchor ATHase mentioned in the 
previous chapter, SavS112A-[Cp*Ir(Biot-p-L)Cl] (Table M2).  
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Table M2: Comparison of performance of SavS112A-[Cp*Ir(Biot-p-L)Cl], SavK121H-[η5-(Biot-
2_2)RhClL2]+ and SavS112H-[η5-(Biot-2_2)RhL3]2+. 
Entry 1 2 3 
ATHase SavS112A-[Cp*Ir(Biot-p-
L)Cl] 
SavK121H-[η5-(Biot-
2_2)RhClL2]+ 
SavS112H-[η5-(Biot-
2_2)RhL3]2+ 
Reaction conditions - 1 mol% complex 
- 0.33 mol% SavS112A  
  tetramer 
- 69.0 mM** substrate 
- 3.65 M HCO2Na 
- 2.9 M MOPS 
- pH 6.5, 55 °C, 2 h 
- 2 mol% complex 
- 1 mol% SavS112A  
  tetramer 
- 22.9 mM substrate 
- 3.8 M HCO2Na 
- 3.1 M MOPS 
- pH 6.5, 55 °C, 12 h 
- 2 mol% complex 
- 1 mol% SavS112A  
  tetramer 
- 22.9 mM substrate 
- 3.8 M HCO2Na 
- 3.1 M MOPS 
- pH 6.5, 55 °C, 12 h 
Ee (%) 85 (R) 50 (R) Rac.  
Convers.(%) 100 95 37 
TON 100 48 19 
Approx. TOF (h-1)* 50  4 2 
*TON divided by number of hours reaction time 
**Note, the substrate concentrations in entries 2 and 3 are 0.33x that of entry 1 and the 
catalyst concentrations are 0.66x that of entry 1 
 
The most prominent differences between the two hybrids (entry 1 and 2 Table M2) concern i) 
the central metal (Ir vs. Rh), ii) the 1st coordination sphere around the functional metal 
(monodentate histidine vs. bidentate TosEN ligand) and iii) the 2nd coordination sphere 
(Figure M12).  
 
 
Figure M12: Superimposition of the crystal structures of the dual-achor ATHase SavK121H-
[η5-(Biot-2_2)RhClL2]+ (surface model and grey stick model) and  the mono-anchor ATHase 
SavS112A-[Cp*Ir(Biot-p-L)Cl] (purple stick model). 
H121 H121*
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Influence of Metal in the Artificial Transfer Hydrogenation: 
Xiao and coworkers have investigated the influence of the metal by comparing the scope of 
the equivalent complexes [Cp*Rh(TosDPEN)Cl] and [Cp*Ir(TosDPEN)Cl] in the ATH of 
ketones and imines in aqueous conditions with sodium formate as hydrogen source. Although 
on average, the rhodium complex is the better catalyst with respect to the reaction rate, the 
turnover number and the enantioselectivity of the reduction of ketones,72 this can change in 
favor of the iridium catalyst when an imine instead of a ketone is employed as substrate.73 In 
case of the dual-anchor ATHase, application of the iridium instead of the rhodium complex in 
SavK121H leads to an erosion of activity and selectivity (Table 2_1, entry 9 and 12). For the 
mono-anchored complex SavS112A-[Cp*Ir(Biot-p-L)Cl], however, employment of the rhodium 
complex led to a slightly lower enantioselectivity and activity profile (Table 1_1, entry 3 and 
4) and, thus, the Rh-cofactor was not tested with any further mutants. In conclusion, the effect 
of the metal, even though it can be very drastic, is hard to predict and, thus, testing different 
metals can be considered a good advice in artificial metalloenzyme design.  
 
Influence of the 1st and the 2nd Coordination Sphere in Artificial Transfer 
Hydrogenation: 
Noyori has reported a nearly 5 fold difference in reaction rate comparing complexes [(η6-
benzene)Ru(TosEn)Cl] (TOF 86 h-1) and [(η6-benzene)Ru(2,2’-bipyridyl)Cl]+ (TOF 18 h-1). 
In complex with Sav, the two different biotinylated complexes SavS112A-[Cp*Ir(Biot-p-L)Cl] 
and SavK121H-[η5-(Biot-2_2)RhClL2]+ follow the same trend.  
In summary, the bidentate biotinylated TosEN ligand, which contains a terminal acidic amine 
proton, is the better cofactor inside Sav compared to the monodentate arene-biotinylated 
cofactor.  
 
3.2.4. Compatibility of a Dual-Anchor Artificial Transfer Hydrogenase with in Vivo 
Screening  
Given that this concept meets one of the basic requirements to perform directed evolution – 
the cofactor activity is accelerated upon binding to SavS112H/SavK121H – initial experiments of 
the ATH of the salsolidine precursor in nearly physiological conditions were carried out by 
Elisa Nogueira and Yvonne Wilson. The following samples were used: i) Sav purified by 
selective precipitation from cell extracts, ii) Sav purified from cell extracts by filtration of 
Sav-bound biotin beads and iii) cell free extracts. Unfortunately, the high activity and 
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enantioselectivity obtained with Sav mutants purified by affinity chromatography could not be 
reproduced with any of the crude Sav preparations.  
Three major problems have been pointed out that hamper the application of in vivo screening 
with the streptavidin-biotin technology:  
• the inactivation of piano stool complexes by cellular thiol compounds (e.g. 
glutathione) 
• the occupation of the biotin-binding sites of Sav expressed in E. coli with intrinsic 
biotin and 
• the transportation of piano stool complex into the cytosol. 
 
Currently, different strategies are followed in the Ward group to address these problems.  
 
3.2.5. Further Applications of Arene-Biotinylated Piano Stool-Streptavidin Complexes 
Upon binding to SavWT, a transition metal piano stool complex, which is biotinylated at the 
arene cap possesses three vacant coordination sites at the metal. Since in the ATH of ketones, 
imines and alkenes only one coordination site is required to form the active metal hydrido 
complex, the remaining two positions can be occupied by mono- or bidentate ligands. Instead 
of the tedious synthesis of biotinylated transition metal complexes, addition of a pool of 
commercially available ligands would be sufficient for the formation and screening of an 
ATHase library. Research towards this end is currently followed in the Ward group. 
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4. OsO4·Streptavidin: A Tunable Hybrid Catalyst for the Enantioselective cis-
Dihydroxylation of Olefins 
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OsO4·Streptavidin: ATunable Hybrid Catalyst for the Enantioselective
cis-Dihydroxylation of Olefins**
Valentin Kçhler, Jincheng Mao, Tillmann Heinisch, Anca Pordea, Alessia Sardo,
Yvonne M. Wilson, Livia Knçrr, Marc Creus, Jean-Christophe Prost, Tilman Schirmer,* and
Thomas R. Ward*
Enzymatic and homogeneous catalysis have evolved inde-
pendently to address the challenges in the synthesis of
enantiopure products. With the aim of complementing these
fields, artificial metalloenzymes, which combine the structural
diversity of biocatalysts with the wealth of metal-catalyzed
reactions, have attracted increasing attention.[1] In homoge-
neous catalysis the cis-selective, OsO4-dependent asymmetric
dihydroxylation (AD) of olefins ranks among the most
powerful methods for the synthesis of vicinal diols. Ligands
for homogeneous catalysis have been largely developed by
Sharpless and co-workers, and are, with few exceptions,
almost exclusively based on quinidine or quinine deriva-
tives.[2] Although most classes of prochiral olefins are
dihydroxylated with good activity and selectivity, the cis-
substituted olefins are problematic. Nature relies on non-
heme iron dioxygenases such as naphthalene dioxygenase
(NDO) to perform a related reaction. These enzymes display
broad substrate scope.[3] It is believed that both the OsO4- and
NDO-catalyzed dihydroxylations proceed by an outer sphere
[3+2] mechanism in which the substrate is not bound to the
metal in the transition state (Figure 1).[2a,f, 3c]
Considering a biomimetic approach, we hypothesized that
anchoring a catalytically competent OsVIII center within a
protein might afford an artificial metalloenzyme for the AD
of olefins. Encouraged by a report by Kokubo et al.,[2d] we set
out to screen various proteins and to test whether the
resulting dihydroxylases could be optimized by genetic
means.
Five proteins were evaluated as hosts for the AD of a-
methylstyrene: Wild-type streptavidin (SAV) clearly per-
formed best. In contrast, bovine serum albumin (BSA)
yielded the opposite enantiomer, albeit with a low turnover
number (Table 1). In view of the size of the proteins (66 kDa
for BSA and 16 kDa for the SAV monomer), the difficult
recombinant production of BSA,[4] and the number of
Figure 1. Postulated transition-state structure for the dihydroxylation of
olefins: a) for the naphthalene dioxygenase; b) for the osmium-cata-
lyzed AD of prochiral olefins; and c) for an artificial cis-dihydroxylase
resulting from anchoring of OsO4 within a host protein.
Table 1: Identification of a suitable host for the AD of a-methylstyrene in
the presence of OsO4.
[a]
Entry Protein ee [%][b] TON[c]
1[d] avidin 2 (R) 16
2 BSA 77 (S) 4
3[e] lysozyme 5 (S) 6
4[f ] human carbonic anhydrase II 25 (S) <1
5[g] SAV 95 (R) 27
[a] Reactions were carried out with 6 mmol substrate in a total reaction
volume of 0.2 mL. [b] ee value determined by HPLC on a chiral stationary
phase; absolute configuration assigned by comparison with literature
data. [c] Determined by reverse-phase HPLC with internal standard.
TON=mol product per mol K2[OsO2(OH)4]. [d] Some precipitation was
observed at the end of the run. [e] Immediate precipitation occurred
upon addition of K2CO3/K3[Fe(CN)6]/K2[OsO2(OH)4] stock solution to
the protein stock solution. [f ] Protein was not fully soluble. [g] Average of
two independent runs.
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was funded by the Swiss National Science Foundation (Grant
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histidine residues in BSA (17 His for BSA vs. 2 His per SAV
monomer), SAV was selected as the host for further studies.
Next, a range of substrates was subjected to AD in the
presence of SAV.With the exception of indene and precocene
I, all the substrates produced the same enantiomer as with the
quinidine scaffold in the Sharpless AD (i.e. AD-mix-b).[2a,h–l]
Although some substrates were converted with a low to
moderate ee value, both cis-b-methylstyrene and a-methyl-
styrene were dihydroxylated with good selectivity (Table 2).
The expected syn specificity of the reaction was demonstrated
unambiguously (i.e. 1% or less anti product detected) by
comparison of the dihydroxylation products of cis-b-methyl-
styrene and trans-b-methylstyrene (see Supporting Informa-
tion).
To investigate the fate of SAV under the oxidizing
conditions, the reaction mixture was subjected to SDS-
PAGE after catalysis, and a remaining biotin-binding capa-
bility was revealed by biotin-4-fluorescein staining of the gel.
As the ee value remained constant over the course of the
reaction, we concluded that any decomposition pathway of
the catalyst leads to species with strongly reduced activity (see
Supporting Information).
Addition of 1.05 equivalents of biotin per SAV monomer
afforded a nearly racemic product for the AD of a-methyl-
styrene. This finding suggests that the catalytically active Os
moiety is located in the vicinity of the biotin-binding pocket
(Figure 2b and 2c). As the carboxylate D128 ··· HNurea
hydrogen bond of biotin is a key interaction for high
biotin·SAV affinity,[8] SAV D128A was tested in the AD. a-
Methylstyrene was converted by the OsO4·SAV D128A
catalyst with significantly diminished selectivity.[9] The AD
of allyl phenyl ether in the presence of SAV D128A afforded
the opposite enantiomer than with SAV and allyl phenyl
sulfide was converted with remarkable selectivity. In contrast,
the conservative mutation SAV D128E, which extends the
side chain of residue 128 by a methylene group, led to less
dramatic changes in the enantioselectivity (Table 2).
Further insight on the location of the catalytically active
Os species was gathered by mutation of further residues
located close to the biotin-binding site. Inspection of the SAV
structure revealed that the l-7,8 loops (residues 113–121,
Figure 2b) of two neighboring monomers line the biotin-
binding pocket.[10] Single point mutants at position S112,
K121, and L124 were combined with various amounts of
K2[OsO2(OH)4] and tested in AD.
[11] Mutation at position
SAV S112 proved most effective for fine-tuning purposes.
Both SAV S112Y and SAV S112M led to an improvement of
selectivity in many cases. a-Methylstyrene was converted with
75% ee (R) with SAV S112Y and 97% ee (R) with SAV
S112M. Allyl phenyl sulfide, which gave nearly racemic
product with SAV, was converted with 71% ee (S) with SAV
S112Y. The best result for the AD of 1,2-dihydronaphthalene
was obtained with SAV S112M (41% ee, 1R,2S). The
conservative mutation SAV S112T, which introduces an
additional methyl group to the amino acid side chain of
residue 112, proved best for the dihydroxylation of precocene
(68% ee, 3R,4R) and of cis-b-methylstyrene (92% ee 1R,2S),
Table 2).
The system performed well on a range of challenging
substrates. Noteworthy results were obtained for allyl phenyl
sulfide (Table 2, entries 6, and 7) and cis-b-methylstyrene
(Table 2, entry 14) and are the highest ee values ever reported
for these substrates to the best of our knowledge.
For other demanding cis-substituted substrates, such as
1,2-dihydronaphtalene and indene, the enantioselectivities
could be significantly improved by site-directed mutagenesis
Table 2: Genetic optimization of the performance of artificial AD.[a]
Entry Olefin SAV mutant
(mol% Os)[b]
ee [%][c] TON[d] Ref.
ee [%]
[Ref.]
1 WT (2.5) 40 (S) 13
88
[2h]
2 S112Y (5.0) 82 (S) 14
3 D128A (2.5) 77 (R) 21
4 D128E (2.5) 0 9
5 WT (2.5) 2 (R) 4
61
[2i]
6 S112Y (5.0) 71 (S) 7
7 D128A (2.5) 71 (R) 10
8 D128E (2.5) 12 (R) 5
9 WT (2.5) 30 (1R,2S) 13
56
[2j]
10 S112Y (5.0) 7 (1S,2R) 12
11 S112M (5.0) 41 (1R,2S) 12
12 WT (2.5) 90 (1R,2S) 26
72
[2j]
13 S112Y (5.0) 45 (1R,2S) 11
14 S112T (2.5) 92 (1R,2S) 16
15[e] S112T (2.5) 91 (1R,2S) !16
16 WT (2.5) 5 (1S,2R) 12
53
[2k]
17 S112Y (5.0) 16 (1R,2S) 12
18 D128A (2.5) 45 (1R,2S) 13
19 WT (2.5) 62 (3R,4R) 6
67
[2l]
20 S112Y (5.0) 26 (3R,4R) 5
21 S112T (2.5) 68 (3R,4R) 6
22 WT (2.5) 95 (R) 27
99
[2n]
23 K121N (5.0) 24 (R) 8
24 L124G (5.0) 16 (R) 11
25 L124K (2.5) 89 (R) 18
26 S112Y (5.0) 75 (R) 15
27 S112M (5.0) 97 (R) 16
28 D128A (2.5) 53 (R) 22
29 D128E (2.5) 80 (R) 21
30[f ] WT (2.5) +
biotin
9 (R) 13
[a] Results are the average of two independent runs, see Table 1 and
Supporting Information for experimental details. [b] The ideal osmate
loading was determined for each mutant (see Supporting Information
and Ref. [7]). [c] ee determined by HPLC on a chiral stationary phase;
absolute configuration assigned by comparison with literature data.
[d] Determined by reverse-phase HPLC with internal standard.
TON=mol product/mol K2[OsO2(OH)4]. [e] Carried out on a 120 mmol
scale; TON is based on yield of isolated product. [f ] 1.05 equivalents of
d-biotin were added relative to protein monomer.
Communications
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(Table 2, entries 11 and 18). For the AD of precocene, the
ee value obtained with SAV S112T matched the best result
obtained with quinidine-derived systems.
Importantly, exchange of the lysine side chain at posi-
tion 121 resulted in low levels of stereoselectivity: the highest
ee value observed for any SAV K121 mutant/substrate
combination was 24% (R) (a-methylstyrene; Table 2,
entry 23). Mutating the leucine L124 had a less pronounced
deleterious (or neutral in one case) effect on selectivity.
With the aim of gaining structural insight on the location
of the Os center, SAV crystals were grown (at pH 4.0 or 7.3)
and subsequently soaked in a solution of K2[OsO2(OH)4].
The resulting crystals were subjected to X-ray analysis (see
the Supporting Information).
Soaking crystals, obtained at pH 7.3, resulted in anom-
alous scattering density (modeled with an Os atom), which
was detected in the proximity of four residues: Nz of K80, Ne
of H87, Ne of H127 and Nz of K132 (Figure 2a). The intrinsic
packing disorder, however, did not allow full refinement but
yielded precious information on potential Os-binding sites. In
contrast, the X-ray data of the crystals obtained at pH 4.0,
yielded a well-behaved structure with a single Os binding site
close to Ne of the H127 side chain (see the Supporting
Information).
The three osmium binding sites identified by X-ray
crystallography located in the proximity of the biotin binding
site (e.g. H87, H127 and K80) were subjected to site-directed
mutagenesis. Catalysis in the presence of single mutants SAV
H87A, SAVH127A, and SAV K80G gave comparable results
to SAV in the AD of a-methylstyrene, (lowest ee 89% (R)
with H87A; see Table S1 in the Supporting Information).[6]
Although the structural data did not allow identification of
the actual catalytic site, it suggests that not all of the osmium
is catalytically active, which accounts for the modest TONs
(up to 27 turnovers per added osmium).[2m]
In summary, we have demonstrated that high selectivity
for challenging substrates can be obtained with an artificial
AD based on OsO4·SAV. Importantly, it was shown that the
hybrid catalyst offers vast opportunities for genetic optimi-
zation: Single point mutations can lead to a significant
increase in enantioselectivity and even to an inversion of
enantiopreference. As for several natural mono- and dioxy-
genases, this artificial metalloenzyme suffers from modest
TONs combined with a high molecular weight. Current
efforts are thus aimed at increasing the TON by identifying
the location and the kinetic profile of the catalytically
competent osmium species and testing other challenging
substrates, including tri- and tetrasubstituted olefins. Finally,
from a biomimetic perspective, combination with a flavin-
coupled NMO-recycling system with H2O2 as the stoichio-
metric oxidant would be of great interest.[2n,o]
Figure 2. Crystal structure of SAV soaked in K2[OsO2(OH)4] at pH 7.3: a) ribbon representation of SAV tetramer highlighting positions of strong
anomalous difference density (in red, contoured at 4s); b) close-up view of the biotin-binding pocket (from PDB 1stp) highlighting the residues
and biotin (stick representation) which strongly influence catalysis; c) surface representation of close-up view.
10865Angew. Chem. Int. Ed. 2011, 50, 10863 –10866 ! 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
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7. Crystal structures of two streptavidin-osmium 
complexes 
 
7.1 Crystallization 
Streptavidin used for crystallization comprised residues 13-159 of the native core streptavidin 
and an N-terminal T7-tag. Stable SAV crystals for osmium soaking were obtained in two 
different forms at pH 4.0 and 7.3 by hanging-drop vapor diffusion at room temperature 
(Table S3). For complex formation, single crystals were equilibrated against an excess of 
K2[OsO2(OH)4] and flash-frozen in liquid nitrogen.  
 
Table S3: Crystallization of streptavidin and osmium soaking. 
 Crystal Form I (pH 4.0) Crystal Form II (pH 7.3) 
Crystallization 2.5µL Sav (26 mg/mL lyophilized protein 
in H2O) + 7.5 µL precipitation buffer (2 M 
NH4SO4, 0.1 M Na acetate, pH 4.0) 
equilibrated against reservoir buffer; 
crystals within 24h  
5µL Sav (15 mg/mL lyophilized protein in 
H2O) + 5 µL precipitation buffer (0.2 M Mg 
acetate, pH 7.3, 30 % PEG 3350) 
equilibrated against reservoir buffer; crystals 
within 1 week  
Metal soaking single Sav crystal was soaked in 10 µL of 
10 mM K2[OsO2(OH)4] in precipitation 
buffer and equilibrated 24 h  
single Sav crystal was soaked in 10 µL of 10 
mM K2[OsO2(OH)4] in precipitation buffer 
and equilibrated 24 h 
Cryo soaking osmate-soaked crystal was cryo-protected 
by soaking in a solution of 20 % glycerol in 
precipitation buffer    
- 
 
7.2 X-ray diffraction experiment and structure determination  
Diffraction data were collected at the Swiss Light Source (beamline X06DA) at a wavelength 
of 0.9793 Å, i.e. slightly below the L-II absorption edge of osmium (1.0010 Å). Crystal 
indexing and data processing was carried out with programs MOSFLM, POINTLESS and 
SCALA from the CCP4 Suite.[6] The phase problem was solved by molecular replacement 
with MOLREP[7] (crystal I) and PHASER[8] (crystal II). Rigid body and restrained refinement 
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was carried out with REFMAC.[9] COOT[10] and O[11] were used for model building and 
DINO1 for figure drawing.   
 
7.2.1 Crystal form I (pH 4.0) 
Molecular Replacement and Structure Refinement. Molecular replacement was carried out 
using as a model the structure with PDB code 2qcb. The initial model was refined by rigid 
body refinement and subsequent restrained anisotropic refinement, including TLS tensors 
(Table S4). Ligand building and refinement was carried out using geometrical restraints as 
derived from a complex of glycol-osmate ester with a cinchona alkaloid ligand deposited in 
the CSD (CSD code ketkez).[12]   
 
Table S4: Data processing and refinement statistics.  
 Crystal Form I Crystal Form II 
Data Processing 
Resolution (Å) 25 - 1.75 (1.84 -1.75) 49 - 2.40 (2.53 - 2.40) 
Space Group I4122 C2 
Cell dimensions (Å) a = 57.5 
b = 57.5 
c = 172.0 
 
a = 81.2 
b = 81.6 
c = 91.5 
β = 90.3˚ 
Rmerge (%) 6.2 (27.6) 10.9 (33.3) 
No. unique reflections 14995 19722  
Multiplicity 7.9 (3.8) 2.7 (2.2) 
Completeness 99.3 (96.9) 84.4 (71.2) 
I/sig(I) 19.4 (4.0) 5.3 (2.1) 
Structure refinement 
Resolution (Å) 30 - 1.75 49 - 2.4 
Rwork/Rfree 16.5 (20.4) 28.6 (30.6) 
                                                 
1 www.dino3d.org  
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 Crystal Form I Crystal Form II 
Overall B-factor (Å2) 12.4 3.4 
R.m.s deviations 
   Bond lengths (Å) 
   Bond angles (˚) 
 
0.0118 
1.396 
 
0.0048 
0.813 
values in parenthesis refer to the highest resolution bin 
 
 
Overall Structure. Crystal form I is of space group I4122 and contains one SAV molecule in 
the asymmetric unit. Application of a crystallographic dyad symmetry generates the 
functional SAV tetramer of 222-symmetry. The final protein model comprises residues 13-
134 with 94.7 % of the residues found in the most-favored regions of a Ramachandran plot, 
and no Ramachandran outliers (Figure S5a). As observed before,[13] both the N-terminal T7 
tag (residues 1-12) as well as 25 residues at the C-terminus are not resolved, probably due to 
disorder. The residues of the flexible loop 45-53 are in the open, non-biotin binding 
conformation.[14] As expected, no cofactor is present in the structure. Instead, the density 
observed in the biotin-binding cavity suggests the presence of two glycerol and five water 
molecules.  
                  
       a                                          b 
Figure S9: Crystal structure of crystal form I (pH 4.0), view along local 2-fold symmetry axis. (A) Ribbon 
representation of SAV tetramer indicating residues next to strong anomalous difference density (in red, 
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contoured at 4 σ), (B) Close-up view of [OsO2(OH)2]2- binding site between two symmetry-related SAV 
monomers.  
  
Osmium-Binding Sites. Strong Fo-Fc (39 σ) and anomalous difference density peaks (44 σ) 
were found next to Nε of H127 (Figure S9a and Table S5) and assigned to osmium atoms. 
The short Os-Nε(H127) distance of 2.2 Å suggests osmium coordination by the nitrogen lone 
electron pair. The Fo-Fc density of the osmium ligand has the shape of an ellipsoid with the 
equatorial plane at right angle to the imidazole plane of H127 (Figure S9b). Four oxygen 
atoms were modeled in equatorial position. The Os-O distances were set to 1.7 Å for one pair 
of cis-related oxygens and to 2.1 Å for the other pair. This is consistent with two Os=O 
double bonds and two Os-OH single bonds. The anisotropic shape of the density might be 
explained by a restricted rotation of the {OsO2(OH)2} moiety around the Os-Nε(H127) bond 
due to H-bonds between the equatorial oxygens and the neighboring Nδ(H127’) as well as a 
glycerol molecule (Figure S9b). The second axial position is not occupied. However, the side 
chain of residue N105, in vicinity to the osmium, is present in two conformations, in one of 
which the amide group is in proximity to coordinate osmium (Figure S9b). The {OsO2(OH)2} 
moiety appears not to be fully occupied. Best refinement results were obtained with an 
occupancy of 80 % for the {OsO2(OH)2} fragment.    
 
Table S5: Positions of strong spots of anomalous scattering and Fo-Fc density. 
 Peak height of 
anomalous density 
[σ] 
Peak height of 
Fo-Fc map [σ] 
Estimated osmium 
occupancy [%] 
Modeled as 
Crystal Form I (pH 4.0)   
His127 44 39 80 {OsO2(OH)2} moiety 
Crystal Form II (pH 7.3)   
Lys80 5-7 9-10 80 Os atom 
His87 14-17 21-24 80 {OsO5} moiety  
	
  73	
   S25 
 Peak height of 
anomalous density 
[σ] 
Peak height of 
Fo-Fc map [σ] 
Estimated osmium 
occupancy [%] 
Modeled as 
His127 6 9-10 0 due to unclear densities no 
ligand was modeled  
Lys132 5 10-11 30 Os atom 
 
7.2.2 Crystal form II (pH 7.3)  
During structure determination of crystal form II, a crystal packing disorder became obvious. 
Probably, layers of Sav tetramers extending in the ab-plane are stacked with a stochastic 2-
fold ambiguous displacement of ± 9.3 Å. A crystallographic report about these interesting 
packing defects will be published elsewhere (Heinisch and Schirmer, unpublished). Despite 
the disorder, the structure could be solved in space group C2 by molecular replacement using 
as a model the C2 form of the structure with PDB code 2bc3 (Table S4). Due to the 
incomplete crystal-packing model, however, rigid body and full restraint refinement yielded 
only a moderate Rfree of 30.6 %.  
 
Overall Structure. Although crystallized at a different pH, the overall SAV structure of 
crystal form II (pH 7.3) is virtually the same as that of crystal form I (pH 4.0). The only 
difference between the two crystal forms is the replacement of the H-bridge D61’-O∂ - H85-
Nε by the salt bridge D61’-O∂ - H87-N∂ in crystal II. The pH-dependent effect has been 
reported by Katz and co-workers.[15] The salt bridge between D61’ and H87 may have a 
positive effect on the osmium coordination to H87-Nε due to a possibly increased charge 
density at H87-Nε.  
 
Osmium-Binding Sites. In contrast to crystal form I, weak density in the anomalous 
difference and the Fo-Fc map was found close to H127A/B (Figure 2a and Table S5; the 
indices A and B indicate the two monomers of a SAV dimer within the asymmetric unit). A 
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stronger peak, however, was located in vicinity to H87A/B. Additional weak density was found 
next to lysine residues K80A/B and K132A/B. The strong density at H87A/B-Nε was modeled as 
an osmium atom surrounded by four equatorial and one axial oxygen. The H87A/B-Nε-Os 
distance was set to 2.1 Å. Because of insufficient electron density, only one osmium atom was 
modeled next to the side-chain amino acid groups of K80 and K131 and no osmium next to 
the side chain of H127. The best refinement results were obtained with ligand occupancies 
between 80 % and 0 % (Table S5).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
  75	
   S27 
8. References 
 
[1]  N. Humbert, A. Zocchi, T. R. Ward, Electrophoresis 2005, 26, 47-52. 
[2] M. Minato, K. Yamamoto, J. Tsuji, J. Org. Chem. 1990, 55, 766-768. 
[3] a) Preparative procedure used for all compounds and comparison for product from 
allylphenylether: Z.-M. Wang, X.-L. Zhang, K. B. Sharpless, Tetrahedron Lett. 1993, 
34, 2267-2270; b) comparison for product from allylphenylsulfide (the assignment of 
the absolute configuration in the cited reference is based on the mnemonic device 
developed by Sharpless and coworkers): P. J. Walsh, P. T. Ho, S. B. King, K. B. 
Sharpless, Tetrahedron Lett. 1994, 35, 5129-5132; c) comparison for product from α-
methylstyrene, cis-β-methylstyrene, dihydronaphthalene and indene: H. Becker, S. B. 
King, M. Taniguchi, K. P. M. Vanheesche, K. B. Sharpless, J. Org. Chem. 1995, 60, 
3940-3941; d) comparison for product from precocene: Z.-M. Wang, K. Kakiuchi, K. 
B. Sharpless, J. Org. Chem. 1994, 59, 6895-6897. 
[4] L. Zheng, U. Baumann , J.-L. Reymond, Nucleic Acids Res. 2004, 32, e115. 
[5] www.basic.northwestern.edu/biotools/OligoCalc.html 
[6] Acta Cryst. D, 1994, 50, 760-763. 
[7] Murshudov, G. N., Vagin, A. A., Dodson, E. J., Acta Cryst. D, 1997, 53, 240-255. 
[8] McCoy, A. J., Kunstleve, R. W., Adams, P. D., Winn, M. D., Storono, L. C., Read, R. 
J., J. Appl. Cryst., 2007, 40, 658-674. 
[9] Brunger, A. T., Acta Cryst. D, 1993, 49, 24-36. 
[10] Emsley, P., Cowtan, K., Acta Cryst. D, 2004, 60, 2126-2132. 
[11] Jones, T. A., Zou, J. Y., Cowan, S. W., Kjeldgaard, M., Acta Cryst. A, 1991, 47, 110-
119. 
[12] Pearlstein, R. M., Blackburn, B. K., Davis, W. M., Sharpless, K. B., Angew. Chem. 
Int. Ed., 1990, 29, 639 - 641. 
	
  	
   	
   76	
   S28 
[13] Creus, M., Pordea, A., Rossel, T., Sardo, A., Letondor, C., Ivanova, A., Letrong, I, 
Stenkamp, R. E., Ward, T. R., Angew. Chem. Int. Ed., 2008, 47, 1400-1404. 
[14] Freitag, S., LeTrong, I., Klumb, L., Stayton, P. S., Stenkamp, R. E., Prot. Sci., 1997, 6, 
1157-1166. 
[15] Katz, B. A., J. Mol. Biol., 1997, 274, 776-800. 
 
 
 
	
  77	
  
4.1. Author Contributions 
General idea:  
Thomas R. Ward 
 
Catalyst screening and experiment design: 
Valentin Köhler, Jinjeng Mao, Tillmann Heinisch, Anca Pordea, Jean-Christophe Prost 
 
Production of streptavidin variants: 
Alessia Sardo, Yvonne M. Wilson, Livia Knörr, Marc Creus,  
 
Crystal structure analysis: 
Tillmann Heinisch, Tilman Schirmer 
 
Manuscript writing: 
Thomas R. Ward, Valentin Köhler and all other authors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
  	
   	
   78	
  
4.2. Comment on Publication 
4.2.1. Sharpless- vs. Enzymatic Asymmetric Olefin Dihydroxylation  
Sharpless Asymmetric Dihydroxylation:  
It is known since the 1930s that osmium tetroxide can be used to dihydroxylate olefins in 
either a stoichiometric or a catalytic reaction using catalytic amounts of pyridine and a 
sacrificial oxidant.74,75 Sharpless and coworkers developed in the 1970s chiral auxiliaries 
based on cinchona alkaloids for the catalytic asymmetric dihydroxylation of olefins (Figure 
M13). Upon testing many different stoichiometric oxidants, K3[Fe(CN)6] was identified as the 
most suitable for the dihydroxylation of a large number of olefins.76 To improve the 
stereoselectivity of the reaction, a biphasic system of tBuOH and water was introduced.77 The 
standard reactants for the efficient laboratory-scale asymmetric olefin dihydroxylation of 
many different olefins are commercially available premixed as AD-mixes α and β.  
 
 
Figure M13: Catalytic cycle of Sharpless asymmetric olefin dihydroxylation in a biphasic 
system. 
 
Although the Sharpless asymmetric olefin dihydroxylation has an impressive substrate scope, 
its application on industrial scale is limited due to the relatively high costs of osmium and 
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cinchona alkaloid ligands, the moderate turnover number, the large amounts of expensive 
oxidant (K3[Fe(CN)6]) needed and the toxicity of osmium tetroxide. Instead, alternative 
synthesis strategies to obtain chiral diols seem to be favored in industry (e.g. via catalytic 
asymmetric hydrogenation).  
Several studies tried to address these problems using i) the oxidant N-morpholino-N-oxide 
(NMO, 5x cheaper than K3[Fe(CN)6]),78 ii) a coupled NMO-flavin-H2O2 system79 or iii) 
molecular oxygen/air80 as sacrificial oxidants. Further improvement of the catalyst 
performance is needed to provide a system of wide acceptance on industrial scale as well as 
for the selective dihydroxylation of reluctant olefins (e.g. cis-disubstituted or tetrasubstituted 
olefins).  
 
Mono- and Dioxygenases for Asymmetric Olefin Dihydroxylation: 
In Nature, oxygenation reactions are catalyzed by heme-iron monooxygenases (cytochromes 
P450), by diiron monooxgenases (e.g. methane monooxygenase), α-ketogluterate-dependent 
non-heme iron monooxygenase (e.g. prolyl hydroxylase) or Rieske non-heme iron 
dioxygenases. The biological functions of these enzymes are to metabolize cellular building 
blocks (e.g. tryptophan) and pollutants (e.g. benzol), to repair DNA or to build collagen (e.g. 
prolyl hydroxylase). Numerous attempts have been made to apply oxygenases in the 
(asymmetric) hydroxylation of small synthons.81  
The asymmetric olefin dihydroxylation catalyzed by the bacterial enzyme naphtalene 
dihydroxylase can be compared to the Sharpless dihydroxylation. The enzyme consists of 
three domains for i) olefin dihydroxylation (catalytic domain), ii) electron transport 
(ferredoxin domain)) and iii) an NAD(P)H-dependent reductase domain (Figure M14).81–83 
Even though the exact mechanism is still a matter of debate, an outer sphere mechanism (as in 
the Sharpless dihydroxylation) has been proposed for the transfer of the two oxygens to the 
substrate’s C=C double bond (Figure 3_1). The enzyme’s substrate scope ranges from the 
cis-dihydroxylation of olefins and aromats to the monohydroxylation of methyl groups, 
sulfoxidations and dealkylation reactions. Very high enantiomeric excess and yield are 
observed in many cases.81 
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Figure M14: Domain organization of naphtalene dioxygenase. 
 
4.2.2. Potential Reaction Mechanisms of the Artificial Olefin Dihydroxylase 
Proposed Active Site and Reaction Mechanisms of the Artificial Olefin Dihydroxylase: 
The crystal structures of complexes of Sav and K2[OsO2(OH)4] solved at pH 4.0 and pH 7.5 
revealed the osmium binding at His87 and His127 as well as Lys80 and Lys132. No osmium 
was detected in the biotin-binding pocket. This result suggests that the biotin-binding site has 
a low affinity for osmium as compared to the mentioned histidines and lysines. Unfortunately, 
CD-measurements of solutions with different Sav-OsO4 stochiometries did not allow to 
determine a Kd value. Further experiments (e.g. ITC) are needed to obtain a measure of 
cofactor affinity. The structure determination of an apo-Sav crystal soaked with 
K2[OsO2(OH)4] and of α-methylstyrene did not yield any bound olefin molecule. Mutation of 
the amino acids involved in osmium binding in the two crystal structures did not change the 
catalytic results significantly. Moreover, the Sav mutant-activity pattern of the 
dihydroxylation α-methylstyrene hints for the importance of the biotin-binding pocket and 
particularly Lys121 in the reaction (Figure 3_2). In order to improve the catalytic 
performance of the Sav-OsO4 system by site directed mutagenesis the knowledge of the active 
site is crucial. Towards this end, future attempts could aim at the synthesis of a stable reaction 
intermediate analogue α-methylstyrene osmate ester, which could be soaked into apo-Sav. 
Based on the results presented in the publication, two sequences of olefin dihydroxylation 
with the artificial dihydroxylase can be hypothesized: i) a substrate-last and ii) a sandwich 
model (Figure M15). 
 
NAD(P)H + H+
NAD(P)+
NAD(P)-Reductase Ferredoxin Oxygenase
OH
OH
2H+
+ O2
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Figure M15: Two models of the reaction mechanism of the asymmetric dihydroxylation with 
Sav-OsO4 catalyst.  
 
The substrate-last model postulates the formation of a Sav-OsO4 complex. The substrate can 
bind to the constituted active site of the artificial metalloenzyme and be dihydroxylated. The 
same mechanism is believed for the Sharpless asymmetric dihydroxylation using a complex 
of OsO4 and a cinchona alkaloid ligand. Similarly, naphtalene dioxygenase consists of a tight 
iron-binding site. Due to the absence of OsO4 in the Sav crystal structure, however, a second 
model is proposed. 
In the sandwich model, a transient substrate-Sav complex is formed prior to attack of the 
OsO4 to the activated olefin. This model would explain the absence of OsO4 in the crystal 
structure. It would allow a facile reoxidation of the osmium after one catalytic turnover. 
Furthermore, the lack of a protein-OsO4 coordination would explain the low turnover 
frequency of the AD as compared to small molecule tertiary amine or imine ligands. 
However, further experiments would need to be carried out to prove the hypothesis: e.g. 
crystallization of Sav with styrene or ITC with Sav and styrene.   
Irrespective of the correct reaction mechanism, low affinities of either Sav-OsO4 or Sav-
substrate have to be assumed from the experimental results. This is in contrast to the high 
affinity of complexes of Sav with biotinylated transition metal complexes. The Os-dependent 
artificial dihydroxylase is an example for the control of selectivity by weak interactions 
between protein, cofactor and substrate. The engineering of weak, transient interactions, 
however, is challenging compared to covalent ones. 
 
 
+ ++
Protein
Substrate
OsO4
Sandwich model
+ + +
Substrate-last model
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5. Human Carbonic Anhydrase II as a Host for Piano-Stool Complexes Bearing a 
Sulfonamide Anchor 
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d6-piano-stool complexes bearing an arylsulfonamide anchor display
sub-micromolar affinity towards human Carbonic Anhydrase II
(hCA II). The 1.3 A˚ resolution X-ray crystal structure of
[(g6-C6Me6)Ru(bispy 3)Cl]
+ C hCA II highlights the nature of
the host–guest interactions.
In recent years there has been an increasing interest in
scrutinizing the interactions between organometallic compounds
and proteins.1–3 This surge is primarily driven by three factors:
(i) the realization that proteins may be privileged targets for
metallodrugs,4–6 (ii) inert transition metals offer versatile
scaffolds for the design of enzyme inhibitors7 and (iii) combining
an organometallic moiety with a protein scaffold may lead to
artificial metalloenzymes with interesting catalytic properties.8–11
In this latter context, three different strategies have been
exploited for the localization of an organometallic moiety
within the protein scaffold: covalent-,12–16 dative-17–21 and
supramolecular anchoring.22,23 Building upon our experience
with artificial metalloenzymes based on the biotin-avidin
technology,24–27 we set out to identify an alternative protein
scaffold for the supramolecular assembly of the organometallicC
protein systems.
The choice of the host protein was based on the following
design criteria:
(i) Large binding pockets capable of accommodating metal
complexes. We anticipated that this may allow in the future to
rely on computational design for the rational tailoring of an
active site.28–31
(ii) Easily derivatizable inhibitors compatible with soft
transition metals and low dissociation constants.32,33 This
should ensure that, upon linking the organometallic moiety
to the inhibitor, nearly quantitative localization of the metal
fragment within the protein cavity would result.
(iii) A robust, monomeric protein that is easy to overexpress
and to purify.9 This could allow to apply directed evolution
strategies for the optimization of the performance of the
organometallic.protein construct.
(iv) The host protein should be overexpressed in certain
forms of cancer. With therapeutic applications in mind, this
feature may be exploited to accumulate the metallo-prodrug in
the cells requiring therapeutic action.34–36
Based on the above considerations, we selected human
Carbonic Anhydrase II (hCA II) as a model host for the
incorporation of organometallic complexes.37 hCA II is a stable
monomeric protein (B29 kDa) with no post-translational
modification. It is readily expressed in large amounts in
E. coli and purified by affinity chromatography.38 The Zn(II)
ion is located at the base of a funnel-shaped cavity and
arylsulfonamides, which bind tightly to zinc, have been
thoroughly investigated as inhibitors. Their affinities vary over
many orders of magnitude (down to sub-nanomolar).39
Considering the size of the cavity (15 A˚ deep and 15 A˚
diameter at its mouth), we anticipated that, depending on
the nature of the spacer between the arylsulfonamide anchor
and the organometallic moiety,40 hCA II may prove as a well-
suited host. Finally, some CA isozymes (in particular CA IX)
are overexpressed in certain forms of cancer.41
Thanks to their potential as catalysts and as metallodrugs,
we selected a d6-piano-stool scaffold bearing an arylsulfonamide
anchor as a model for incorporation within hCA II. The
synthesis of [(Z6-arene)Ru(bispy 3)Cl]+ is presented in
Scheme 1 (see ESIw for full experimental details, including
the production of recombinant hCA II).38 NMR analysis of
[(Z6-benzene)Ru(bispy 3)Cl]+ revealed the presence of a single
diastereomer as evidenced by an NOE cross-peak between the
Z6-benzene and HCbridge (see Scheme 1 and ESI,w Fig. S1).
The binding profiles of [(Z6-arene)Ru(bispy 3)Cl]+ towards
hCA II were determined using the esterase assay based on the
hydrolysis of p-nitrophenyl acetate at pH 8.0.42,43 Compared
to the parent carboxylic acid 4-carboxybenzenesulfonamide,
all complexes bearing the bispy 3 ligand display increased
affinity. Interestingly, [(Z6-biphenyl)Ru(bispy 3)Cl]+displays
the highest affinity towards hCA II, whereas [(Z6-C6Me6)-
Ru(bispy 3)Cl]+displays a significantly reduced affinity. These
data illustrate the subtle complementarity between the piano-
stool moiety and the funnel-shaped cavity (Table 1).
aDepartment of Chemistry, University of Basel, Spitalstrasse 51,
CH-4056 Basel, Switzerland. E-mail: thomas.ward@unibas.ch;
Fax: +41 61 267 10 05; Tel: +41 61 267 10 04
b Biozentrum, University of Basel, Klingelbergstrasse 50/70,
CH-4056 Basel, Switzerland. E-mail: tilman.schirmer@unibas.ch;
Fax: +41 61 267 21 09; Tel: +41 61 267 20 89
w Electronic supplementary information (ESI) available: Modified
protocol for the expression of hCA II in E. coli. Detailed description
of the X-ray structure. Synthesis and characterization of the
[(Z6-arene)Ru(bispy 3)Cl]+. See DOI: 10.1039/c1cc10345h
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To gain structural insight on the guest–host interactions,
crystals of hCA II were soaked in a solution of [(Z6-C6Me6)-
Ru(bispy 3)Cl]+ and diffraction data were collected at the
synchrotron to 1.3 A˚ resolution. After refinement of the protein
structure, strong residual positive and anomalous difference
density was apparent in the funnel-shaped sulfonamide-binding
cavity, which could be modeled as the Ru-complex. The
various interactions between the molecules’s benzene–sulfonamide
anchoring group and the protein are reminiscent to related
hCA II–sulfonamide complexes (see Fig. 1a and b and ESIw).
Additionally, the head group, including ruthenium, bispyridine
and hexamethylbenzene, interacts with the cavity’s ‘‘hydrophobic
wall’’ (residues V121, F131, V135, L141, L198, P202, L204, see
Fig. 1b). The piano-stool moiety lies at the entrance of the
funnel-shaped sulfonamide binding site and the chlorine is
exposed to the solvent. While the refinement of the bispy 3 part
of the Ru-ligand gave the best results with an occupancy of
100%, for the ruthenium, hexamethylbenzene and chlorine the
occupancy was set to 50%. We assume that a partial dissociation
of the metal from bispy 3 and the 10-fold increased affinity of
the latter fragment for hCA II may explain this observation.
The phenyl group of residue F131 was found to adopt two
alternative, equally populated conformations. The dihedral
angle w2 of the first, tense conformation (F131-T) has a value
of 161, whereas in the second, relaxed conformation (F131-R)
has a w2 of 931 (Fig. 1a and b and ESIw). Clearly, the relaxed
conformation is incompatible with ligand binding (clashes are
indicated by a red arrow), whereas the tense conformation is
stabilized by a CH/p interaction between a methyl group of
the ligands hexamethylbenzene and the F131 phenyl group
(green dotted line).
The propitious position of the piano-stool complex at the
entrance of the funnel-shaped sulfonamide binding site should
allow to site specifically engineer the protein and/or the piano-
stool moiety to improve interactions towards incoming substrates.
Taken together, these findings lay the basis for the development of
organometallic carbonic anhydrase inhibitors with potential use as
drugs or as hybrid catalysts.
Scheme 1 Synthesis of [(Z6-arene)Ru(bispy 3)Cl]+. Reagents and
conditions: (i) H2KPO4, H2O/acetone (1/6), rt, 24 h (93%);
(ii) [(Z6-arene)RuCl2]2, H3CCN, reflux, 2 h (23–67%).
Table 1 Binding affinity of [(Z6-arene)Ru(bispy 3)Cl]+ complexes
determined by the decrease in hydrolytic activity of hCA II towards
p-nitrophenyl acetate (see ESIw)
Entry Ki/nM
1 4-Carboxybenzenesulfonamide 569.2 ! 29.4
2 Bispy 3 45.3 ! 6.7
3 [(Z6-benzene)Ru(bispy 3)Cl]+ 194.1 ! 18.7
4 [(Z6-p-cymene)Ru(bispy 3)Cl]+ 275.3 ! 12.6
5 [(Z6-C6Me6)Ru(bispy 3)Cl]
+ 329.1 ! 16.1
6 [(Z6-biphenyl)Ru(bispy 3)Cl]+ 145.3 ! 11.9
Fig. 1 Crystal structure of complex [(Z6-C6Me6)Ru(bispy 3)Cl]
+ C
hCA II (PDB code 3pyk). (a) Close-up view of the sulfonamide
binding cavity. Hydrogen bonds between the sulfonamide anchoring
group and protein are highlighted as black dotted lines. Upon ligand
binding the phenyl of F131 undergoes a conformational change from
F131-R to F131-T to prevent clashes (red arrow) and to form a CH/p
interaction (green dotted line). The 2Fo-Fc map is shown in blue at
1.0s, the anomalous difference density map in red at 3.0s. (b) Surface
representation showing contacts between the ligand and the protein’s
‘‘hydrophobic wall’’ at the entrance of the ligand binding site.
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Crystal Structure Analysis
Crystallization
hCA II was crystallized by hanging drop vapor diffusion using virtually the same conditions as
described by Kim et al.:11 4.5 µL protein solution (20 mg/mL lyophilized hCA II in 50 mM Tris-
sulfate (pH 8), 1 mM methyl mercuric acetate) and 0.5 µL precipitating buffer (2.6 M ammonium
sulfate, 50 mM Tris-sulfate (pH 7.7)) were mixed and equilibrated against 500 µL precipitating
buffer at 4 ◦C. Crystals appeared within two days. Single crystals were stabilized by soaking with
glutaraldehyde using a method described by Lusty.12 The central hollow of a sitting-drop plate
was filled with 5 µL of a 50 % glutaraldehyde solution. The reservoir was filled with 300 µL
precipitating buffer. A cover slide with hCA II crystals was placed upside down on the sitting-
drop well and the system equilibrated at room temperature for 1 h. While native crystals did
dissolve immediately after transfer them into a water droplet, glutaraldehyde-treated crystals did
not dissolve even after 2 h, indicating the improved stability of the cross-linked crystals. The ligand
soaking solution was prepared by mixing 9.5 µL precipitating buffer and 0.5 µL of a solution of
30 mM [(η6-C6Me6)Ru(bispy 3)Cl]+ in 75 % DMSO. Single cross-linked hCA II crystals were
transferred into the soaking solution and equilibrated for 7 h at room temperature. Immediately
after soaking one crystal was subjected to the diffraction experiment, without intermediate storage
in liquid nitrogen.
Data Collection and Structure Solution
Diffraction data of a [(η6-C6Me6)Ru(bispy 3)Cl]+ ⊂ hCA II crystal were collected at a wave-
length of 1.0000 Å at the SLS beamline PXIII. Indexing and integration of the diffraction data was
carried out with the program MOSFLM and scaling with the program SCALA of the CCP4 Suite
(Table S3).13 The structure was solved by molecular replacement with program MOLREP13 using
as a search model the structure of apo-hCAII (PDB code 2CBA), excluding water molecules. The
initial protein model was refined by rigid body refinement followed by TLS and full atomic refine-
S12
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ment with program PHENIX.REFINE of the PHENIX package14 (Table S3). Energy minimized
PDB coordinates of ligand [(η6-C6Me6)Ru(bispy 3)Cl]+, excluding groups Ru, benzene and chlo-
ride, were calculated with the program PRODRG.15 The PRODRG output pdb file was used as
input for program SKETCHER (part of program LIBCHECK13 of the CCP4 Suite) to generate a
library file of the truncated ligand. After several rounds of refinement of the protein-ligand com-
plex, the remaining moities Ru, benzene and chloride were added to the pdb file and restraints of
these groups were added to the ligand-restraints-file. Electron and anomalous difference densities
were displayed with programs COOT16 and O,17 figures of the protein structure were drawn with
DINO1.
Table S3: Data Processing and Refinement
Data Processing
Resolution (Å) 32.0 - 1.3
Space Group P21
Cell dimensions a=42.1Å, b=41.5Å, c=72.4 Å, β=104.3 ◦
Rmerge (%) 3.9 (23.6)*
No.unique reflections 59043
Multiplicity 3.9 (3.1)
Completeness 98.8 (95.3)
I/sig(I) 15.4 (3.7)
Structure Refinement
Resolution (Å) 30.6 - 1.3
Rwork/R f ree 14.6/18.3
B-factors (Å2)
Protein 13
Ligand 17
Water 32
R.m.s deviations
Bond lengths (Å) 0.008
Bond angles (◦) 1.40
* values in parenthesis are for the highest resolution bin (1.37 - 1.30 Å).
1www.dino3d.org
S13
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Structure Description
Overall Structure: The asymmetric unit comprises one molecule of hCA II. Residues 3 to 261 are
defined by the electron density (see Figure S3). The imidazole groups of histidines 94, 96 and 119
coordinate to a Zn atom, which was indicated by a strong peak (20 σ , note that the f”Zn = 2.4 e− at
the enployed wavelength of 1.000 Å) in the anomalous difference density map. Strong anomalous
difference density (63 σ ) was also found close to the thiol group of C206. This was modeled as
CH3Hg
+ (PDB identifier MMC), which is present in the crystallization buffer (the f”Hg is 8.3 e−
at the employed wavelength). The structure was deposited in the PDB with code 3pyk.
[(η6-C6Me6)Ru(bispy 3)Cl]+ binding to protein: Residual positive electron density indicated
the binding of [(η6-C6Me6)Ru(bispy 3)Cl]+ in the conical sulfonamide binding cavity, reaching
from the zinc binding site about 14 Å towards the outer protein sphere. At the sulfonamide group,
one lone electron pair of the deprotonated amino terminus is coordinated to the Zn2+, whereas
the proton forms an H-bond with Oγ of residue T199 (2.8 Å). A sulfonamide oxygen forms an
H-bridge with the T199 main-chain-amide (3.0 Å) (Figure 1a). The benzene ring next to the
sulfonamide group interacts with the side chains of residues V121 and L198 via van der Waals
forces. A peak in the anomalous difference density (6 σ ) indicated the position of the Ru atom
(f”Ru = 1.5 e− at the given wavelength) at the exit of the sulfonamide binding site.
S14
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(a)
(b)
Figure S3: Crystal Structure of human carbonic anhydrase II in complex with ligand [(η6-
C6Me6)Ru(bispy 3)Cl]+. (a) Overall structure, (b) stereo view of the ligand binding site.
S15
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5.2. Comment on Publication 
5.2.1. Structural Aspects of the Design of an Artificial Transfer Hydrogenase Based 
on Human Carbonic Anhydrase II 
In this study, the potential of the hCAII-arylsulfonamide system to be used in AME design 
was investigated. As a model reaction, the ATH of cyclic imines was chosen (Figure M16). 
In a first step, the affinity and structures of different benzenesulfonamide-hCAII complexes 
had to be solved. The high-affinity ligand benzensulfonamide was used to tether various 
bispyridine-Ru-arene complexes for subsequent complexation with hCAII. Only Ru-arene 
complex precursors with reported activity in the ATH of imines or ketones were used 
(benzene, p-cymene, C6Me6, and biphenyl).56 The bispyridyl group was expected to act as a 
secondary recognition element via interaction with the hydrophobic hCAII residues P202, 
L204, V135 and P131.84  
An increase of affinity of the bipyridyl complex 4_3 by a factor of three (Kd = 45 nM) as 
compared to the amide benzensulfonamide precursor was indeed observed. However, each 
Ru-arene function led to a 3-7 fold decrease in affinity. The crystal structure of hCAII in 
complex with the compound [(η6-C6Me6)Ru(4_3)Cl] was solved. In the structure, the 
hydrophobic interactions between the bispyridyl group and amino acids P202, L204, V135 
and P131 were confirmed. Furthermore, a CHπ bond was observed between a methyl 
group of the C6Me6 cap and the side chain of Phe131. However, since the side chain of 
Phe131 has to be rotated by about 80° from a relaxed into a tense state, the total energy 
balance for the establishment of the CHπ bond is presumed to be negative. This would 
explain the low affinity of this complex as compared to the related benzene complex, which 
presumably does not require rotation of the Phe131 side chain for binding. Unfortunately, 
none of the Ru-arene complexes was active in catalysis.   
After publication of the crystal structure and affinities of the inactive complexes, Günnaz et 
al. reported that bidentate ligand benzensulfonamide-N-2-methylpyridine in complex with Ru-
p-cymene yields high activity in the ATH of acetophenone.85 Tethering benzensulfonamide in 
para-position to benzensulfonamide-N-2-methylpyridine yielded complex M4, which indeed 
was found to be active and enantioselective in the ATH of the salsolidine precursor inside 
hCAII (Figure M16). To analyze the structural differences between the inactive complexes 
4_3a-d and active M4, crystal structural studies and computational docking are currently in 
process.  
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Figure M16: ATH of salsolidine precursor using hCAII-arylsulfonamide system. 
 
5.2.2. Future Structure-Based Computational Design of Artifcial Metalloenzymes 
Based on Human Carbonic Anhydrase II 
Future AME development based on hCAII could be guided by structure-based computational 
design. Numerous studies have presented correlation functions derived from experimental 
structure-affinity data that allow in silico affinity predictions for novel ligands.86,87 The 
affinity of metal-containing ligands so far was hard to predict due to problems with metal 
parametrization. Schmid et al. have now presented a method of facile parametrization of piano 
stool transition metal complexes, which can be used in silico for affinity prediction.88 
However, in silico prediction of whole reaction pathways and transition states inside a protein 
scaffold is far more complex than affinity prediction since generally a multitude of possible 
conformations of enzyme-substrate intermediates, including high-energy arrangements, have 
to be sampled. High-throughput in silico screening methods such as Monte Carlo, that can 
handle various conformations in short time, do not consider high energy (low probability) 
conformations (e.g. transition states).89 In contrast, more detailed algorithms for transition 
state calculation, such as QM or QM-MM, are low-throughput and the number of possible 
conformations needs to be restricted to only few e.g. by knowledge of the protein-cofactor 
structure or the cofactor-substrate transition state structure.   
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So far, the most promising strategy of AME design in hCAII is to start from an active 
metallocofactor and synthesize a number of arylsulfonamide-tethered derivatives prior to 
screening for activity and enantioselectivity in the presence of hCAII. In future, structural and 
functional data from these experiments can be used to create algorithms that may allow in 
silico metallocofactor design to achieve high activity and enantioselectivity. 
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IV  Structural Analysis of Piano Stool Ruthenium Complexes 
Bound to hCAII and Streptavidin: Implications for Future 
Metallodrug Design 
 
 
6.  Introduction  
Diseases are complex biological events. While classic drug development often relayed on 
serendipity, today the knowledge of disease mechanisms and the structure and function of key 
biomolecules involved (e.g. proteins, DNA or RNA) allows the specific design of small drug 
molecules with high affinity and selectivity for target biomolecules.  
Most drugs consist of a small number of atoms (e.g. H, C, N, O) and metals play only a 
marginal role in drug development. This is in contrast to the various functions that metals 
have in biological systems.4,5 Moreover, metal atoms have some specific properties, which 
can be exploited for drug design:  
• metal complexes often are positively charged (they bind e.g. to DNA phosphate 
backbone, acidic amino acids)   
• metals are Lewis acids that bind Lewis bases (e.g. DNA phosphate backbone, 
nucleobases, electron lone pairs of amino acids in proteins)  
• metals are redox active, they can reduce/oxidize biomolecules 
• metals can have multiple coordination geometries, which allows to build a large 
number of 3D architectures with high target affinity by structure-based design  
• the coordination geometry can change with the redox state, which can be used to 
improve target selectivity (prodrug strategy). 
• metals can be radioactive, which can be used to destroy tumor cells. 
• metal complexes can be more stable in vivo than organic molecules, because of the 
lack of a degradation/efflux machinery. 
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7. Human Carbonic Anhydrase II as a Host for Piano-Stool Complexes Bearing a 
Sulfonamide Anchor 	
  
7.1. Comment on Publication 
7.1.1. Structure-Based Design of Metallodrugs for Human Carbonic Anhydrase II 
Structure-based drug design to date is common in industry and academic research. However, 
only few examples exist in literature about the structure-based rational design of 
metallodrugs.90,91  
Staurosporin inhibits many protein kinases with nanomolar affinity by mimicking the 
nucleobase as well as the ribose of ATP. Based on the crystal structure of a complex of 
staurosporin and protein kinase PIM 1, Meggers et al. have designed a metallo derivative of 
staurosporin with a sugar ring exchanged for a Ru-arene-CO half-sandwich group (Figure 
M17).90 This organometallic compound has an affinity of 220 pM as compared to 65 nM of 
staurosporin for PIM 1, for which the metal inhibitor is highly selective with respect to other 
kinases. The crystal structure of complex PIM 1-Ru-complex demonstrates that no direct 
metal-protein interactions are present and that the high affinity is constituted solely by the 
geometrical constitution of the Ru complex. This demonstrates the potential of using the 
architectures of inert metal complexes as enzyme inhibitors.  
 
 
Figure M17: Superposition of crystal structures of complexes Pim 1-staurosporin (grey, PDB 
1YHS) and the complex of Pim 1-ruhtenium piano stool staurosporin mimick (orange, PDB 
2BZI). Ruthenium is depicted as a green sphere; hydrogen bridges of staurosporin are shown 
as white dashed lines and those of its Ru-mimick in orange dashed lines. 
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Human carbonic anhydrases are key enzymes ubiquitous in all organisms that regulate 
essential physiological processes such as respiration, vision, signaling and memory, 
development and function of bones or muscles. Consequently, they are involved in a large 
number of diseases. Numerous hCA inhibitors are on the market or in clinical trial for the 
treatment of glaucoma, epilepsy, hypertension, osteoporosis or tumor suppression.52 The 
wealth of structural and functional data on hCA holds great potential to evaluate the scope and 
limitations of structure-based rational metallodrug design.  
Jude at al. have demonstrated the ease of engineering a secondary recognition element in 
hCAII, which is based on an iminodiacetate (IDA) Cu2+ complex.92 Indeed, after optimization 
of the linker region, a benzensulfonamide tethered IDA-Cu2+ complex with an affinity of 28 
nM (as compared to 660 nM of benzenesulfonamide) for hCAII was obtained. In addition, 
this complex is more selective for hCAII as compared to hCAI by a factor of four. Crystal 
structure analysis of the protein-inhibitor complex revealed coordination of the IDA-Cu2+ 
group to the imidazole of His64, which is located opposite to the hydrophobic wall in the 
substrate-binding site. This result encourages the structure-based design of novel metal 
inhibitors for hCAII.  
 
7.1.2. Piano Stool Complexes as Secondary Recognition Elements for the Inhibition of 
Human Carbonic Anhydrase II  
Ruthenium-arene piano stool complexes as developed by Sadler and coworkers are in clinical 
trials as potential cancer therapeutics (Figure M18).93–95 The primary target of Ru-arene 
piano stool complexes are the nucleobases of DNA. However, Meggers and coworkers have 
shown the potential of a related Ru complex in kinase inhibition (Figure M17). 
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Figure M18: Metallodrugs that are on the market (cisplatin) or in clinical trials. Numbers 
indicate IC50 values (in µM) in A2780 human ovarian cancer cells after 24 h incubation 
time.94 
 
In the study by Monnard et al., based on the crystal structure of hCAII, various 
benzenesulfonamide-bound bispyridyl-Ru-arene complexes were designed, and their potential 
as secondary metallo recognition elements in hCAII inhibition was tested.  
As discussed above, the affinity of the bipyridyl complex 4_3c was increased as compared to 
the amide precursor, while the Ru-arene functions tested led to a decrease in affinity. No 
direct Ru-protein coordination was observed in the crystal structure. Thus, the designed Ru-
arene-bispyridyl groups do not act as secondary recognition elements. In contrast, the affinity 
is negatively affected by their presence. Complex M4 was shown to have low nanomolar 
affinity (10 nM) for hCAII. The crystal structure of the complex will elucidate how the piano 
stool complex of M4 acts as a secondary recognition element.   
Based on the fact that the bispyridyl moiety, tethered to benezesulfonamide, undergoes 
beneficial hydrophobic interactions with the hydrophobic wall of hCAII, piano stool metal 
functions could be linked to this scaffold in various positions. In accordance with Jude et al., a 
linker could position the free coordination site of a piano stool complex in proximity to the 
His64 side chain to coordinate it. Alternatively (or in addition), the arene cap could be 
designed to experience hydrophobic interactions with residues in proximity to His64, opposite 
of the hydrophobic wall. Next to ruthenium, metals iridium and rhodium or osmium could be 
tested for their impact on affinity. Moreover, a library of piano stool sulfonamide complexes 
should be tested not just against hCAII but also its isoforms (e.g. hCAI) to evaluate the target 
selectivity. 
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8. Chemo-Genetic Optimization of DNA Recognition by Metallodrugs Using a 
Presenter-Protein Strategy 
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Introduction
DNA is a privileged target of anticancer metallodrugs like
cisplatin. However, such drugs often suffer from high toxici-
ty and drug resistance due to non-selective binding to other
than oncogenic DNA.[1] To minimize metallodrug toxicity,
several interactions with cancer-associated DNA sequences
would be desirable, but such extensive interactions are hard
to achieve with small-molecule drugs. Ultimately, designed
assemblies of metallodrugs with presenter proteins[2] may
lead to effective mechanisms of small-molecule delivery to
preferred macromolecular targets.
To increase selectivity of small molecule drugs for macro-
molecular targets, “surface borrowing” can be used to pro-
vide additional surface contacts through a presenter protein,
which modulates the specificity and affinity of ligand–mac-
romolecule interaction.[2] The use of bifunctional molecules
based on biotin–streptavidin technology has been used for
targeting RNA, in which a contribution from protein con-
tacts to the anti-tobramycin RNA aptamer was suggested.[3]
Inspired by these presenter protein strategies and our previ-
ous experience of enantioselective artificial metalloen-
zymes,[4] we anticipated that metallodrug-mediated protein–
DNA interactions could be engineered leading to a stable
ternary metallodrug–protein–DNA complex (Figure 1). Such
complexes with DNA would be reminiscent of the binding
of high-mobility group (HMG)-domain proteins to platinat-
ed DNA that mediate cytotoxicity in vivo.[5] Analogous
mechanisms of action ultimately involving ternary com-
plexes have also been described for other clinically useful
drugs, such as the immunosuppressive antibiotic rapamy-
cin.[6]
Abstract: The mode of action of pre-
cious metal anticancer metallodrugs is
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target. However, the poor specificity of
such drugs often requires high doses
and leads to undesirable side-effects.
With the aim of improving the specific-
ity of a ruthenium piano-stool complex
towards DNA, we employed a present-
er protein strategy based on the biotin–
avidin technology. Guided by the X-ray
structure of the assembly of streptavi-
din and a biotinylated piano-stool, we
explored the formation of metallodrug-
mediated ternary complexes with the
presenter protein and DNA. The as-
semblies bound more strongly to telo-
mere G-quadruplexes than to double-
stranded DNA; chemo-genetic modifi-
cations (varying the complex or mutat-
ing the protein) modulated binding to
these targets. We suggest that rational
targeting of small molecules by pre-
senter proteins could be exploited to
bind metallodrugs to preferred macro-
molecular targets.
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Organometallic drugs have received increasing attention
spurred on by their non cross-resistance with Pt-based
drugs.[7] Specifically, the study of ruthenium piano-stool
complexes (e.g., see compounds 1 and 2, Figure 1) as poten-
tial anti-tumour drugs has begun to establish structure–activ-
ity relationships.[8] These studies also highlighted the impor-
tance of non-covalent interactions in the second coordina-
tion-sphere, such as hydrophobic interactions between the
h6-arene ligand of the piano stool (Figure 1) and DNA that
help improve selectivity.[9] Recently, the nature of the
second coordination sphere has also been shown to influ-
ence both kinetic- and thermodynamic properties of the
binding to proteins, which constitute alternative macromo-
lecular targets of anticancer drugs.[10]
Results and Discussion
Construction of a presenter protein and metallodrug assem-
bly : As proof-of-concept that target selectivity can be engi-
neered into a supramolecular assembly of drug and present-
er protein, we synthesized a biotinylated metallodrug (com-
pound 1, Figure 1) inspired by promising anticancer RuII
piano-stool complexes,[7] for incorporation into streptavidin
(Sav). The strong binding affinity of Sav for 1 was confirmed
by isothermal titration calorim-
etry (ITC; Kd<60 nm ;
Figure 2).
X-ray structure : The crystal
structure of the 1!Sav tetramer
assembly determined at 2.0 !
resolution (Figure 3 and Sup-
porting Information Figures S1–
S3) from protein crystals
soaked in excess of 1 shows
that the four biotin binding
sites are fully occupied with the
metallodrug. Ruthenium is co-
ordinated by four ligands, two
amino groups of the 3,4-(R,R)-
ligand, a chloride molecule and
the aromatic ring of the p-
cymene (Table 1). The metal
complex has a distorted tetra-
hedral “piano-stool”-like geom-
etry. In addition to the well
documented biotin–Sav interac-
tions,[11] other interactions be-
tween 1 and Sav found in the
crystal structure enforce the lo-
calisation of the piano-stool
moiety within the biotin bind-
ing pocket (Figure 3): 1) hy-
drogen bonding of a diamino-
pyrrolidine nitrogen to the side
chain of S112; 2) apolar interactions of p-cymene with
Thr114 (Supporting Information, Figure S3) and 3) indirect
binding of the labile chloride (or water) ligand to the back-
bone carbonyl of S122 through a well-ordered water mole-
cule. The diaminopyrrolidine S112 H-bond is reminiscent of
a critical interaction between a Pt ligand N"H group and
the phosphate backbone of double-stranded DNA (dsDNA)
Figure 1. Presenter protein strategy for targeting telomeric DNA with ruthenium metallodrugs. The ruthenium
drug embedded into tetrameric Sav in a 2:1 molar ratio forms a supramolecular complex that may allow exten-
sive interactions with a DNA (here depicted as G-quadruplex telomeric DNA; G4A). Chemo-genetic optimi-
zation, that is, mutations of defined streptavidin residues (e.g., K121 and S112) or modifying the arene cap of
the Ru complex, can modulate the affinity of the assembly for the DNA target. Compound 1= [(h6-p-
cymene)Ru ACHTUNGTRENNUNG(Biot-L)Cl]CF3SO3 and 2= [(h6-biphenyl)Ru ACHTUNGTRENNUNG(Biot-L)Cl]CF3SO3; Biot-L=Biotin-N-(R,R)-3,4-di-
aminopyrrolidine.
Table 1. Geometrical properties of the primary coordination sphere of
the ruthenium in 1 as bound to streptavidin. For simplicity the hydrogen
atoms of the amine groups and the neighbouring atoms of the pyrrolidine
carbons are omitted. Angles [8] and distances [!] relative to the p-
cymene group refer to the centre of the aromatic ring.
N1-Ru-N2 83 N1"Ru 2.48
N2-Ru-Cl 67 N2"Ru 2.37
Cl-Ru-N1 97 Cl"Ru 2.83
cym-Ru-N1 130 cym"Ru 1.83
cym-Ru-N2 139
cym-Ru-Cl 121
N1-C1-C2-N1 89
www.chemeurj.org " 2010 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Chem. Eur. J. 2010, 16, 12883 – 1288912884
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identified by Lippard in both cisplatin and oxaliplatin X-ray
structures.[12]
In the crystal structure, symmetry related cis-Ru atoms
are 10.4 ! apart (Figure 3). In the absence of a neighbour-
ing cis compound 1 (see Supporting Information: Video 1),
the size and charge of the pocket would allow multiple inter-
actions with an incoming DNA molecule. The orientation of
the labile Ru!Cl bond is compatible with coordination to
electron-rich N7 atoms of purines[13] in an endo-base of
single-stranded DNA (ssDNA).
Metallodrug binding to quadruplex DNA : Although the
target of DNA-binding metallodrugs is generally thought to
be mainly dsDNA, G-quadruplexes also offer attractive al-
ternative therapeutic targets;[14] they are abundant in telo-
meres at the end of chromosomes and are found as potential
regulatory elements in genes, including oncogenes. Thus, we
next investigated the binding of 1"Sav, assembled by mixing
two equivalents of complex 1 with one equivalent of tetra-
meric Sav, to a model G-quadruplex telomeric DNA,
namely G4A, consisting of 39 bases (Figures 4 and 5).[15]
ITC titration (Figure 4a) suggests the formation of a ter-
nary complex between the drug-presenter protein assembly
(1"Sav) and G4A, with sub-micromolar affinity (Table 2,
entry 2). The binding of Sav alone with G4A was markedly
weaker in the absence of complex 1 as determined by elec-
trophoretic mobility-shift assays (EMSA; compare Table 2,
entries 1 and 2) and by ITC (Figure 4b). EMSA gels
(Figure 5) and ITC (Figure 4c) using G4A as target were
also carried out with 1 alone (in the absence of Sav). These
data reveal the formation of a mixture of fast migrating spe-
cies that cannot be resolved by EMSA or by ITC, support-
ing the expected multiple strong binding events to the
DNA: there is ample experimental evidence for related Ru
piano-stool complexes that display preferential binding to
N7 guanine in DNA;[13] a QM–MM calculation predicts a Kd
Figure 2. ITC profile for the binding of 1 to Sav. Titration was carried out
at 25 8C in 3-(N-morpholino)propanesulfonic acid (MOPS) buffer
(75 mm) at pH 6.5 with 10 mm of KOH. Every 4 min, 5 mL of 1 (1 mm)
was injected in the reaction cell (Vcell=1.5 mL) filled with Sav (40 mm of
monomer). The heat values are plotted as a function of 1/Sav molar
ratio, to give the corresponding binding isotherms. The resulting iso-
therms were then fitted to a two set binding sites model. Although bind-
ing was strong and probably beyond the sensitivity of ITC, each tetramer
of Sav bound approximately four complexes of 1 with affinities of Kd<
60 nm.
Figure 3. Crystal structure of 1 embedded into the Streptavidin presenter
protein (1"Sav). a) Close-up view of 1 bound to a Sav monomer
(orange) also showing the cis-related ruthenium moiety (upper-left
corner) that is bound to the symmetry-related Sav monomer (aquamar-
ine). Selected Sav residues are shown in full and are labelled. Primed res-
idues belong to the symmetry-related monomer. The 2 Fo-Fc electron
density map of 1 is contoured at 1.0 s. The ruthenium atom is tetrahe-
drally coordinated by two amino groups of the diaminopyrrolidine, the p-
cymene and a putative chloride ion (shown in green). b) Molecular sur-
face representation of the Sav tetramer showing two cis-related rutheni-
um moieties. The Sav surface is coloured according to amino acid, with
blue=basic residues; red=acidic residues; green=polar residues; grey=
hydrophobic residues. The structure has been deposited in the Protein
Data Bank (www.pdb.org) with accession code 2WPU.
Chem. Eur. J. 2010, 16, 12883 – 12889 " 2010 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chemeurj.org 12885
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of 0.1 mm for a related Ru piano stool.[16] Addition of 1!Sav
produced a concentration-dependent change in migration of
G4A in EMSA, leading to a single slow migrating species at
high concentration that is also consistent with the formation
of a ternary complex with a defined 1:1 stoichiometry
(DNA/1!Sav) (Figure 4). Affinities obtained by varying the
ratio of 1/Sav from 1:1 to 4:1 are comparable (Table 2 en-
tries 2, 14 and 15 and Supporting Information Figure S4).
The 2:1 ratio was selected for all subsequent studies as it
yielded a well defined 1:1 stoi-
chiometry (1!Sav/G4A) by
ITC (Figure 4a) and EMSA
(Figure 5).
Selectivity for single stranded
DNA (ssDNA): To test whether
1!Sav recognizes structural
features of G4A or simply its
nucleotide content, we used a
scrambled telomeric sequence
(scG4A) that could not form a
G-quadruplex structure. The
binding of 1!Sav to this control
oligonucleotide (scG4A) was
measurably weaker than for
G4A, which is bound stoichio-
metrically in our EMSA assay
(Table 2, entries 2 and 11). The
ITC titration curve of scG4A
could not be fitted to a one-site
binding model (Figure 4d).
Therefore, under these condi-
tions, 1!Sav binds strongly to
the G-quadruplex in a defined
1:1 stoichiometry that fits a
single-binding site mechanism
and also binds to other ssDNA
with marginally less affinity and
in a complex mode.
Competitive binding : To test
the selectivity of a ternary com-
plex with DNA in the presence
of potentially interfering mac-
romolecules, first competition
studies with glutathione were
carried out. Glutathione has
been shown to coordinate anti-
cancer Ru complexes in vitro[17]
and has also been implicated in
metallodrug inactivation in
vivo.[1,18] Although complex 1
could bind glutathione (Sup-
porting Information Figure S5
and Table 2), the presence of a
300-fold excess glutathione with
respect to G4A (final concen-
tration of glutathione=1 mm ; i.e., within the physiological
range) did not appreciably affect formation of the complex
with G4A as evidenced by EMSA (Figure 5).
An excess of competing ssDNA co-incubated with G4A
(up to 157 equivalents of competing ssDNA with respect to
G4A) lowers binding of the metallodrug–protein assembly
as determined by EMSA, but only marginally (Table 2 en-
tries 12 and 13 and Figure 6a). The 12mer ssDNA was
better at inhibiting G4A binding than the GGG-trinucleo-
Figure 4. DNA-binding monitored by ITC: a) binding of 1!Sav to G4A: a single set of identical sites model
provided an association constant of (1.35"0.28)!106m#1, enthalpy of (1.23"0.355)!104 kcalmol#1, and stoi-
chiometry of 0.90"0.02; b) binding of Sav to G4A: a single set of identical sites model gives an association
constant of (6.56"2.35)!104m#1, enthalpy of (1.055"0.124)!103 kcalmol#1, and stoichiometry of 1.81"0.09
(the binding affinity of the protein alone is more than ten times weaker than in the presence of compound 1);
c) binding of 1 to G4A is apparently strong, exothermic in the conditions used and very different from that
found for the ruthenium drug assembled with the presenter protein (see Supporting Information); d) binding
of 1!Sav to a “scrambled” telomeric DNA (scG4A) is markedly different and cannot be fitted to a one-site
binding-model (compare panels d and a).
www.chemeurj.org " 2010 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Chem. Eur. J. 2010, 16, 12883 – 1288912886
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tide, which may intimate the existence of a more extended
interaction with the 1!Sav assembly compared with the
smaller GGG-trinucleotide. These results support the notion
that G4A is a privileged target.
Genetic control of the second coordination sphere : Next, we
investigated the influence of the second coordination sphere
on G4A binding through site-directed mutagenesis. The
crystal structure reveals two lysines (K121 of the two adja-
cent monomers) within 10 ! of the Ru, at the entrance of
the largely hydrophobic biotin binding pocket (Figure 3).
Mutation of this positively-charged residue (K121A) de-
creased affinity significantly (Figure 5 and Table 2 entry 5).
A decrease in affinity upon lysine mutation has also been
observed in other nucleic acid binding proteins[19] and sug-
gests that the lysines might form a salt bridge with the phos-
phate backbone. Similarly, the introduction of a negative
charge in the vicinity of the Ru (S112D) also reduced bind-
ing-affinity (Figure 5 and Table 2 entry 4), perhaps caused
Figure 5. Binding of assembly of metallodrug and presenter protein
(1!Sav) to G4A monitored by electrophoretic mobility shift assay
(EMSA) on agarose gels: EMSA on agarose gels of 1!Sav variants wild-
type (WT); WT in the presence of 1 mm glutathione; S112F; S112D or
K121A incubated with G4A. Lane 1: DNA Marker. Lane 2: G4A. Lane
3: G4A (3.3 mm)+Sav (39.6 mm); Lane 4: G4A (3.3 mm)+1 (85.7 mm).
Lanes 5-10: G4A (3.3 mm)+1!Sav at increasing concentrations: 0.8, 1.6,
3.9, 7.9, 19.8, 39.6 mm, representing a 1!Sav/G4A ratio from 0.2 to 12. In
all cases 500 ng of DNA was loaded onto the gel.
Table 2. Summary of dissociation constants (Kd) of Ru–Sav assemblies
for various DNA targets, as estimated from EMSA.
Entry DNA
Target
Metal
complex
Ratio
Ru/Sav
Sav Kd estimated by
EMSA [mM]
1 G4A none – WT >145[a]
2 G4A 1 2 WT <1.6[b,c]
3 G4A 1 2 S112F <1.6[c]
4 G4A 1 2 S112D 12.2
5 G4A 1 2 K121A 28
6 G4A
(GSH)[d]
1 2 WT <1.6[c]
7 dsOnc 1 2 WT 37.9
8 dsOnc 1 2 S112F 37.9
9 dsOnc 2 2 WT 37.9
10 dsOnc 2 2 S112F 18.2
11 scG4A[e] 1 2 WT 2.3
12 G4A
(GGG)[d]
1 2 WT 2
13 G4A
(12mer)[d]
1 2 WT 5.4
14 G4A 1 1 WT 2.3
15 G4A 1 4 WT <1.6[c]
[a] Kd determined by ITC: 15.2 mm (see Supporting Information; Fig-
ure S6); [b] Kd determined by ITC: 0.74 mm ; [c] Binding was stoichiomet-
ric and probably beyond the sensitivity of these EMSA; [d] In brackets
competing species: glutathione (GSH), trinucleotide GGG (GGG) and
ssDNA 12mer (12mer); [e] “Scrambled” G4A has identical nucleotide
content to G4A but with a different sequence and structure.
Figure 6. Binding of assembly of metallodrug and presenter protein
(1!Sav) to ssDNA, monitored by EMSA on agarose-gels: a) Binding to
G4A DNA in the presence of competing DNA substrates. Lane 1:
Marker (M). Lane 2: G4A. Lane 3: G4A (3 mm)+GGG trinucleotide
(206.5 mm) or 12mer ssDNA (462 mm) respectively. Lane 4: G4A (3 mm)+
GGG (206.5 mm) or 12mer (462 mm) respectively +complex 1 (76.5 mm).
Lane 5–10: GGG (206.5 mm) or 12mer (462 mm) were co-incubated with
G4A (3 mm) and the 1!Sav assembly at increasing concentrations: 0.7,
1.4, 3.5, 7, 17.7, 35.3 mm ; under these conditions, the molar ratio 1!Sav/
G4A ranges from 0.2 to 12, while GGG/G4A and 12mer/G4A ratio is 69
and 154, respectively. Lane 11: G4A (3 mm) and 1!Sav assembly
(35.3 mm). Lane 12: GGG (206.5 mm) or 12mer (462 mm) in the presence
of 1!Sav assembly (35.3 mm); GGG or 12mer are barely visible by ethid-
ium bromide staining due to lack of intercalation of the dye in ssDNA.
b) Binding to a ssDNA with a “scrambled” G4A sequence (scG4A)
unable to form a DNA quadruplex. Lane 1: DNA Marker. Lane 2:
ScG4A. Lanes 3–11: G4A (3.3 mm)+1!Sav at increasing concentrations:
0.4, 0.6, 0.8, 1.6, 3.2, 3.9, 7.9, 19.8, 39.6 mm, representing a 1!Sav/G4A
ratio from 0.12 to 12. In all cases 500 ng of scG4A was loaded onto the
gel.
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by charge repulsion. In contrast, the introduction of an aro-
matic residue at the same position (S112F) did not apprecia-
bly change the affinity for G4A (Figure 5 and Table 2
entry 3). These results show that DNA binding of the cation-
ic Ru complex 1 is influenced by the second coordination
sphere provided by the protein, particularly by charged resi-
dues in the vicinity of Ru.
Chemo-genetic optimization for improved binding to
dsDNA : We also explored whether Sav could present metal-
lodrug 1 to dsDNA (Figure 7 and Table 2 entries 7 and 8).
For this purpose, we used an 18 base pair dsDNA that in-
cludes the sequence of the common Braf V599E oncogenic
mutation (dsOnc).[20] Compared with the affinity for G4A
(Kd!<1.6 mm as estimated by EMSA; Figure 5), the affinity
for dsOnc is significantly lower, with Kd!37.9 mm (Figure 7a
and Table 2 entry 7). We hypothesize that a different organi-
zation of functional groups, as well as the reduced flexibility
of dsDNA, hampers efficient interaction between the ruthe-
nium and nucleophilic sites on the bases. To further demon-
strate that DNA binding can be fine-tuned using an assem-
bly of drug and presenter protein, we sought to improve
binding to dsDNA chemo-genetically, either with an interca-
lator,[21] such as h6-biphenyl piano-stool complex 2, or by ge-
netic introduction of an aromatic residue to the position
closest to Ru (S112). The biphenyl-containing S112F variant
(2"Sav S112F) increased the affinity to dsOnc (Figure 7d
and Table 2 entry 10), suggesting that modulation of non-co-
valent interactions in complexes of metallodrugs and pre-
senter proteins can be engineered chemo-genetically to
afford more specialised binders.
The importance of the extended second coordination
sphere that is provided by the presenter protein for selective
binding of a small molecule to a macromolecular target is
shown by the following: 1) the different modes of binding of
cationic Ru complex 1 to G4A in presence or absence of
Sav and 2) the influence of chemogenetic modifications on
DNA binding, for example decreasing binding to G4A using
a K121A mutant or by increasing the affinity for dsDNA by
a judicious combination of genetic variant (S112F) and com-
plex 2 (containing a biphenyl arene cap). In contrast, selec-
tive DNA binding is difficult to achieve with small metallo-
drugs, such as cationic Ru complex 1 alone, because there
are only limited interactions available for recognition of the
target.
Conclusion
We have shown that a supra-
molecular assembly consisting
of a metallodrug (i.e., biotiny-
lated ruthenium piano stool)
combined with a presenter pro-
tein (i.e. , streptavidin) modu-
lates the recognition profile in
vitro through the provision of
additional non-covalent interac-
tions. Such extended contacts,
which are not typically avail-
able to small molecule drugs,
allow modulation of affinity
and selectivity towards DNA
telomeres, even in the presence
of competing targets (such as
glutathione and dsDNA).
In the present form such as-
semblies cannot be delivered
easily into cells, thus hampering
in vivo studies. To overcome this challenge, our current al-
ternative efforts include the following: 1) appending cell-
penetrating peptide sequences to the presenter protein;
2) exploring non-DNA,[10] extracellular targets, which cir-
cumvents the need for intracellular delivery and 3) ex-
ploiting endogenous species as presenter proteins, such as
those overexpressed in cancer cells. The latter would thus
only require cell penetration of the metallo-prodrug. The ul-
timate aim of these experiments is to use such tethered or
cross-linking drugs[6,22] in which an initial kinetic binder[23]
does not merely act as a “carrier”[24] or “reservoir”[25] but
also chaperones the drug selectively to a macromolecular
target in vivo, contributing ultimately to the inhibitory (bio-
active) species.
Experimental Section
Experimental details can be found in the Supporting Information.
Figure 7. Chemo-genetic optimization of assemblies of drug-presenter proteins improves binding to dsDNA.
Comparison of WT streptavidin (a and c) to a genetic variant S112F (b and d) illustrates that the nature of the
metallodrug and presenter protein can influence the binding to dsDNA, as revealed by EMSA on agarose
gels. Lane 1: Marker (M). Lane 2: dsOnc. Lanes 3–11: dsOnc (3.12 mm)+concentration increase of 1"Sav: 0.4,
0.6, 0.8, 1.6, 3.2, 3.9, 7.9, 19.8, 39.6 mm with a 1"Sav/dsOnc ratio from about 0.12 to 12. Lanes 12–20: dsOnc
(3.12 mm) +concentration increase of 2"Sav: 0.4, 0.6, 0.8, 1.6, 3.2, 3.9, 7.9, 19.8, 39.6 mm with a 2"Sav/dsOnc
ratio from about 0.12 to 12. In all cases 500 ng of DNAwas loaded onto the gel.
www.chemeurj.org ! 2010 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Chem. Eur. J. 2010, 16, 12883 – 1288912888
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Crystallization 
X-Ray Crystallography 
Apo-streptavidin was crystallized using the hanging drop vapor 
diffusion technique, as described elsewhere.[6] Rhombohedrally 
shaped crystals were obtained by mixing 5 µL protein solution 
(26 mg/mL in water) with 5 µL crystallization buffer (2 M 
(NH4)2SO4, 0.1 M Na acetate, pH 4.0) and equilibrating the 
droplet against a reservoir of 500 µL crystallization buffer 
for 24 h at room temperature. The soaking solution containing 
[(η6-p-cymene)Ru(Biot-L)Cl] (Biot-L= Biotin-N-(R,R)-3,4-
diaminopyrrolidine) -compound 1- was prepared by mixing 9 µL 
stabilization buffer (3 M (NH4)2SO4, 0.1 M Na acetate, pH 4.0) 
with 1 µL compound 1 solution (50 mM in water). Lyophilized 
streptavidin (about 100-300 µg) was added to the soaking 
solution subsequently to scavenge non-modified biotin. A 
single apo-streptavidin crystal was soaked for 24 h at room 
temperature. Then, the crystal was placed into cryo buffer 
(1.5 M (NH4)2SO4, 0.1 M Na acetate pH 4.0, 25 % glycerol) for 
30 s before it was shock frozen in liquid nitrogen.  
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Diffraction data collection, structure solution and refinement 
Diffraction data were collected at the Swiss Light Source 
(beamline X06DA) using a mar225 mosaic CCD detector at a 
wavelength of 1.589 Å. The crystal diffracted to beyond 2 Å 
resolution. Crystallographic data are given in Supporting 
Table 1. Crystal indexing and data processing was carried out 
using programs MOSFLM/SCALA of the CCP4 suite. The phase 
problem was solved by rigid body refinement with program 
REFMAC 5.5 of the CCP4 suite.[7] For this, the model of the 
isomorphous crystal structure of the [η6-(benzene)RuCl-(Biot-
L)] ⊂ S112-streptavidin (PDB reference code 2QCB) was used, [3]  
with biotinylated Ru complex and water molecules removed. Full 
atom refinement against the maximum likelihood target 
including TLS refinement was performed with REFMAC 5.5.[8] 
Restrained individual B-factors were refined at later stage. 
SigmaA weighted Fo-Fc and 2Fo-Fc electron density maps[9] as 
well as anomalous scattering difference maps[10] were displayed 
with O[11] and COOT.[12] PyMOL was used to produce the structural 
figures for this paper. Coordinates and structure factors have 
been deposited in the Protein Data Bank with identifier 2WPU.  
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Supporting Table 1. Data collection and refinement statistics 
for compound 1 ⊂ streptavidin.*  
*Values in parentheses are for the highest-resolution shell. 
Data Collection 
Resolution (Å) 28.8 – 2.0 
Space Group I4122 
Cell Dimensions (Å) a = 57.7 b = 57.7  c = 183.7 
Rmerge (%) 7.9 (28.1) 
No. unique reflections 10764 
Multiplicity 10.1 (3.4) 
Completeness 97.9 (86.3) 
I/s(I) 17.6 (4.5) 
Refinement 
Resolution (Å) 28.8 – 2.0 
Rwork/Rfree (%) 17.2/ 19.8 
No. atoms  
   Protein  
   Ligand/ions 
   Water 
 
1768 
73 
391 
B-factors (Å2)  
  Protein   
  [?6-(p-cymene)-RuCl(Biot- L)] 1 
  Water 
 
22.0 
26.7 
40.0 
R.m.s deviations   
   Bond legth (Å)  
   Bond angles (o) 
 
0.020 
1.25 
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Overall Structure 
The final protein model comprised residues 13-134 with 96.7 % 
of the residues found in the most-favored regions of a 
Ramachandran plot, and no Ramachandran outliers. As observed 
before[3], both the N-terminal T7 tag (residues 1-12) and 25 
residues at the C-terminus are not resolved, probably due to 
disorder (Fig. S1). 
 
After modeling the well-resolved biotin moiety, the Fo-Fc 
electron density map showed strong residual density extending 
outwards from the biotin, which could be easily interpreted as 
[(η6-p-cymene)Ru(Biot-L)Cl] (Biot-L= Biotin-N-(R,R)-3,4-
diaminopyrrolidine), compound 1 (Fig.S1c). The anomalous 
scattering difference map was consistent with the sulfur and 
ruthenium located in the biotinylated complex 1 as well as 
with a sulfate molecule located close to His87 (Fig. S3d).  
 
Streptavidin forms a tight crystallographic tetramer of 222 
(D2) symmetry with all four biotin binding sites fully 
occupied with compound 1. Residues of two loop regions close 
to the ruthenium head group show slightly increased average B-
factors (Ser 88 (19 Å2), Ser112 (20 Å2), Thr114 (21 Å2), Asn118 
(28 Å2), Trp120 (21 Å2), Lys121 (26 Å2)) compared to β-barrel 
residues next to the biotin head group (Ser27 (19 Å2), Tyr43 
(15 Å2), Asp128 (15 Å2)). The B-factors of the Ru-biotin atoms 
vary from 14 Å2 (for the strongly bound biotin moiety) to 48 Å2 
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(for the solvent-exposed ruthenium head group) (Fig.S2). 
Thereby, the isopropyl and methyl group of p-cymene exhibit 
the highest B-factors (40-43 Å2) and electron density for these 
groups in the 2Fo-Fc map is only about 1σ, indicating that p-
cymene is probably rotationally disordered around the ring 
normal. The B-factors of the ruthenium head group are only 
about 10 Å larger than the surrounding residues. 
 
Apart from the interactions of the biotin core with the 
streptavidin β-barrel that are discussed elsewhere[13] the 
ruthenium head group interacts with loop regions of one 
streptavidin monomer (Fig.S3). We observed the loss of a H-
bridge between the side chain of Ser88 and the carboxylic 
group of biotin due to its amidation. 
 
Finally, the model also contains 116 water molecules, one 
sulfate and one glycerol molecule. 
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Fig.S1 Crystal structure of tetrameric 1 ⊂ Sav: overall 
structure (a and b) and detail of complex 1 bound to 
streptavidin monomer (c and d). (a) Top view of tetrameric 1 ⊂ 
Sav showing the two biotinylated piano-stool complexes in 
relative cis-constellation. (b) Side view on tetrameric 1 ⊂ 
Sav. Cis- and trans-constellations of complexes 1 are 
indicated. See also Fig.3a. (c) Residual electron density in 
the Fo-Fc omit map of the head-group comprising the piano-
stool moiety contoured at 3σ. (d) Anomalous scattering 
difference map contoured at 4.5σ.  
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Fig.S2 Detailed view of two cis-related biotinylated piano-
stool complexes (compound 1) bound by two streptavidin 
monomers. Compound 1 is represented by its surface and color-
coded according to B-factors that range from 12 Å2 (blue) to 43 
Å2 (red).  
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Fig.S3 Stereoview on the binding site between streptavidin and 
the head group of Ru-biotin. Close-up view of the ruthenium 
head group of 1 bound to a Sav monomer (orange) and partially 
interacting with another Sav monomer (aquamarine) also 
containing complex 1 (toward the right of the image). Selected 
residues are shown with side-chains and are labeled. Primed 
residues belong to the monomer in aquamarine. The 2 Fo-Fc 
electron density map of complex 1 bound to one Sav monomer is 
contoured at 1.0 σ. Hydrogen bonds are shown as dashed lines: 
a water bridges the labile chloride ligand and the carbonyl of 
Ser122; the side-chain hydroxyl of Ser112 hydrogen-bonds with 
a Ru-bound amine; the main-chain amide of Asp49 is H-bonded to 
the carbonyl of the biotin moiety of 1. See also Fig.3a. 
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Ruthenium coordination  
In the “piano-stool”-like conformation of the complex, the 
angles between the legs varying between 68o and 92o (Fig.4). 
The aromatic p-cymene is located approximately perpendicularly 
to the axial coordination direction at a distance of 1.83 Å to 
the ruthenium and displays significantly larger angles 
compared to these between the legs. The N1-C1-C2-N2 torsion 
angle is 89o which is by 21o larger than the angle obtained 
after PRODRG[14] energy minimization of 3,4-(R,R)-
diaminopyrrolidine. The bond lengths between ruthenium and the 
amino groups are 2.48 and 2.37 Å, respectively, which is about 
0.2-0.3 Å longer compared to an average value of 2.12 Å (σ = 
0.025 Å) of Ru-NH2R bonds derived from 27 structures in the 
Cambridge Structural Data Base (CSDB).[15] The distance between 
ruthenium and chloride is 2.83 Å. This is by 0.41 Å longer 
than the average of 2.42 Å (σ = 0.049 Å) derived from 115 
structures in the CSDB.[15] We also tried to model a water 
molecule in the electron density. The B-factor of water (37 Å2) 
was smaller than that of chloride (47 Å2) while the B-factor of 
the ruthenium atom was the same in both cases (41 Å2). 
Therefore, it is probably chloride that is bound to ruthenium. 
Furthermore, the distance between ruthenium and water is 2.73 
Å, which is significantly larger compared to an average of 
2.07 Å (σ = 0.050 Å) extracted from 12 structures of the CSDB. 
[15]  Nevertheless, partial substitution of chloride by water 
cannot be excluded, since no chloride was provided during the 
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crystallization and soaking process. The aromatic p-cymene 
undergoes π-bonding to ruthenium. The distances between 
ruthenium and the carbon atoms of the aromatic p-cymene ring 
are between 2.15 and 2.34 Å.  
 
Complex-DNA Interactions 
The pocket in which the ruthenium head group is located is 
composed mainly of polar (Asn149, Ser269, Asn185, Thr1115, 
Asn1118) and basic (His187, Arg184, Lys1121, Lys3121) residues 
from three different streptavidin monomers (subscripted 
letters next to residue identifier refer to different 
monomers).  When omitting one of the cis-related Ru-biotin 
(which would be the predominant constellation in a 2 : 1 
assembly of 1 ⊂ Sav, as used for DNA-binding studies) a large 
pocket would be available for DNA binding (Supplementary Video 
1). This pocket might provide a suitable binding groove for 
DNA: ionic interactions between the DNA phosphate groups and 
the positively charged residues on the protein surface (e.g. 
K121) as well as the substitution of the ruthenium-bound 
chloride by a nucleotide-base nitrogen (N7 or N1 in case of 
purine bases and N3 in case of pyrimidine bases)[16] is 
conceivable. 
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V   Towards in Vivo Catalysis with Artificial Metalloenzymes 
 
 
9. Introduction 
Artificial metalloenzymes are desired to be functional in biological systems amongst others 
for three different reasons: i) to optimize AMEs by directed evolution, ii) to implement AMEs 
in metabolic pathways and iii) for the selective transformation of a prodrug into a drug by 
employment of an AME. 
 
9.1. Directed Evolution of Artificial Metalloenzymes 
The potential of artificial metalloenzymes based on the streptavidin-biotin technology, and 
other systems in asymmetric catalysis has been demonstrated: high enantioselectivity and 
turnover number, reactivity in water at room temperature. The principle opportunity of such 
systems to be further optimized (e.g. high substrate scope, TON, TOF) by chemical and 
genetic means can be acquired by the development of high-throughput in vivo screening 
technologies.  Three main problems need to be addressed to do high-throughput screening of 
streptavidin-biotin-based AMEs: i) the inactivation of many metallocofactors by the cellular 
matrix (mainly by thiol groups, e.g. glutathione), ii) the occupation of Sav with intrinsic biotin 
and iii) the transportation of the cofactor into the cytosol. 
 
9.2. Artificial Metalloenzymes in Metabolic Engineering   
The application of whole cells (e.g. E. coli, bakers yeast) as biocatalyst is thousands of years 
old. To date, numerous technologies are applied to find a good cellular biocatalyst for a 
reaction of interest: i) screening of many microorganisms,96 ii) screening of metagenomes97 or 
iii) metabolic engineering.98 In the latter technique model organisms (e.g. E. coli, bakers 
yeast) are genetically engineered and equipped with heterologous DNA that expresses 
enzymes relevant for the production of pharmaceuticals, fine chemicals or biofuels.  
In principle, synthetic metabolic pathways can be equipped with AMEs to i) reduce the 
number of reaction steps by the use of bioorthogonal reactions (e.g. olefin metathesis) or ii) to 
provide alternative reaction conditions using cheap starting materials (e.g. formate with 
ATHase). Conceptually, an optimized AME can be coexpressed with the metabolic pathway 
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in a heterologous host. Alternatively, an AME can be encapsulated into a cell-permeable 
nanoreactor which is taken up by endocytosis.  
 
9.3. Artificial Metalloenzymes in the Prodrug Strategy 
AMEs that catalyze bioorthogonal reactions (i.e. no background reactivity of the catalyst or 
the substrate with any biomolecule in the organism) can be used to release a drug from an 
inactive prodrug by reaction with a bioorthogonal caging function. AMEs can be encapsulated 
in vesicles that are surface-functionalized with cell-recognition motifs. The AME would be 
transported by the vesicle to the site of interest in the body. An administered unselective 
prodrug would only be transformed into the active drug once it got in contact with the AME 
in the target tissue.  
 
9.4. Vesicular Delivery Systems for the Cellular Uptake of Enzymes 
Amphiphilic molecules can self-assemble to mimick natural membranes and form vesicles. 
Properties of the vesicles like i) size/inner volume, ii) solubility in water, iii) pH-, oxidation-, 
temperature-, magnetic field-, enzyme-stability, iv) incorporation/permeability of cargo or v) 
cell-permeability can be engineered by the selected use of different chemical building blocks 
(e.g. Figure M19).99 Vesicular drug delivery systems (DDS) are important medical tools to 
shield drugs from biodegradation and to improve the pharmacokintetics and target 
selectivity.100 Both, specific uptake of DDSs in human cells by surface-functionalization with 
receptor recognition tags and unspecific endocytosis of unfunctionalized DDSs e.g. by human 
macrophages is possible.  
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Figure M19: Vesicle-forming diblock- and triblock-copolymers. The copolymers are made 
by combination of polymers poly(ethylene ethylene) (PEE), poly(ethylene oxide) (PEO), 
poly(methyloxazoline) (PMOXA), poly(dimethylsiloxane) (PDMS), poly(butadiene) (PBD), 
poly(propylene sulfide) (PPS), poly(styrene) (PS) or poly(acrylic acid) (PAC).99  
 
Meier and coworkers have encapsulated numerous enzymes and enzyme cascades (e.g. beta-
lactamase, lipase, peptidase, peroxidase) in PMOXA-β-PDMS-β-PMOXA-type vesicles.101 
Since the membrane of these vesicles is permeable only for very small or hydrophobic 
solutes, bacterial porin protein OmpF, which is selective for polar compounds, was 
incorporated into the membrane.102 Although the length of the individual blocks of the 
synthetic membrane is significantly larger than the transmembrane part of OmpF, strong 
compression of the polymer is entropically favored and allows incorporation of functional 
porins.103 Inside the stable nanoreactors, enzymes remain functional for several months. It has 
been reported that human macrophages can take up PMOXA-β-PDMS-β-PMOXA-type 
nanocontainers unspecifically. However, functionalization of the vesicle surface with poly 
guanine tags, which specifically recognize cell surface receptors, increases the rate of 
endocytosis.104 Meier and coworkers detected surface-functionalized vesicles charged with a 
fluorescent dye in lysosomes, the Golgi apparatus and the endoplasmatic reticulum of 
macrophages after 1 h incubation time. The vesicles remained structurally integer inside the 
cell for at least 36 hours. Moreover, trypsin-loaded PMOXA-β-PDMS-β-PMOXA vesicles 
(but not empty ones) were found to catalyze the release of a dye from a non-fluorescent 
peptide substrate inside the macrophage. These results encourage the idea to use PMOXA-β-
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PDMS-β-PMOXA-based nanoreactors equipped with streptavidin-biotin-based AMEs for in 
vivo catalysis.   
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10. Fluorescence-Based Assay for the Optimization of  Artificial Transfer 
Hydrogenase Activity within a Biocompatible Compartment 
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Hydrogenase Activity within a Biocompatible Compartment 
  
Tillmann Heinisch[a], Karolina Langowska[b], Pascal Tanner[b], Jean-Louis Reymond[c], Wolfgang Meier[b], Cornelia 
Palivan[b] and Thomas R. Ward[a]* 
In recent years, artificial metalloenzymes which result from 
incorporation of an organometallic cofactor within a host protein 
have emerged as an alternative to the more traditional 
catalysts.[1] We recently reported an artificial transfer 
hydrogenase (ATHase) for the enantioselective reduction of 
imines.[2,3] The ATHase, consisting of a biotinylated [Cp*Ir(Biot-
p-L)Cl] combined with streptavidin (Sav hereafter), was shown 
to remain active under dilute conditions and was compatible 
with cellular debris. While such characteristics are common for 
enzymes, very few homogeneous catalysts have been shown to 
function under such conditions.[4] We thus contemplated the 
possibility of adapting the ATHase for use in chemical biology. 
With this goal in mind, we identified two challenges which need 
to be addressed: i) the development of a transfer-hydrogenation 
reaction which leads to the generation of a fluorescent signal[5] 
and ii) the incorporation of the functional ATHase in a 
biocompatible compartment, Figure 1.[6]  
In order to develop a transfer hydrogenation reaction giving 
rise to a fluorescence signal, we relied on the propensity of 
enones to undergo 1,4-addition in the presence of d6-pianostool 
transfer hydrogenation catalysts.[3d],[7] For this purpose, we 
designed the enone-substrate 1 bearing a caged dye. We 
speculated that the reduced ketone intermediate 2 would 
spontaneously undergo E1cB elimination under physiological 
conditions thus releasing umbelliferone 3, Scheme 1 (See SI for 
the synthesis and characterization of enone 1). 
 
Figure 1. Encapsulation of a hybrid catalyst (protein ribbon display) within a 
polymersome (orange-blue capsule, block-co-polymer PMOXA-β-PDMS-β-
PMOXA) equipped with a pore protein (grey trimer, bacterial pore protein 
OmpF) affords catalytically active artificial organelles (a). The hybrid catalyst 
results from the supramolecular incorporation of a biotinylated pianostool 
complex [Cp*Ir(Biot-p-L)Cl] (stick representation) within streptavidin (solvent-
accessible surface displayed, X-ray crystal structure, PDB code 3PK2) (b). 
 
 
 
 
 
Scheme 1. Fluorescence-based assay for the detection of transfer 
hydrogenase activity. 
When subjected to transfer hydrogenation in the presence 
of ATHase (1 µM [Cp*Ir(Biot-p-L)Cl], 0.5 µM tetrameric Sav), 
aqueous solutions containing enone 1, rapidly became 
fluorescent (λex and λem = 323 and 470 nm, respectively), 
Figure 2. GC- and HPLC chromatographic analysis of the 
reaction mixture revealed the formation of umbelliferone and 2-
methylcyclohexanone as main products (See SI).  
With this straightforward fluorescent assay at hand, the 
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performance of the ATHase was optimized by screening various 
Sav isoforms bearing mutations in the proximity of the Ir-center. 
For this purpose, positions Ser-112 or Lys-121 were selected. 
While most mutations had little or a deleterious effect on the 
ATHase activity, Lys121Phe and Lys121Tyr lead to a significant 
increase in fluorescence in the presence of the corresponding 
ATHases [Cp*Ir(Biot-p-L)Cl]·SavK121F and [Cp*Ir(Biot-p-
L)Cl]·SavK121Y (abbreviated ATHaseK121F and ATHaseK121Y 
hereafter), Figure 2. In the presence of ATHaseK121F, fifty 
turnovers were observed by HPLC after 22 hours. 
With chemical biology applications in mind, the following 
challenges facing ATHase need to be addressed: i) cell 
penetration properties, ii) catalytic activity in vivo and iii) non-
immunogenicity. In view of the size of the artificial 
metalloenzyme (Mw 65 kDa, thus limited uptake by passive 
diffusion or endocytosis)[8] and the reported immunogenicity of 
Sav,[9] we sought to incorporate it into a biocompatible 
polymersome.[6e-f] In recent years, Meier and coworkers 
addressed the challenges outlined above by developing artificial 
organelles.[10] These consist of a triblock ABA copolymer poly(2-
methyloxazoline)-β-poly(dimethylsiloxane)-β-poly(2-methyl-
oxazoline) (PMOXA-β-PDMS-β-PMOXA hereafter) which, even 
in the presence of an enzyme, self-assembles in aqueous 
solution to yield catalytically active compartments of nanometer 
size. These were shown to i) penetrate human macrophages by 
endocytosis, ii) remain stable for several days without leakage 
of the cargo and iii) be non-immunogenic.[10c] Addition of the 
bacterial pore protein OmpF, favors the transit of small 
hydrophobic molecules (Mw < 600 Da) between the artificial 
organelle and its environment, Figure 1 a.[11]  
 
 
 
 
 
Figure 2. Genetic optimization of the catalytic performance of the ATHase 
revealed by the increase in fluorescence upon reduction of substrate 1 with 
concomitant release of umbelliferone 3. [Cp*Ir(Biot-p-L)Cl]·SavWT (red, 
background fluorescence in the absence of ATHase: green), Sav mutants with 
significantly improved activity are highlighted in blue.  
The most active artificial metalloenzyme identified above 
(ATHaseK121F) was encapsulated in PMOXA-β-PDMS-β-PMOXA 
by self-assembly in presence and absence of the bacterial pore 
protein OmpF to yield the corresponding vesicles abbreviated 
ATHaseK121F⊂nanoreactor and ATHaseK121F ⊂nanoreactorOmpF. 
The self-assembly process was followed by extensive dialysis to 
remove the non-encapsulated ATHase and non-incorporated 
OmpF. Titration experiments with biotin-4-fluorescein revealed 
no residual streptavidin on the nanoreactor’s outer-surface after 
dialysis (See SI). The resulting vesicles were characterized by 
transmission electron microscopy imaging as well as 
fluorescence correlation spectroscopy (FCS) (See SF 9). The 
spherical nanocompartments display a diameter varying 
between 10 - 100 nm (Figure 3, left). The encapsulated iridium 
concentration of ATHaseK121F in a nanoreactor sample was 
determined by ICP-MS: ATHaseK121F⊂nanoreactor 7 µM and 
ATHaseK121F⊂nanoreactorOmpF 22 µM. This corresponds to a 
total encapsulation efficiency of ca. 7 % and 22 %, respectively. 
As previously observed the encapsulation efficiency varies 
depending on the protein type.[10d] 
Next, the catalytic activity of both ATHaseK121F 
⊂nanoreactorOmpF and ATHaseK121F⊂nanoreactor was evaluated 
by fluorescence. Catalytic amounts (1 mol% based on iridium 
concentration as determined by ICP-MS) of either 
ATHaseK121F⊂nanoreactor and ATHaseK121F⊂nanoreactorOmpF 
were added to substrate 1 in the presence of sodium formate at 
pH 6.7. The activity of ATHaseK121F⊂nanoreactor is significantly 
reduced compared to free ATHaseK121F. Introduction of OmpF to 
the nanoreactor contributes to partially restore the ATHase 
activity, which remains well below that of the free ATHaseK121F. 
We speculate that the hydrophobic character of both substrate 1 
and product 3 hamper their rapid transit through OmpF which is 
selective for polar solutes, Figure 3.[11] These findings support a 
porin-selective migration of substrate 1 into the nanoreactor, 
although passive diffusion through PMOXA-β-PDMS-β-PMOXA 
occurs to some extent as well. The activity of the 
ATHaseK121F⊂nanoreactorOmpF gradually decreases upon going 
from pH 7.5 to pH 5.0 (See SF 7), thus suggesting that such 
systems may be compatible with cytosolic (pH 7.5) as well as 
early endosomal environments (pH 6.0).[12] Control experiments 
with empty nanoreactors, that were prepared analogous to the 
catalytically competent nanoreactors, showed no fluorescence, 
suggesting that the empty nanoreactors are not catalytically 
competent.   
 
 
Figure 3. Transmission electron microscopy (TEM) image of 
ATHaseS112A⊂nanoreactorOmpF (left). Activity profile of encapsulated and non-
encapsulated ATHaseK121F for the reaction with substrate 1 (right). The 
reactions were carried out at 25 °C at pH 6.7 (100 mM MOPS) using 100 µM 
substrate 1, 0.5 mol% tetrameric SavK121F, 1 mol% [Cp*Ir(Biot-p-L)Cl] and 1.4 
M HCO2Na. The concentration of ATHaseK121F inside nanoreactor was 
determined by ICP-MS.  
Within its spaciotemporal distribution limit, laser scanning 
microscopy (LSM) experiments highlight the formation of 
umbelliferone 3 in the presence of catalytically competent 
nanoreactors. For visualization purposes, sulforhodamine B (a 
dye which is known to remain stranded within vesicles[10c]) was 
incorporated within the nanoreactors. Catalytic amounts (4 
mol%) of ATHaseK121F-loaded and control samples of 
nanoreactorOmpF lacking the ATHase (but including 
sulforhodamine B), were incubated with substrate 1 and formate 
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at pH 6.7. The generation of a fluorescence signal was detected 
after 90 minutes in the proximity of 
ATHaseK121F⊂nanoreactorOmpF. In contrast, the empty 
nanoreactorOmpF did not lead to the generation of the 
fluorescence from umbelliferone 3 (Figure 4 c and d). This 
observation highlights i) the activity of the nanoreactors and ii) 
the slow diffusion of the generated umbelliferone 3 (but not 
sulforhodamine B) out of the nanoreactor as expected from its 
polar character.  
Figure 4. Laser scanning microscopy (LSM) images highlighting 
umbelliferone 3 formation (green color) only in the presence of 
catalytically competent ATHaseK121F⊂nanoreactorOmpF (a and c), 
while the empty nanoreactorOmpF is inactive (d). Sulforhodamine 
B (red color, b, c, e) was co-encapsulated to help localize the 
nanoreactors. The presence of umbelliferone 3 occurs primarily 
in the proximity to vesicles (c, superposition of a and b). The 
reactions were carried out in presence of 250 µM substrate 1, 
~2 mol% tetrameric SavK121F and ~4 mol% [Cp*Ir(Biot-p-L)Cl] 
inside nanoreactorOmpF and 1.5 M HCO2Na at pH 6.7 (100 mM 
MOPS) for 90 min at room temperature. The scalebars 
represent 5 µm. 
Herein we report our efforts to develop a fluorescence-
based assay to visualize transfer hydrogenase activity. For this 
purpose, enone 1 bearing a caged dye was synthesized and 
shown to undergo a cascade 1,4-addition followed by an E1cB 
elimination leading to the release of umbelliferone 3. Genetic 
optimization of the ATHase led to the identification of artificial 
metalloenzymes with significantly improved activities (initial 
rates of ATHaseWT and ATHaseK121F 7.5 and 147 AU/min, 
respectively). It was further shown that ATHase activity was 
maintained upon incorporation of the artificial metalloenzyme 
within a biocompatible vesicle. Importantly, these 
nanocontainers remain active under highly dilute conditions (i.e. 
1 µM Ir-concentration) and are stable under aerobic 
physiological conditions for several months (See SF 8). Current 
efforts are aimed at testing these functional artificial organelles 
in vivo.   
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General Information 
 
Analytical RP-HPLC (Agilent Series 1100):  
Separations were carried out with a Dr. Maisch Reprospher C18-DE column (150 x 4.6 mm, 5 µm 
particle size) using eluent A (water, 0.1 % trifluoroacetic acid (TFA)) and B (acetonitrile, 0.1 % 
TFA). The following method was used: flow rate 1 mL/min, detection of umbelliferone and its 
derivatives at 323 nm; 0 - 2 min (80 % A, isocratic), 2 - 10 min (gradient 80 → 20 % A).     
 
Semi-preparative RP-HPLC (Waters PrepLC4000):  
Separations were carried out with a Dr. Maisch Reprospher C18-DE column (150 x 20 mm, 5 µm 
particle size) using eluent A (water, 0.1 % TFA) and B (acetonitrile). The following method was 
used: flow rate 15 mL/min, UV detection at 254 nm; 0-3 min (70 % A, isocratic), 3-18 min 
(gradient 70 → 20 % A).   
 
Chiral phase GC (FID, Agilent 6890 Series):  
Separations were carried out on a Supelco-β-dex 120 (60 m x 0.25 mm, 0.25 µm film thickness). 
The following method was applied: 0 - 30 min (70 °C, isothermal). 
 
Substrate Synthesis 
 
 
Supporting Figure 1: Two-step synthesis of substrate 1 
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Synthesis of Compound 0 
  
0 
 
The synthesis of alcohol 0 was carried out following a literature protocol.[1] To a solution of 1-
cyclohex-2-enone (14.9 g, 155 mmol) and 4-dimethylaminopyridine (DMAP, 1.83 g, 15 mmol) in 
50 mL THF a 37 % aqueous formaldehyde solution (25.2 g, 310 mmol) was added and the mixture 
was stirred at room temperature for 20 h. To the brown solution, 1.5 N hydrochloric acid was added 
dropwise until the color of the solution turned red (final pH 2 - 4). The aqueous solution was 
extracted with 2x 100 mL DCM and washed with saturated bicarbonate solution and brine. The 
organic layer was dried with Na2SO4 before the solvent was evaporated at the rotavap. Silicagel flash 
chromatography with an eluent mix of EtOAc:Hex (2:3) yielded 10.5 g (55 % yield) of a yellow oil.   
NMR-Spectroscopy: 1H-NMR (400 MHz, CDCl3): δ 6.88 (1H, t, J = 4.2, Hallyl), 4.14 (2H, d, J = 1.4, 
CH2), 3.17 (1H, bs, Halcohol), 2.36 - 2.29 (4H, m, CH2), 1.93 - 1.88 (2H, m, CH2). 13C-NMR (400 
MHz, CD3CN): δ 200.4, 146.7, 138.2, 61.1, 38.1, 25.5, 22.6 
 
Synthesis of Substrate 1 
     
 
   1 
A 25 mL Schlenk flask was flame-dried under vacuum and flushed several times with nitrogen 
before adding umbelliferone (64.2 mg, 0.40 mmol) and triphenylphosphine (105 mg, 0.40 mmol), 
which were dissolved in 5 mL dry THF by stirring at room temperature. Next, alcohol 0 (50 mg, 
0.40 mmol) was added and the solution was cooled to 0 °C on an ice bath. To start the reaction, 
diisopropyl azodicarboxylate (DIAD, 80.9 mg, 0.40 mmol) was added within 10 min to the colorless 
solution. After thirty minutes, the mixture was allowed to warm up to room temperature. The 
progress of the reaction was followed by reversed-phase HPLC, which indicated reaction 
completion after 2 hours. The reaction mixture was first separated by silicagel  chromatography 
(EtOAc:Hex 1:2), which yielded a mixture of umbelliferone and substrate 1. Pure compound 1 was 
obtained after additional purification by semi-preparative HPLC (see details above). Acetonitrile 
O
OH
O OO
O
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was removed under reduced pressure. The remaining aqueous solution was frozen in a liquid 
nitrogen bath prior to lyophilization overnight to yield a white powder of substrate 1  (48 mg, 45 % 
yield). 
 
MS (ESI, positive mode, Bruker Micro-TOF): m/z 271.10 [M + H+], 293.1 [M + Na+] calculated 
mass for C16H14O4 270.09 
 
1H-NMR (400 MHz, CD3CN): δ 7.78 (1H, d, J = 9.6, HAr), 7.49 (1H, d, J = 9.3, HAr), 7.16 (1H, t, J 
= 4.2, Hallyl), 6.90 - 6.87 (2H, m, HAr), 6.20 (1H, d, J = 9.5, HAr) , 4.70 (2H, d, J = 1.4, CH2), 2.45 - 
2.40 (4H, m, CH2),  2.03 - 1.97 (2H, m, CH2) 
 
13C-NMR (400 MHz, CD3CN): δ 198.9, 162.8, 161.7, 156.9, 150.2, 144.7, 135.0, 130.3, 113.9, 
113.6, 102.6, 66.5, 38.8, 26.5, 23.5  
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Synthesis of [Cp*Ir(Biot-p-L)Cl]  
 
Complex [Cp*Ir(Biot-p-L)Cl] was synthesized according to Letondor et al.[2] 
 
Synthesis of PMOXA-β-PDMS-β-PMOXA (PMOXA16-PDMS72-PMOXA16) block 
copolymer.  
 
Poly(2-methyloxazoline)-block-poly(dimethylsiloxane)-block-poly(2-methyloxazoline) (PMOXA16-
PDMS72-PMOXA16) (Supporting Figure 2) block copolymer was synthesized by cationic ring 
opening living polymerization (CROP) according to the method.1,[3] 
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Supporting Figure 2: PMOXA-β-PDMS-β-PMOXA block copolymer. 
 
 
Expression and Purification of Streptavidin Mutants 
 
Sav mutants were expressed and purified as described in Humbert et al. and Klein et al.[4],[5]  
 
 
PH Stability of Substrate 1 
 
To determine the stability of the umbelliferone derivative 1 at different pH values, solutions of 50 
µM 1 in 100 mM MES (pH 5.7), 100 mM MES (pH 6.2), 100 mM MOPS (pH 6.7), 100 mM MOPS 
(pH 7.3), 100 mM MOPS (pH 7.9), 100 mM Tris (pH 8.1) and 100 mM Tris (pH 8.6) were prepared 
and the solution’s emission at 470 nm (λexcitation = 323 nm) was followed over time on a Tecan Safire 
plate reader (Supporting Figure 3).  
 
 
Supporting Figure 3: pH stability of substrate 1. 
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Determination of Absorption and Emission Maximum of Umbelliferone and 
Substrate 1  
 
Stock solutions of umbelliferone and substrate 1 (10 mM in DMF) were diluted 1000x in 100 mM 
MOPS, pH 6.7 before measuring absorption (Shimadzu, UV-1800) and emission spectra (excitation 
wavelength 330 nm, on a Shimadzu, RF-5301PC) in a quartz cuvette (Supporting Figure 4).  
 
 
Supporting Figure 4: Absorption (solid line) and fluorescence (dashed line) spectra of substrate 1 
(red) and umbelliferone (blue) 
 
General Procedure for Transfer Hydrogenation of 1 by ATHase  
 
The following stock solutions were prepared: (I) 3 M sodium formate in 100 mM MOPS, pH 6.7, 
(II) 0.0275 mM tetrameric Sav mutant in 100 mM MOPS, pH 6.7, (III) 0.550 mM [Cp*Ir(Biot-p-
L)Cl] in DMF, (IV) 0.2 mM substrate 1 in 10 % DMF and 100 mM MOPS, pH 6.7. 
 
To prepare an ATHase stock solution of 50 µM concentration (with respect to the biotinylated 
iridium complex), the stock solutions of Sav mutant (II) and of complex [Cp*Ir(Biot-p-L)Cl] (III) 
were mixed in the ratio 10:1 and were incubated for 10 min. Unless otherwise mentioned, reactions 
were carried out as following: In a 96-well black Nunc plate, 120 µL stock solution I (1.44 µM final 
formate concentration) were mixed with 5 µL ATHase stock solution (final concentration of 
biotinylated iridium complex 1 µM). The reaction was initiated by addition of 125 µL substrate 
stock solution (IV) (final substrate concentration 100 µM) and vigorous shacking of the 96-well 
plate in a plate reader (Tecan Safire). Fluorescence change was followed at 25 °C in 1 min intervals 
at excitation and emission wavelengths of 323 and 470 nm, respectively. Prior to measuring, 
300 400 500 6000
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samples were shaken for 10 seconds. All samples were determined in triplicate. 
 
Transfer Hydrogenation of 1 with Different ATHase Mutants 
 
Supporting Table I: Initial rates of reactions of ATHaseS112X-K121X mutants with substrate 1 and 
conversion/turnover number of ATHaseK121F. The reaction conditions used were those described 
above using 1 µM complex [Cp*Ir(Biot-p-L)Cl] and 0.5 µM tetrameric Sav mutant.   
Sav mutant Initial rate (AU/min) 
No ATHase  -7 
WT 7.5 
S112A 5 
S112R 4 
S112T 8 
S112K 2 
S112E -5 
S112F 13 
S112L 1 
S112V 7 
S112Y 7 
S112Q -3 
S112N 0 
S112C 0 
S112H 5 
K121H -5 
K121D 1 
K121A 22 
K121R 13 
K121F 147a 
K121Y 96 
K121N 54 
aThe conversion (50%), correspoding to 50 turnovers, was determined using the HPLC method 
described in the general information. The response factor (1.1) between umbelliferone 3 and enone 
1 at 323 nm was established using purified compounds 1 and 3. The substrate conversion was then 
determined by integration of the peak areas of substrate 1 and product 3. No other product could be 
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detected by 1H NMR. 
 
Characterization of Reaction Products by Chiral-Phase GC 
 
 
Supporting Figure 5: A reaction in presence of ATHaseS112A was carried out as described above. 
For GC analysis of the reaction products, the reaction mixture was extracted with Et2O and the 
organic phase was analyzed by chiral-phase GC as described above. Comparison of the 
chromatogram with that of pure racemic 2-metylcyclohexanone (red curve) indicates exclusive 
formation of (rac)-2-methylcyclohexanone in presence of ATHaseS112A.  
 
 
Preparation of Catalytic Nanoreactors 
  
In a 10 mL flask 15 mg PMOXA16-PDMS72-PMOXA16 polymer were dissolved in 1 mL EtOH 
using a vortex. If needed 200 µL OmpF stock solution (1.7 mg/mL in H2O) were added to the 
suspension. Next, the suspension was connected to a rotavap and the EtOH was evaporated (40 °C, 
160 mbar) for 15 - 30 min. The pressure was then reduced to 70 mbar for another 30 min to remove 
water until a thin film remained at the bottom of the flask. To form the nanoreactors, 2 mL ATHase 
racemic, 99% purity
O
O O O
[Cp*Ir(Biot-p-L)Cl] (1 mol%)
tetrameric SAVS112A (0.5 mol%)
MOPS buffer (0.1 M), pH 6.7
HCO2Na (1.4 M)
O
OH O O
+
O[Cp*Ir(Biot-p-L)Cl] (1 mol%)
tetrameric SAVS112A (0.5 mol%)
MOPS buffer (0.1 M), pH 6.7
HCO2Na (1.4 M)
O
0.1 mM
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solution (0.05 mM tetrameric Sav mutant and 0.1 mM complex [Cp*Ir(Biot-p-L)Cl]  in 100 mM 
MOPS, pH 6.7) were added to the polymer film and the mixture was stirred for 12 hours after which 
the solution became turbid. The suspension was transferred into a dialysis tube (300 kDa cut off) 
and dialyzed against 3x 500 mL of 10 mM MOPS, pH 6.7, for 72 hours. Finally, the suspension was 
stored at 4 °C. 
 
Control Experiments to Measure ATHase Adhesion on the Nanoreactor Surface 
 
Because of the high affinity (KD < 10
-14 M), the fast association and the non-cooperative binding of 
the fluorescent molecule biotin-4-fluorescein (B4F) to Sav, it is routinely used to determine the 
number of free biotin binding sites in Sav.[6] To determine if residual streptavidin is present on the 
nanoreactor outer surface, 0.05 mM tetrameric SavWT were incubated with 2.0 eq. (0.1 mM) 
[Cp*Ir(Biot-p-L)Cl] in 100 mM MOPS buffer (pH 6.7) thus affording only half occupied 
streptavidin tetramers. Such tetramers are thus prone to bind up to two equivalents B4F. ATHaseWT 
was encapsulated in the presence and the absence of OmpF. After extensive dialysis, samples of 
nanoreactors were diluted 10x and were titrated with aliquots of B4F (0.025 – 2 µM) in 100 mM 
MOPS (pH 6.7). The fluorescence of the resulting samples was measured. All measurements were 
carried out in triplicate. After the first measurement, ATHaseWT⊂ nanoreactor was treated with 2 % 
triton X 100 for 2 days at 4 °C and the fluorescence measurement was repeated. Fluorescence 
quenching is detected in samples of nanoreactor in presence of pore OmpF highlighting B4F 
binding to streptavidin inside the nanoreactor (Supporting Figure 6). In absence of OmpF 
fluorescence quenching of B4F is only detected after preincubation of the nanoreactor with 
detergent for 2 days. This strongly supports the absence of streptavidin on the nanoreactor outer 
surface after extensive dialysis. As expected, the control experiment with 1 µM BSA did not yield 
any fluorescence quenching.  
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Supporting Figure 6: Investigation of nanoreactors for Sav binding on the outer surface by B4F 
titration in presence of: ATHaseWT⊂nanoreactorOmpF (green circles, molar ratio tetrameric Sav: 
complex [Cp*Ir(Biot-p-L)Cl] is 0.5:1.0), ATHaseWT⊂nanoreactor (blue circles, molar ratio 
tetrameric Sav : complex [Cp*Ir(Biot-p-L)Cl]  is 0.5:1.0), ATHaseWild-Type⊂nanoreactor incubated in 
presence of 2 % triton X 100 for 2 days (red squares) and BSA (orange diamonds). Intersections of 
lines indicate saturation of streptavidin with B4F. 
 
Determination of the Concentration of [Cp*Ir(Biot-p-L)Cl] Inside the 
Nanoreactors by ICP-MS 
 
Samples of purified ATHaseK121F⊂nanoreactorOmpF  and ATHaseK121F⊂nanoreactor were analyzed 
by Solvias LTD by ICP-MS analysis. The iridium concentrations were 3.9/4.5 mg/kg (duplicate) 
(average: 22 µM iridium) and 1.4/1.4 mg/kg (duplicate) (7.3 µM iridium) for 
ATHaseK121F⊂nanoreactorOmpF  and ATHaseK121F⊂nanoreactor, respectively.  
 
PH-Dependency of the Activity of ATHaseK121F⊂NanoreactorompF  
With in vivo applications of ATHaseK121F⊂nanoreactorOmpF in mind, the colorimetric assay was 
tested at pH 7.5 (to simulate cytosol), pH 6.0 (to simulate early endosomes) and pH 5.0 (to simulate 
late endosomes and lysosomes).[7] Reactions were carried out as described in the general procedure 
using a final concentration of 2 µM (2 mol%) ATHaseK121F inside nanoreactorOmpF. To adjust the 
pH, buffers using acetic acid (pH 5.0), MES (pH 6.0) and MOPS (pH 6.7 and 7.5) were used 
(Supporting Figure 7).  
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Supporting Figure 7: PH-dependency of reactivity of ATHaseK121F⊂nanoreactorompF. 
 
Stability of ATHaseK121F⊂NanoreactorompF  
To investigate the stability of the most reactive ATHaseK121F inside the nanoreactorOmpF, the 
colorimetric activity was measured two weeks and 14 weeks after the encapsulation. The 
ATHaseK121F⊂nanoreactorOmpF was stored under aerobic conditions at 4 °C. Catalytic reactions were 
carried out as described in the general procedure using 1 µM (1 mol%) ATHaseK121F in the 
nanoreactorOmpF. 
 
 
Supporting Figure 8: Stability of ATHaseK121F⊂NanoreactorompF under aerobic conditions. 
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Determination of the Hydrodynamic Radius of the Catalytic Nanoreactors by 
Fluorescence Correlation Spectroscopy (FCS) 
 
Fluorescence correlation spectroscopy (FCS) measurements were performed at room temperature in 
special chambered quartz glass holders (Lab-Tek; 8-well, NUNC A/S), on a Zeiss LSM 510-
META/ConfoCor2 laser-scanning microscope equipped with a Helium/Neon laser (543 nm) and a 
40x water-immersion objective (Zeiss C/Apochromat 40x, NA 1.2), with pinhole adjusted to 78 µm. 
Spectra were recorded over 10 s, and each measurement was repeated 30 times. The excitation 
power of the HeNe laser was PL = 1 mW, and the excitation transmission at 543 nm was 5%. The 
diffusion time for the free dye (sulforhodamine B) was independently determined and fixed in the 
fitting procedure. The results were presented as a mean value of three independent measurements. 
 
The encapsulation of a fluorescent dye was analyzed via fluorescence correlation spectroscopy. 
Laser-induced fluorescence of molecules passing through a small confocal probe volume auto-
correlates over time and provides information on the diffusion time of the molecule, τD.[8]  
Differences in diffusion times are related to changes in the hydrodynamic radius via the Stokes-
Einstein relation, and permit the determination of interactions with larger assemblies such as the 
encapsulation in polymeric systems.[9] The normalized FCS autocorrelation curves of dye-
containing vesicle solutions were compared to those of free dye. (Supporting Figure 9) Significant 
differences in the diffusion times were obtained. While the diffusion time of the free dye was 
calculated to 47 ± 7 µs, the best fit of the autocorrelation function of the dye-containing vesicle 
solution, taking into account only one population, resulted in a clearly increased diffusion time of 
10.8 ± 1.6 ms. This points out that sulforhodamine B is most probably encapsulated inside the 
aqueous cavity of polymeric vesicles. The diffusion time was used in order to calculate the 
hydrodynamic radius of the free dye and the dye-encapsulated vesicles according to the Stokes-
Einstein equation.[10] The hydrodynamic radius of sulforhodamine B was evaluated to be 0.5 ± 0.1 
nm, which corresponds to the theoretical value of 0.6 nm calculated on basis of the molecular 
weight of the dye. For the measured vesicles, the hydrodynamic radius was determined to 126 ± 19 
nm. This is in good agreement with observations from TEM microscopy. 
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Supporting Figure 9: Normalized FCS autocorrelation curves of A) free sulforhodamine B and B) 
sulforhodamine B-encapsulated vesicles. Dotted lines are fitted curves. 
 
 
Imaging the Cleavage of Substrate 1 Inside the Catalytic Nanoreactors by 
Fluorescence Microscopy 
 
Fluorescent product formation by catalyst- and sulforhodamine B-encapsulated vesicles were 
imaged with a confocal laser scanning microscope (Zeiss LSM 510-META/Confcor2), in LSM 
mode, using the Laser Diode 405 (405 nm) with a power of 25 mW and 30 % transmission and a 
Helium/Neon laser (543 nm), power 1 mW, 28.5 % transmission, in combination with a 40x water-
immersion objective (Zeiss C/Apochromat 40x, NA 1.2). Pinhole-, gain-, amplifier offset- and 
amplifier gain-settings were corrected for solvent-background and fixed for further measurements. 
The settings were crosschecked in order to exclude imaging artefacts. 
 
20 µL of the vesicle solutions were placed in special chambered quartz glass holders (Lab-Tek; 8-
well, NUNC A/S) and the measurements of the samples containing catalyst-encapsulated vesicles as 
well as of vesicles without catalyst after addition of substrate respectively were performed at room 
temperature for duration of 90 min.  
 
 
 
 
 
 
	
  	
  	
   144 
SI Bibliography 
 
[1] F. Rezgui; M. M. ElGaied; J. Chem. Res. 1999, 576–577. 
[2]  C. Letondor; A. Pordea; N. Humbert; A. Ivanova; S. Mazurek; M. Novic; T. R. 
Ward; J. Am. Chem. Soc. 2006, 128, 8320–8328. 
[3]  C. Nardin; T. Hirt; J. Leukel; W. Meier; Langmuir 2000, 16, 1035–1041. 
[4]  N. Humbert; A. Zocchi; T. R. Ward; Electrophoresis 2005, 26, 47–52. 
[5]  G. Klein; N. Humbert; J. Gradinaru; A. Ivanova; F. Gilardoni; U. E. Rusbandi; T. R. 
Ward; Angew. Chem. Int. Ed. 2005, 44, 7764–7767. 
[6]  G. Kada; H. Falk; H. J. Gruber; Biochim. Biophys. Acta 1999, 1427, 33–43. 
[7]  C. Lafourcade; K. Sobo; S. Kieffer-Jaquinod; J. Garin; F. G. van der Goot; PloS one 
2008, 3, e2758. 
[8]  S. Litvinchuk; Z. Lu; P. Rigler; T. D. Hirt; W. Meier; Pharm. Res. 2009, 26. 1711-
1717. 
[9]  F. Axthelm; O. Casse; W. H. Koppenol; T. Nauser; W. Meier; C. G. Palivan; J. Phys. 
Chem. B 2008, 112, 8211-8217. 
[10]  P. Zhang; L. Li; C. Dong; H. Qian; J. Ren; Anal. Chim. Acta 2005, 546, 46–51.  J. 	
  	
  	
  	
  
 
 
 
 
 
 
 
	
  	
  145 
10.1. Author Contributions 
General idea:  
Thomas R. Ward 
 
Synthesis of substrate: 
Tillmann Heinisch, Jean-Louis Reymond 
 
Activity screening of Sav mutants: 
Tillmann Heinisch 
 
Synthesis and characterization of polymer: 
Karolina Langowska 
 
Production of nanoreactors: 
Tillmann Heinisch, Karolina Langowska 
 
Transmission electron microscopy experiments:  
Karolina Langowska 
 
Fluorescence microscopy experiments: 
Pascal Tanner, Tillmann Heinisch 
 
Manuscript writing: 
Tillmann Heinisch, Thomas R. Ward and all other authors 
 
 
 
 
 
 
 
 
 
	
  	
  	
   146 
10.2. Comment on Publication 
10.2.1. Compatibility of the Fluorescence Assay with in Vivo Conditions 
The stability of quenched umbelliferone 6_1 in a cellular matrix was tested in an E. coli 
cell free extract which was resuspended in an aqueous buffer at pH 7.3. Shortly after 
addition of the substrate, fluorescence release was observed (Figure M20a). Cellular thiol 
compounds were suspected to react with the Michael-acceptor function of the substrate. To 
test this hypothesis, the substrate was added to an aqueous solution with 3 mM glutathione 
(the estimated concentration of glutathione in the cytosol of E. coli is 17 mM)105 and 
buffered at pH 6.7. Indeed, a rapid increase in fluorescence was observed immediately 
after the start of the reaction (Figure M20b).  
 
a)       b) 
Figure M20: Stability of quenched umbelliferone 6_1 in E. coli cell free extract (a) and in 
presence of glutathione (b). 
  
10.2.2. Outlook 
Although we choose an artificial transfer hydrogenase developed in our group with high 
TON and TOF for encapsulation in PMOXA-β-PDMS-β-PMOXA type vesicles, in 
principal any AME can be encapsulated. The priority of future experiments will be the 
demonstration of in vivo activity of encapsulated AMEs. Towards this end, a substrate has 
to be developed together with an AME, which is bioorthogonal. For example, an 
encapsulated olefin metathesis AME could be used in conjunction with a non-fluorescent 
bis-olefin substrate that would become fluorescent upon ring-closing metathesis.47 
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Moreover, in addition to the AME, other enzymes can be encapsulated to test the concept 
of reaction cascades in a nanoreactor.106  
The 1,4 addition of an enone by a ATHase was demonstrated for the first time in this work. 
This concept can be expanded towards other enones with multiple substitution patterns and 
functionalizations. Of special interest would be to test the potential of the ATHase in the 
ATH of enones.  
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VI  Quantitative Model of a Streptavidin-K2[OsO2(OH)4] Crystal 
with an Ambiguous Packing Disorder 
 
 
11. Introduction 
The Bragg reflections scattered by a crystal lattice represent a time- and space-average of a 
multitude of different atomic positions within the crystal. Positional variation of molecules 
within the crystal is not expressed in the diffraction pattern as long as it does not affect the 
periodicity of translation of individual unit cells. Once the periodicity is altered or broken, 
it is manifested by an increased symmetry of the crystal lattice (e.g. indication for 
merohedral twinning), the presence of satellite reflections next to the Bragg reflections 
(indication for alternative unit cells) or by diffuse spots (indication for non-periodic 
disorder).107 Although the crystallization of most small molecules and proteins can be 
achieved without significant packing defects, pathological crystals exist for which, in order 
to solve the structure, it is essential to understand and model the packing disorder.108,109 
In this study, upon soaking an apo-Sav crystal with K2[OsO2(OH)4], problems were 
encountered in structure solution, which were traced back to an incommensurate crystal 
packing disorder.  
 
12. Experimental Part 
Sav Crystallization and K2[OsO2(OH)4] Soaking: 
Purified wild type Sav (a construct with the 12 N-terminal residues of native Sav replaced 
for a T7-tag) was crystalized by the sitting-drop vapor-diffusion technique within one 
week. A volume of 0.2 µL of a protein stock solution (15 mg/mL in water) was mixed with 
0.2 µL of crystallization buffer (0.2 M magnesium acetate, 30 % PEG 3350, pH 7.5). The 
flat, square-shaped crystals where soaked for 1 h in 10 µL of an osmium solution (10 mM 
K2[OsO2(OH)4], 0.2 M magnesium acetate, 30 % PEG 3350, pH 7.5). After the soaking, 
crystals were shock-frozen in liquid nitrogen.  
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X-ray Data Collection: 
Diffraction data were collected at the Swiss Light Source beam line PX3 at a wavelength 
of 0.9793 Å at 100 K to a resolution of 2.4 Å. Reflection sampling was carried out on a 
CCD detector at a φ-slicing resolution of 1° per image.   
 
Data Indexing, Processing, Molecular Replacement and Structure Refinement:   
The diffraction data was indexed and processed using software MOSFLM (ccp4 suite). 
Program POINTLESS (ccp4 suite) was consulted for analysis of the crystal lattice and 
space group determination. The integrated reflections were merged and truncated using 
software SCALA and TRUNCATE (both ccp4 suite), respectively. Molecular replacement 
was carried out with MOLREP (ccp4 suite) and rigid body, as well as full atomic 
refinement with program REFMAC 5 (ccp4 suite). Program O was used to illustrate the 
crystal packing and the electron density distribution. Diagrams were drawn with PROFIT.  
 
13. Results and Discussion 
Data Processing in P1 and Analysis of Crystal Lattice: 
The reflections were indexed in space group P1 with the unit cell dimensions being very 
close to those of a cuboid (a virtually the same as b; α, β and γ close to 90°, Table M3). 
Inspection of the indexed reciprocal lattice indicated sharp reflections on lattice planes 
orthogonal to c* (Figure M27). In contrast, diffuse reflections were observed along c*, 
e.g. on lattice plane [-2 k l]. The observation of diffuse reflections along c* will be 
rationalized later in this chapter. 
After integration of the reflections in P1, analysis of the crystal lattice with POINTLESS 
revealed two 2-fold symmetry axes along the two diagonals of the a,b-face of the P1 cell 
and an additional 2-fold axis along c. These observations indicated the presence of a 
Cmmm space group.  
 
Merging of Reflections in P1,C222 and C2: 
To find the correct space group, the P1-processed data were reprocessed and scaled in all 
space groups that correspond to Cmmm (Table M3, C2221 not shown). Note that the 
assignment of the crystallographic axis in C2 can be either along [1 1 0] (C2a) or [-1 1 0] 
(C2b) with respect to the triclinic cell. Scaling in C2a gave slightly better statistics.  
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Table M3: Statistics of data processing and merging of different space groups compatible 
with the osmium-soaked Sav crystal. 
 P1 C222 C2a C2b C2 (2bc3)  
Space Group P1 C222 C2 C2 C2 
a 57.46 81.20 81.20 81.60 81.70 
b 57.66 81.60 81.60 81.20 82.39 
c 91.50 91.50 91.50 91.50 46.71 
α 89.90 90 90 90 90 
β 89.73 90 90.26 90.12 103.48 
γ 90.28 90 90 90 90 
Rsym  0.109 0.095 0.104  
I/s(I)  8.4 6.7 5.6  
Multiplicity  4.6 2.7 2.5  
Nref  7154 11926 12889  
 
The Molecular Replacement Model and Native Patterson Map: 
First, molecular replacement in the highest symmetry space group C222 was carried out. 
As a search model, the Sav dimer (half of one Sav homotetramer) in the asymmetric unit 
of the structure with pdb code 2bc3 was used. The search model crystalized in a monoclinc 
C2 cell with the lengths of axes a and b, as well as the angles α and γ being virtually 
identical to the corresponding axes and angles in the C222 cell (Table M3). In 2bc3, the 
crystallographic dyad along b is identical with the local 2-fold axis r that relates the two 
monomers of the dimer in the AU (Figure M21a, Figure M23a and b). Application of the 
local dyad q, which is close to parallel to a, constitutes the Sav tetramer. Alternatively, the 
Sav tetramer can be formed by application of the rotational symmetry along the local 2-
fold axis p, which is virtually orthogonal to a and b. In the a,b-plane, neighboring Sav 
tetramers form c-centered layers (Figure M21b). Neighboring layers span an angle equal 
to unit cell angle β with the a,b-plane. The relative translation in b-direction, ±Δb, of 
successive layers can be calculated as  
 
Δb = c * sin (β ± 90°) = 46.7 Å * sin (103.5° ± 90°) = ±10.5 Å 
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In fractional coordinates, this is equal to  Δy = ±0.13. The translation vector of successive 
layers in all three dimensions is (0.00 0.13 0.50). 
A strong (12 σ) pseudo-origin peak with coordinates (0.00 -9.28 45.75) was detected in the 
native Patterson map of the C222 cell. This corresponds to the fractional coordinates (0.00 
0.11 0.50), which are virtually identical to the translation vector of two successive layers in 
the search model. This observation and the similarities of the crystallographic c-faces, 
strongly suggest an identical packing of successive a,b-layers in the crystal 2bc3 and the 
osmium-soaked crystal. However, the Bragg reflections of the osmium-soaked crystal did 
not allow the indexing in C2 with the same unit cell dimensions as the search model 2bc3.  
 
  
a                                                                  b  
Figure M21. Crystal packing of streptavidin structure with pdb code 2bc3 (space-group 
C2). a) Representation of b-face with view along b (a horizontal). b) Representation of c-
centered face with view along c (b horizontal). 
 
 
Molecular Replacement in C222: 
As expected from the volume of the C222 cell and a number of eight AUs in the unit cell, 
a Sav dimer was found in the MR search procedure. Besides axes a and b, that are 
exchanged in C222 relative to the search model, the c-face is equally organized in both 
crystals. However, due to the doubled length of axis c (Figure M23c), the unit cell 
accommodates two a,b-layers (layer I and II), which are related by a crystallographic 21-
axis along c. The dimer in the asymmetric unit can be transformed into a tetramer by 
application of the crystallographic dyad along b (equal to local q axis), the crystallographic 
dyad parallel a (equal to local r axis) and the local 2-fold rotation axis parallel c (equal to 
local p axis, Figures M22a and b and Figure M23c). Since the orientations of axes c and 
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p are virtually identical (0.55°), the same is true for the orientation of layers I and II. Thus, 
application of the 21-screw symmetry along c is virtually identical to a translation of a Sav 
dimer along vectors ±t, which correspond to the pseudo-translation peak in the native 
Patterson map and the orientation of the c axis in the search model.  
Rigid body refinement of the crystal in C222 converged at a relatively high value of Rfree 
of 40 %. Molecular Replacement (MR hereafter) in C2221 did not yield a solution. For this 
reason the MR and refinement procedures were repeated in lower symmetry space group 
C2a.  
 
  
a                                                                       b 
Figure M22. Crystal packing of osmium-soaked Sav crystal (space-group C222). a) 
Representation of a-face (b horizontal). b) Representation of c-centered face with view 
along c (b horizontal). Note: molecular axis q (horizontal) is congruent with 
crystallographic dyad in b direction (z=¼), see also Figure M23c.  
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Figure M23: Locations of local (green color, see panel b for axes’ definition) and 
crystallographic (black color) symmetry axes in 2bc3 (a), C222 (c) and C2 (d). 2-fold 
rotational symmetry axes are shown as arrows and ellipses, 21-screw symmetry axes are 
shown as half-arrows.  
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Figure M24: Ambiguity of stacking of successive a,b-layers of Sav tetramers (barrels) in 
±Δb.   
 
 
Molecular Replacement in C2 and Ambiguous Packing Disorder: 
When reducing the symmetry from C222 to C2a, all crystallographic symmetry axes along 
a and c become local symmetry axes. Sav tetramers in layer I and II are not anymore 
related by a 21-screw axis along c. Instead, the volume of the AU is doubled and 
accommodates two Sav dimers, one in layer I and a second in layer II. Here, a packing 
ambiguity occurs in layer II, since the second dimer can be located either in position (0.00 
0.11 0.50) or (0.00 -0.11 0.50) (Figure M24). To proof this, a search procedure to find the 
dimer position in layer II with the lowest R-factor was carried out by rigid body refinement 
(Figure M25). Indeed, two clear minima were found in positions (0, 9.31, 45.75) (ghosta) 
and (0, -9.31, 45.75) (ghostb). 
To investigate the average relative abundance of the two dimers in positions (0, 9.31, 
45.75) and (0, -9.31, 45.75) throughout the whole crystal, the occupancy with the 
minimum R-factor was determined (Figure M26). For each dimer in position (0, 9.31, 
45.75) and (0, -9.31, 45.75), a minimum was detected at an occupancy of 0.2 (the dimer in 
layer I was set to 100 % occupancy). However, a model including both dimers with each 
an occupancy of 0.2 in layer II and one dimer with 100 % occupancy in layer I yielded a 
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significantly worse R-factor. This could be due to the technical problem of excluding 
intermolecular interactions (between the dimers in layer II) in the refinement procedure. 
In summary, the rigid body search procedure for the optimal position and occupancy of the 
Sav dimer in layer II of the AU of the monoclinic unit cell yielded two equivalent 
solutions and confirms the hypothesis of an ambiguous disorder of the packing of 
successive a,b-layers. 
 
Figure M25. R-factor search for position of dimer in layer II with fixed dimer in layer I (at 
100 % occupancy) with rigid body refinement. Blue color respresents low and red high R-
value. 
 
 
Figure M26. R-factor search for occupancy of dimer in layer II with fixed dimer in layer I 
(at 100 % occupancy) with rigid body refinement. Dimers in layer II were positioned at the 
optimal positions that are as given in Figure M25 (Ghosta: x,y,z= 0, 9.31, 45.75 Å; ghostb 
= 0, -9.31, 45.75; ghosta+b: both positioned). 
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Diffuse Scattering: 
With the physical model of an ambiguous Sav dimer displacement along b at hand, the 
diffuse reflections in the reciprocal lattice can be rationalized. As a consequence of the 
displacement, two unit cells with different angles β can be drawn which show a 
displacement of the reflections in the reciprocal space along c* (Figure M27, right 
panel). Indeed, diffuse reflections in the reciprocal lattice are observed exclusively along 
c* (Figure M27, left panels).  
 
Figure M27: (Left panels) Photographs of the reciprocal space layers [-2 k l] (upper 
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panel) and [h k 2] (lower panel). Reflections are diffuse only in c* direction. (Right panel) 
Representation of 2bc3 cell (pink) and C222/C2 cells of osmium-soaked crystal (black) in 
the real (upper panel) and the reciprocal space (lower panel). Displacement of layer II in 
±Δb yields displacement of reflections in ±Δc* in the reciprocal space.   
 
Quantitative Model of Ambiguous Crystal Packing Disorder: 
The displacement in fractional coordinates of an a,b-layer ni relative to its next neighbors, 
ni±1, is (0.00 ±0.11 ±0.50). Since y is not an integer multiple of the displacement Δy 
(±0.11), the packing disorder is incommensurate. Given there is an incommensurate 
ambiguity of packing of successive layers, the question arises, how is the system forming 
packing periodicity in direction b as is observed by the Bragg reflections along c* in the 
reciprocal space?     
The probability of a layer ni (i=1,2,3,…) of a population of N successive a,b-layers to be 
located in either (0.00 0.11 0.50) or (0.00 -0.11 0.50) relative to layer ni-1 is given by the 
Pascal triangular. Layer positions in proximity to the symmetry axis of the triangular have 
the highest probabilities. To test whether the packing of the osmium-soaked crystal can be 
described by the probability distribution of the Pascal triangular, the probabilities of the 
dimer positions within an average unit cell were calculated given that the sum of 
probabilities equals one over all possible positions in one layer  (Figure M28). Dimer 
locations of maximum probability are indeed found at the origin of the cell and at the end 
points of vectors (0.00 0.11 0.50) and (0.00 -0.11 0.50). This is in accordance with the 
results from the native Patterson map and the rigid body refinement. Moreover, the 
occupancies with minimal R-factor of the molecules in positions (0.00 0.11 0.50) and (0.00 
-0.11 0.50) as found by rigid body refinement (Figure M26) and the Pascal triangular-
probabilities of molecules in the same positions have almost the same value (0.200 and 
0.235, respectively). Thus, the positional probability distribution of Sav molecules in the 
unit cell as given by the Pascal triangular is a good quantitative model of the average a,b-
layer distribution in the crystal and explains the formation of packing periodicity in b 
direction and Bragg (as well as diffuse) reflections along c* in the reciprocal space. 
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Figure M28: Representation of the probability distribution (colors blue to yellow) of 
different locations of Sav in the monoclinic unit cell according to the Pascal triangular. 
The total probability in each layer I (0≤y<1, z=0) and II (0≤y<1, z=0.5) equals one. 
 
Structure Solution in C2: 
With no other method at hand, the structure was solved in C2 with only one dimer in layer 
I and an empty layer II (Table M4). Pronounced electron density in the 2|Fo|-|Fc| map was 
only found in layer I (Figure M29a). The overall structure of the Sav tetramer is the same 
as in 2bc3. However, 24 residues at the C-terminal end are not resolved in the electron 
density, probably du to high flexibility. The two biotin-binding pockets in the AU are 
empty. Positive electron density in the |fo|-|fc| map was apparent in proximity to the side 
chain-nitrogens of residues His127, His80, Lys132 and Lys80. Furthermore, in the same 
positions anomalous scattering density peaks were found. Since the wavelength of 0.9793 
Å of the data collection is close to the L-I absorption edge of osmium and with an osmium-
f’’ of 11-12 e-, the anomalous density peaks can be attributed to osmium binding. This is in 
accordance with the electron donor and metal coordinating properties of the side chain 
nitrogens Nε and Nζ of His and Lys, respectively. Indeed, Os could be modeled in the four 
positions.  
When filling up layer II with either of the two dimers in position (0.00 0.11 0.50) or (0.00 -
0.11 0.50), the osmium, which is coordinated to the side chain of His87, is located in the 
interface of two layers I and II (Figure M29b). In the search model 2bc3, this position is 
occupied by a SO42- from the buffer solution.  
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a)          b)  
Figure M29: Representation of 2|Fo|-|Fc| electron density map (aquamarine, at 3 σ in a 
and at 4.1 σ in b) and anomalous difference density map (red, at 3.2 σ) of the structure of 
the osmium-soaked Sav crystal solved in the C2 unit cell. Layer I is contoured much 
stronger than layer II by the 2|Fo|-|Fc| map (a). Osmium atoms are bound next to His87 in 
the interface between layer I and II (b). 
 
Table M4: Structure refinement of the monoclinic unit cell (C2a) with only one dimer in 
the AU. 
 R  Rfree  rmsd bonds (Å) 
MR    (10-4 Å) 44.6 %   
Rigid body refinement 
(10-4 Å) 
39.4 % 35.7 %  
Full atom refinement 
(10-2.4 Å), r1 
30.6 % 32.9 % 0.019 
r2 (with TLS) 29.7 % 30.9 % 0.019 
r3 (with TLS) 29.8 % 30.6 % 0.014 
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14. Summary  
In summary, the pathologic observations of an osmium-soaked Sav crystal with respect to 
i) diffuse scattering along c*, ii) a pseudo-origin peak in the native Patterson map and iii) 
the problematic rigid body and full refinement could be rationalized by an incommensurate 
ambiguous crystal packing disorder. The time and space average of the osmium-soaked 
Sav crystal is best represented by a unit cell with C2 symmetry and two Sav dimers in the 
AU. One Sav dimer in the AU is located within the c-centered layer I. The second dimer 
can occupy two positions in layer II with equal likeliness. Using the probability 
distribution of the Pascal triangular, a quantitative model of the average crystal packing 
could be derived, that correctly predicts the positions of layers I and II.  
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